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Peptide chemistry is a versatile tool in the development of diverse compounds that 
can be applied in various contexts: biology, drug development, organic synthesis, chemo 
sensing, combinatorial library design, and unnatural foldamer formation. This chemistry 
is highly optimized that commercial instruments are available for the fast production of 
these compounds. Despite the optimization, there are new, engaging avenues scientists 
can still explore in this well-established field. Our work in the Anslyn group is currently 
focused to incorporate more functionality into peptides beyond the repertoire given by 
nature. These efforts are targeted for many uses as described in this dissertation. The 
lessons learned from synthetic peptide design have directed our group also to explore the 
development of new oligomer systems that take a modular approach in its elongation as 
used in peptide chemistry. The use of synthetically accessible monomers that are linked 
by a reliable reaction is the simple, but powerful guiding principle behind the work 
presented here. 
Chapter 2 describes the development of a methodology to modify peptides in a 
sequential and selective manner targeting the most reactive amino acids. The chemistry 
presented in this chapter serves as the basis for the synthesis of model peptides with 
 vii 
fluorescent probes. In chapter 3, these fluorescently labeled peptides are used for proof-
of-concept studies for a new single-molecule protein-sequencing platform. Inspiration 
taken from chapters 2 and 3 brings chemistries facilitating the introduction of ortho- 
(aminomethyl)boronic acids into peptides. Chapter 5 explores chemical modifications 
ligands allowing for induced higher-order structuring. Finally, Chapter 6 leaves the 
peptide space to explore a supramolecular oligomer that will serve as the foundation for a 
new backbone branched with side chain functionalities.
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Chapter 1: Peptide and Unnatural Oligomer Chemistries1 
 
1.1 INTRODUCTION 
In the late 19th century, chemists began to explore ways to make polypeptides. Work 
started with simple synthesis of dimers1, 2 Since then, peptide chemistries have been the 
focus of heavy optimization. Increasing the number of residues into a sequence was the 
goal by improving the efficiency of amide coupling.3 In large part, this research focused 
on solid-phase approaches, but solution-phase chemistries remained popular.3-6 Such work 
allowed the synthesis of natural peptides for biological and therapeutic applications. The 
more chemists delved into making natural peptides, groups began the integration of 
unnatural residues. Studies on these non-canonical side chains probed into their 
bioactivities and biomedical applications. 7 Many found use in research settings to gain 
better insight into many biological processes and pharmacological drug design.8 
This kind of research also provided insight into rationally designed, controlled 
growth of polypeptides. Despite the research done in this field, peptide chemistry continues 
to be an exciting area of research. As a fundamental backbone in nature, the polypeptide 
will still be one of the preeminent natural scaffolds employed for designing a set of diverse 
compounds by changing side chain functionalities and sequence. In addition, this 
knowledge in linear synthetic design of peptides has inspired chemists to make unnatural 
oligomers.9, 10 
The past two decades has provided a host of unnatural backbones made to study 
their folding properties.11 Folding of these structures in complex arrangements was given 
the term “foldamer formation,” and are geared to have biomimetic properties with the 
intended purposes of improving bioactivities of natural analogues prone to degradation in 
																																																						
1 Adapted from T. Kimmerlin and D. Seebach, J. Pep. Res., 2005, 65, 229-260. 
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vivo.7, 12 The current state-of–the-art explores foldamers in their design of building blocks, 
elongation of them into a sequence, characterization of higher order structures, followed 
by identifying any applications they could have in biological, medical, materials, and 
organic chemistry settings.13 
The work presented in this dissertation is an exploration of synthetic peptide 
chemistry in its manipulation post-solid phase synthesis. Manipulation of peptides inspired 
work in appending functionalities that could induce folding of peptides with unnatural 
moieties. The chemistries employed for these kinds of modifications included well-
established techniques known in mass proteomics and the incorporation of residues 
derivatized with simple modifications, such as alkylations. The overarching aim has been 
to find unnatural moieties that can be used for various applications like binding to target 
analytes.  
Finally, from this research, a different way to conceptualize unnatural oligomer 
design is proposed. It is an approach that tries to resolve issues that include scaling-up of 
building blocks, improving sequence reproducibility, and arriving to a set of diverse 
sequences by a straightforward functionalization of the backbone. Designing this new 
oligomer included using dynamic, covalent bonds with well-established supramolecular 
interactions, and reflected the need to integrate many sub-disciplines in chemistry that 
include but are not exclusive to physical organic, polymer, biological, analytical, and 
materials chemistry. As with many projects, this work found inspiration outside of 
chemistry, particularly in systems biology and molecular biology. Collaborations with 
bioinformatcians and molecular biologists brought to light the need for supramolecular 
chemists to dive deeper into larger-scale production and characterization of a diverse set 
of molecules interacting in a confined space. To be more aware of designing chemistries 
that can function orthogonally with others and inducing folding of peptides and unnatural 
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oligomers will allow new and exciting advancements in the field. The aim should be to 
emulate the diversity of compounds and functions as observed in nature. 
1.2 Abridged Literature Review 
1.2.1 Solution-Phase Peptide Synthesis: Short Peptides Initially Made 
Starting in the 1880s, chemists, like Theodore Curtius, began devising chemistries 
to form polypeptides. One of the first made was a sequence consisting of two glycine 
residues. Although, the N-terminus remained protected, this peptide preceded the more 
notable work of Emil Fisher who made the same sequence by hydrolyzing 
diketopiperazine. Fisher’s work marked the beginning of peptide chemistry, starting in the 
early twentieth century. Both men took different approaches to making polypeptides.  
Curtius relied on an azide coupling methodology, whereby he would build a 
sequence from the N-terminus. The next building block displaced an azide alpha to the 
carbonyl group. Introduction of hydrazine, followed by nitrous acid generated the azide, 
thus propagating the sequence (Figure 1.1). Fisher focused on acylchlorides. In the 
presence of free amino acids and PCl5 in a solution of acetyl chloride, peptides could be 
generated. The limitations of both methodologies were the inability to isolate 
enantiomerically pure compounds and the difficulty to remove the protecting groups used. 
 
 

























































The following decades led to advances in the use of different protecting groups that 
facilitated synthesis of L-peptides. This work pioneered by chemists such as Bergman and 
Zervas employed carbobenzoxy (Cbz) for protection of the N-terminus. Deprotection done 
by hydrogen with palladium, sodium with aqueous ammonia, or hydrobromic acid in acetic 
acid afforded release of the amino group. With a viable means to protect and deprotect the 
α-amine, several naturally occurring peptides were synthesized. By the late 1950s, 
Carpino, McKay, and Albertson reported the boc-protecting group. This protecting group 
was stable to hydrogenation and basic conditions. Acidic treatment removed this protecting 
group and so it was orthogonal to other conditions required for other groups like Cbz1 
Further advances in protecting group chemistries facilitated the design and 
synthesis of longer sequences, such as β-Corticotropin. Along with advancements in 
protecting groups, amide coupling also played an important role. To minimize 
racemization, coupling reagents such as N,N’-dicyclohexylcarbodiimide, 1-ethyl-3-(3-




Figure 1.2: Amide Coupling Reactants. 
In addition to formulating protecting methodologies for the N-terminus and C-














certain amino acid residues can interfere with the coupling process, orthogonal protecting 
groups that survive amide-coupling conditions have been devised. Decades of research 
have afforded coupling reagents and protecting groups geared to improve efficiencies in 
coupling while minimizing racemization. 
Despite advances in solid-phase chemistries, solution-phase peptide chemistries 
continue to be reported. Such work strives to minimize the use of harsh conditions to 
generate polypeptides. Other groups have employed solution-phase strategies to minimize 
the costly and inefficient consumption of starting materials used in solid-phase approaches. 
Recent work by the Li group demonstrated chiral and achiral auxiliaries for purification of 
peptides in what was referred to as group-assisted purification (GAP).  The authors claim 
these auxiliaries facilitated peptide synthesis by isolating tyrosine modified with N,N’-Di-
phenyl-1,2-ethyldiamino O-phosphonyl groups.14 
Many of the peptides synthesized via solution-phase approaches proposed is to have 
methodologies that allow for facile scale-up of peptides for research and therapeutic 
applications. Solid-phase approaches do not readily lend themselves for scaling up of 
peptides. Finding solution-phase approaches will remain an important area of research, 
particularly with an emphasis of devising more environmentally responsible means of 
synthesizing peptides. 
1.2.2 Solid-Phase Peptide Synthesis: Preferred Method for Short Polyamides 
Instead of relying on solution-phase approaches, which required onerous 
purification steps before incorporating the next amino acid, Merrifield conceptualized a 
new way to make peptides.15 His approach immobilized the first residue on a solid support 
followed by introduction of the next amino acid building block. The linker connecting the 
peptide to the polystyrene support was acid labile and orthogonal to the basic conditions 
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for amide coupling. Mixtures of solvents and reactants along with the use of insoluble 
polymer made automating peptide synthesis possible. 
Cleavage of peptide from the solid support coincided with deprotection of acid-
labile groups protecting the side chain residues. To date, several companies offer 
automated peptide synthesis instruments, which rely on the chemistries developed for over 
a century. Recent advances have included the use of microwave reactors to improve 
efficiency of coupling and deprotection of the fluorenylmethyloxycarbonyl (Fmoc) group, 
decreasing the time to synthesize a peptide. To date, with these highly optimized systems, 
10 amino acids can be added into a sequence in about an hour. 
 Solid supports available are numerous16, but the most used is the preloaded Wang 
resin, because of its reliable cleavage and high yields. Choice of resin is important for 
minimizing deletion products and the accommodation of sequences longer than 20 
residues.17 Other resins are available to release the C-terminal end with different 
functionalities. For example, cleavage of peptide from the rink amide, releases the C-
terminus as an amide. To release a thiol-terminated C-terminus, cysteamine 4-
methoxytrityl resins can be used. These resins tend to be hydrophobic and the use of polar 
solvents or aqueous mixtures shrinks the resin, or causes them to aggregate. When aqueous 
mixtures are required, hydrophilic resins are available. These are known as Tentagel resins, 
and they are functionalized with PEG chains, improving swelling of solid supports in more 
polar solvents. 
 To date, several groups continue optimizing solid-phase chemistries, to resolve 
issues that include residue protecting group instability, deletion products, and overall 
efficiencies. Efforts have brought about a host of protecting groups tailored for solid 
supports. Amide coupling reagents developed for solution-phase approaches have been 
transferred for solid-phase chemistries. In particular, phosphonium coupling reagent, like 
 7 
BOP, AOP, PyBOP, PyAOP, HBTU, HATU, HBPyU, and HAPyU, have gained 
popularity for automated synthesis (Figure 1.3).18 
 
 
Figure 1.3: Amide Coupling Reactants Used in Solid-Phase Peptide Synthesis (SPPS) 
 
 Chemistries cleaving peptides from the solid support have also been optimized. The 
byproducts formed by removing acid-labile protecting groups from residues lead to 
reactive species, such as 2-methylpropan-2-ylium, triphenylmethylium, or (4-
methoxyphenyl)dipheylmethlium (Figure 1.4). To quench these reactive byproducts, 
introduction of weak reducing reagents, such as triisopropylsilane (TIS), and nucleophiles, 
such as water, are commonly employed. These become part of the acidic cocktail to 


























































Figure 1.4: Cationic Species Formed from Deprotecting Side Chains. 
 
In addition to TIS or water, ethane dithiol (EDT) can be added to outcompete thiol 
residues from reacting with electrophilic species or from forming disulfide bonds. Other 
protecting groups like 4-methoxy-2,3,6-trimethylbenzensulphonyl (Mtr) for Arginine 
residues, different additives such as thioanisole and bromotrimethylsilane (TMSBr) are 
preferred. Photocleavable and oxidative cleavable resins are also available, and are used to 
overcome issues associated with deprotection of immobilized peptides with acid labile 
protecting groups and preventing cleavage from the solid support. For example, derivatives 
of 1,2-dimethoxy-4-nitrobenzene have been utilized as photocleavable linkers. Copper 
acetate can be used for oxidative cleavage of hydrazino benzoyl linkers. All these resins 
are aimed to improve isolation of desired peptide, while minimizing side reactions between 
unprotected residues and post-deprotection byproducts. 
 Post-synthesis these peptides are purified by High-Performance Liquid 
Chromatography (HPLC). This purification method remains the most commonly used way 
to isolate peptides. Impurities removed come from side products formed during 





characterization takes place with mass spectrophotometry, and sequence information can 
be confirmed via fragmentation along the backbone. Because peptide chemistry is highly 
optimized, sequence fidelity for synthetic peptides are regarded to be reliable, especially 
with current instrumentation. Therefore, synthetic peptides are normally characterized by 
identifying exact mass to confirm the correct sequence was made. More traditional organic 
analytical methods like NMR are not a common technique for routine analysis of synthetic 
compounds. However, it is possible to obtain sequence information, but two-dimensional 
techniques are required. 
1.2.3 Natural Residue Synthetic Peptides: Chemistry Approaches to Making 
Peptides 
Over 7000 naturally occurring peptides are known, and many of these have been 
synthesized using chemistries described in previous sections.19 These peptides play 
important roles as hormones, growth factors, ion channel ligands, neurotransmitters, and 
anti-microbial agents.20, 21 Some of the first to be made were polypeptides such as 
glutathione by Harington in 1935. Vigneaud synthesized oxytocin, a naturally occurring 
cyclic peptide, in 1953. By the 1960s, peptides like β–corticotropin, a 39 amino acid long 
polypeptide, were synthesized.  
Peptides with naturally occurring post-translation modifications (PTMs) have been 
obtained with solid-phase methods. For example, palmitoylation, myristoylation, 
farnesylation, and geranylation of peptides are used for anchoring peptides into the cell 
membrane. These peptides can be used for signaling vesicular transport, differentiation, 
and cell growth. Appending oligosaccharides, glycosylation, is also possible for making 
synthetic peptides that participate in promoting cell-cell interactions, targeting of cell, and 
extending protein half-life. Signal transduction can also be promoted by peptides that have 
been phosphorylated, and strategies to phosphorylate are reported. Biosynthetic means are 
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available for making these PTMs peptides, however, usually small quantities are isolated 
at great expense, and mixtures of sequences are obtained.20 These mixtures make it difficult 
to determine which sequences have a role in biological processes. Drug candidates such as 
antitumor vaccines MUC1 and TLR2 glycolipopepetides have been designed with solid-
phase approaches. Fragment condensation approaches in solution have also been made to 
make larger sequences of naturally occurring peptides. Native chemical ligation (NCL) in 
solution and on a solid support has been used. These chemistries rely on thioesters 
becoming modified with amino group attacking the carbonyl group. The amine is the α-
amino group from the peptide coupled to the C-terminus. In solution, a cysteine residue is 
exposed and becomes part of the sequence of the large peptide formed (Figure 1.5). 
 
 
Figure 1.5: Native Chemical Ligation (NCL). 
 
1.2.4 Unnatural Synthetic Peptides: Expanding the Residue Repertoire 
It can be argued the origins of unnatural residues stem from amino acid building 
block synthesis. With the development of methods to make natural amino acid building 
blocks and modification chemistries to alter natural residues, peptide chemists also began 
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and make them stable for further modification, by clever means to make natural amino acid 
building blocks, provided intellectual fodder for non-canonical side chains. A common 
approach to introduce unnatural side chains has relied on azido lysine or alkyne-based 
amino acids. Triazole formation via an alkyne and copper catalyst has been used for 
solution-phase and solid-phase modifications. Many examples demonstrate peptides 
modified with alkynes altered with different peptides, fluorophores, fluorinated aromatic 
rings, analine derivatives, and ferrocenes.28 
Peptides with unnatural residues have found commercial use and are lauded for 
their improved proteolytic stability while still retaining the relevant biological activity of 
their natural counterparts. Registered drugs like Abarelix, a gonadotroping releasing 
hormone, has an N-isoproyl Lysine. Lacosamide used to treat onset seizures and 
neuropathic pain is a dipeptide with a methylated serine. In conjunction with natural 
residues, single substitution for one amino acid can improve the efficacy of a peptide-based 
drug. In research settings, the Anslyn group has used modification of cysteine residues with 
SOX fluorophores to differentiate MAP kinases.29 
1.2.5 Foldamers: Expanding the Backbone Repertoire for Biomimicry9, 30 
 Elongation of amino acid building blocks with methodologies developed for 
converting between protecting groups paved ways for chemists to consider new backbone 
designs that could fold in arrangements like biopolymers. Forces governing the folding of 
polymers include various non-covalent interactions, like hydrogen bonding, ion pairing, 
van der Waals and hydrophobic interactions.31 For proteins, there is a balance between 
maximizing favorable side chain interactions and reducing the contacts of hydrophobic 
residues with the solvent. Folding, in other words, has been defined as a balance between 
the entropic loss, gained by restricting conformational degrees of freedom, and enthalphic 
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gains made by maximizing favorable interactions with solvophilic residues.31 Keeping in 
mind these kinds of approaches can also be applied in the design of foldamers. 
The Gellman group substituted residues with β amino acids to make α,β peptides 
that were more resistant to degradation compared to their natural counterparts.32 Other 
unnatural building blocks employed for foldamers include peptoids, oligoureas, and aza 
peptides.33 Moieties like aryl amides and phenylene ethynylene foldamers serve as 
examples that differ from the flexible building blocks mentioned. Higher order structure 
such as β-sheets and α-helices have been reported with these building blocks. With analine 
derivatives, double helices were possible. These unnatural oligomers have also been used 
for devising molecular structures that bind a target analyte by finding the most 
thermodynamically favorable state when bound. For example, m-phenylene ethylene 
helical hosts binding chiral guests, such as α-pinene, have been reported. 
1.3 Summary 
Since the late 19th century, optimizing synthetic peptide chemistry has been the 
focus of much research. Solution-phase approaches were first developed, but suffered from 
difficult purifications and racemization. The introduction of protecting groups, like Cbz 
and Boc, helped to minimize these issues and improve efficiencies of peptide bond 
formation. These advancements led to the first syntheses of naturally occurring peptides. 
To overcome further inefficiencies and minimize the need for purification steps, solid-
phase approaches were developed. Both natural and unnatural peptides have been made 
with these methodologies, and synthesized peptides have found use in research and 
therapeutic settings. From these chemistries, a rich environment of building block design, 
protecting group strategies, and side chain functionalities served as inspiration for 
unnatural oligomer design. Like peptides, these oligomers are studied for their folding 
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properties in hopes of finding unnatural analogues that exhibit activities and properties 
found in nature. 
1.4 Dissertation Outlook 
The work presented in this dissertation describes utilizing well-established 
chemistries to forge new paths for modifying side chains, advancing proteomic 
technologies, and inducing folding of unnatural peptides. Extensive work done in designing 
and synthesizing peptides inspired new ways of conceptualizing the making of unnatural 
oligomers. The aim is to take the best of peptide chemistries and mitigate some of its 
drawbacks when considering making biomimetic analogues. Chemists, however, seeking 
to make foldamers should appreciate the work that began over a hundred years ago to make 
one of the foremost “natural foldamers.” Therefore, this work focuses strongly on peptide 
design, and only begins to explore unnatural oligomers towards the end. 
1.4.1 Chapter 2: Natural Side Chain Modifications 
In this chapter, reactions known in mass proteomics were used in a sequential, 
linear implementation for modifying the most reactive natural residues. The modifications 
targeted Cysteine, Lysine, Aspartate, Glutamate, the N-, and C-termini. Modification of 
side chains first occurred in solution and was transitioned to the solid phase for labeling 
model peptides KDYWEC and KDYWE. After learning these modifications, work on 
incorporating functional handles for selective labeling of residues with fluorophores 
became a focus. 
1.4.2 Chapter 3: Fluorescent Peptides Used for a Single-Molecule Peptide 
Sequencing Platform 
In collaboration with the Marcotte group, unnatural peptides modified with 
fluorescent probes were made. These peptides were used in proof-of-concept studies for a 
new peptide-sequencing platform aimed to extract sequence information at the single 
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molecule level. The chemistries required for making peptides with appropriate controls 
required expanding our understanding of synthetic peptide design. For example, synthesis 
of fluorescently labeled building blocks and incorporation into automated synthesis 
provided lessons of introducing unnatural functionality during solid-phase synthesis. Or, 
labeling of peptides at the N-termini with dyes on the solid support, demonstrated the 
straightforward methodologies to incorporate, complex unnatural functionality post solid 
phase synthesis. 
1.4.3 Chapter 4: Secondary Amine Residue Peptides Alkylated with Boronic Acids 
Incorporation of unnatural side chain functionality of peptides became an important 
goal in our synthetic strategy for introducing non-canonical side chain functionalities. To 
do so, we developed three approaches to incorporate secondary amines into our sequences. 
These methodologies included using solution-phase and solid-phase chemistries followed 
by alkylation of these amines to form boronic acid peptides. 
1.4.4 Chapter 5: Secondary Amine Residue Peptides Alkylated with Bipyridines to 
Induce Folding 
Secondary amines were used again for appending bipyridines off the amide 
backbone. These unnatural moieties in the presence of Fe2+ and free bipyridines in solution 
caused cyclization of these synthetic peptides. After forming higher order structures, these 
cyclic peptides were introduced into a solution of hydrazone forming peptides and studied 
for higher order structures formed. 
1.4.5 Chapter 6: Modular Oligomer Design Achieved by Using a Guanidinium, 
Boronic Acid, and Dione 
A new oligomer was designed from literature reported side chain modification 
strategies. Diones and boronic acids form a tri-component assembly with guanidyl groups 
like Arginine, and this reaction was used for the synthesis of a synthetic oligomer 
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incorporating terpyridines complexing about Zn2+. The design of this oligomer arose from 
the principles of “modular oligomer design,” a term conceived from research done in 
peptide chemistry. The term aims to emphasize the need for designing synthetically 
accessible building blocks, the use of simple and reliable “linking” strategies for oligomer 
formation, and the ability to modify the backbone post oligomer formation. With these 
principles, peptide and unnatural oligomer chemistry will facilitate synthesis of foldamers. 
In addition, the Anslyn group believes modular oligomer design will direct efforts to 
improve the scaling-up of building blocks, improve the atom economy of oligomer 
formation, and decrease time spent before characterizing these structures. The hope will be 
to increase the scale, reproducibility, and structure complexity of synthetic structures 
designed to emulate macromolecules in nature. 
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Chapter 2: Solution-Phase and Solid-Phase Sequential, Selective 
Modification of Side Chains in KDYWEC and KDYWE as Models for 
Usage in Single-Molecule Protein Sequencing2 
2.1 INTRODUCTION 
 
2.1.1 Need for Selective Labeling of Amino Acid Residues for Emerging Single-
Molecule Sequencing Technologies 
 
Recent theoretical work on single-molecule peptide or protein sequencing suggests 
that modifying proteins with amino acid side chain specific labels, and determining the 
order of the subset of modified amino acids (e.g. via single molecule fluorescence 
microscopy in combination with Edman sequencing1 or nanopore-based sequencing)2 can 
be sufficient to identify proteins in complex mixtures at the single molecule level. Such a 
technology offers the potential for multiple orders of magnitude improvements in 
sensitivity and throughput over existing approaches, but still faces barriers for its practical 
implementation. A key barrier is the development of a side-chain specific labeling scheme 
capable of modifying multiple amino acid types with specific and detectable labels, such 
as residue specific fluorophores. In such a scheme, only the positions of the fluorescent 
amino acids are determined for a peptide or protein, which is then identified by comparison 
with the sequences expected based upon that organism’s known genome sequence. Thus, 
more amino acid-specific modifications translate directly into richer sequence information 
about a given peptide or protein, ultimately allowing for greater coverage of that 
organism’s proteome. Computational modeling suggests that schemes incorporating 
																																																						
2 Hernandez, Erik; Swaminathan, Jagannath; Marcotte, Edward M.; Anslyn. Eric V. “Peptide Modification 
Chemistry: Solution-phase and Solid-phase Sequential, Selective Modification of Side Chains in KDYWEC 
and KDYWE.” New Journal of Chemistry. 2017, 41, 462-469. Designed peptides and did labeling 
chemistries proving sequential, selective modification. 
 18 
modifications to cysteine, lysine, tryptophan, aspartic, and glutamic acid residues can in 
principle provide a high coverage of the human proteome.1 
2.1.2 Chemistries Available for Selective Modification of Peptides 
Fortunately, work developed for mass spectrometry proteomics has provided 
optimized chemistries that selectively target residues for modification. These techniques 
have gained widespread use and are employed to understand biological processes such as 
expression, post-translation modifications, and protein interactions. These labeling 
chemistries are highly regarded for their efficiency and low cross-reactivity. Side chain 
specific protocols are routinely used to tag and modify proteins with high selectivity, where 
little to no cross-reactivity has previously been established.3 For example, kits are 
commercially available for targeting cysteine and lysine. The cysteine is modified with an 
iodoacetamide, followed in the same-pot by selective modification of lysine using o-
methylisourea hemisulfate.4 Acylation and reductive alkylation are also employed to 
modify both Ne-amines and N-termini.5 Cross-modification of threonine, serine, and 
tyrosine can occur with acylation and alkylating conditions.6 Recently, peptide amines have 
been modified via reductive methylation preventing cross-reactivity with alcohol and 
phenol residues. Once these amines were modified, the Smith group achieved global 
modification of aspartate and glutamate via amidation with amine-containing compounds. 
Furthermore, studies with less abundant side chains have been explored. For example, 
Horton, Koshland, and Scoffone demonstrated the modification of tryptophan under acidic 
conditions using 2-hydroxy-5-nitrobenzyl bromide and dinitrophenylsulfenyl chloride.7–9 
More recently, studies of the N-terminus using pyridinecarboxyaldehydes have expanded 
the chemical repertoire available for selective targeting of functional groups.10  
2.1.3 Scientific Aim: Modify Most Reactive Amino Acids on Model Peptides 
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However, missing in these studies is a route integrating all these selective 
modifications into a sequential protocol. Such a route, taking advantage of these 
techniques, could have potential applications not only in these emerging single-molecule 
technologies, but also in protein/peptide mass spectrometry studies. In addition, devising a 
generalized sequential route consisting of the selective modification of side chains also has 
applications for synthetic peptide and protein design.11–13  
Herein, we describe studies that put this sequential strategy described in scheme 
2.1 and 2.2 into practice. As described, a series of selective modification steps for 
KDYWEC (2.1) and KDYWE (2.2) was achieved. Modification studies were initially 
 
 




Figure 2.2: Solid-phase modification of KDYWE. (a) Modification of lysine was done 
similarly for immobilized KDYWEC. (b) Two repetitions were performed 
to drive reaction to completion. (c) Modification of tryptophan. (d and e) 
Cleavage with water releases C-terminus as an acid. (f) Cleavage with amine 
functionalized C-terminus with an alkyne. 
 
performed in solution-phase targeting cysteine, lysine, the N-terminus, aspartic, glutamic 
acid, and tryptophan. For ease of identification and purification, solution-phase studies 
were performed. These chemistries were transitioned to the solid-phase. Both peptides 







It was presumed that global modification of several amino acids of different classes 
should be possible if the appropriate conditions and the right sequence of derivatization 
steps were used. For example, by using iodoacetamide, guanidination reagents, amide-
coupling reagents, and aromatic-targeting electrophilic reagents, we may selectively 
functionalize cysteine, lysine, aspartic and glutamic acids, and tryptophan, respectively, if 
used in the proper protocol. Minimizing cross-reactivity between each step was to be 
achieved if the nucleophilicity and pKa of each side chain, as well as the reactivity of 
modification of reagents, reactions times, and temperature are all considered. Good 
nucleophiles, such as the thiol in cysteine or the amine in lysine, and the N-terminus, should 
be targeted first. Selective modification of cysteine between pH 7–8 is possible, while 
modification of amines is possible at a higher pH.14 Because guanidinating reagents are 
selective for amines, distinguishing between the Ne-amine of lysine and the terminal a-
amine was possible. As described herein, a different modification of reagent is required for 
each kind of amine. Once the most nucleophilic sites were modified, we tested if the 
carboxylate side chains could then be targeted followed finally by modification of 
tryptophan. 
Characterization of the resulting peptides in nearly all these examples is performed 
only with HPLC for purity and mass spec for identity due to the minimal quantity of 
material produced. As is the case with the studies reported herein, the quantity of material 
is not amenable to 1H and/or 13C NMR spectroscopy. Our goals herein were to create a 
protocol for sequential modification of numerous side chains using known selective 





Figure 2.3: Modified model peptide intermediates. 
 
2.2.1 Solution-Phase Sequential, Selective Modification of KDYWEC 
In the experimental design we implement here, we are exploiting reagents that have 
already been proven to have high selectivity for their individual amino acid side chains. 
Our goal was to direct the derivatizations by modifying experimental conditions and then 
use each derivatization step sequentially, which, to our knowledge, has not been previously 
accomplished. The order of steps in scheme 2.1 took into consideration the nucleophilicity 
and acid/base-dependent reactivity of the target side chains in KDYWEC. This peptide was 
synthesized to contain the most reactive natural amino acids. The sulfhydryl group in 
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cysteine is the most nucleophilic, and is prone to oxidation and disulfide bond formation. 
To ensure selectivity in future modification steps, cysteine 
was first alkylated with iodoacetamide, forming a stable thioether. Maintaining a pH 
between 7–8 ensured the amines remained protonated, thus limiting the possibility of 
undesired alkylation. Subsequently, the pH was raised to 11 and 2-methylthio-2-
imidazoline hydroiodide (MDI) was introduced. Modification of the Ne-amine occurred in 
24 minutes when heated to 50 1 °C. Longer reaction times increased the extent of N-
terminal modification. The Cys and Lys modification steps were performed in one-pot. The 
yield of peptide 3 after purification was 38%. Because the lysine was modified while 
heating under basic conditions, the thioether and guanidinium group were considered to be 
stable in future derivatization steps. 
Of the remaining nucleophilic sites, the N-terminus was first targeted. Protection 
of the N-terminus was required prior to modification of aspartate, glutamate, and the C-
terminus. If not, concatenation of peptides could occur during amidation. The modification 
conditions of the N-terminus also required a group compatible to both basic and acidic 
conditions in subsequent derivatization steps. Literature accounts have reported using 1-
(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl to protect amines during peptide 
synthesis. This protecting group is stable to highly basic and acidic conditions, and is 
removed under hydrazinolysis conditions.15 However, refluxing overnight to efficiently 
add the protecting group is common. Heating overnight was undesired so as to minimize 
observed degradation. Thus, we devised the use of 5,5-dimethyl-2-(3-methylbutanoyl)-3-
oxocyclohex-1-en-1-yl diethyl phosphate (phos-DOD) as an alternative. Diethyl phosphate 
was anticipated to be a better leaving group, thereby facilitating the reaction. This 
compound was formed with chloro diethyl phosphate in situ, followed by incubation with 
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a basic solution of peptide 3 overnight. Post-purification the yield of peptide 4 was 67%. 




Once the most nucleophilic sites in the model peptide were modified, the carboxyl groups 
were targeted. Amidation has been used for derivatization of aspartate, glutamate, and the 
C-terminus.16 Unlike the modification of lysine and the N-terminus, distinguishing among 
these target side chains was not possible. Also, because there were three sites for reaction, 
an efficient modification approach was necessary. Highly efficient, global modification 
using (7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate 
(PyAOP) and N-methylmorpholine (NMM) has been reported.6 Peptide 5, amidated with 
benzylamine dissolved in MeCN/H2O mixtures, and purification of the resulting modified 
peptides was possible. Yield for peptide 5 was 29%. To improve the solubility of the model 
peptide, 3-dimethylaminopropylamine (DMAPA) was used to increase the overall positive 
charge under acidic conditions. Purity checks of the peptide demonstrated an approximate 
10-minute difference in elution when comparing peptide 5 and 6. For peptide 7, 
isobutylamine was explored as an alternative, believed to form a peptide less hydrophobic 
than peptide 5, but more hydrophilic than peptide 6. Peptide 7 readily dissolved in 
MeCN/H2O mixtures, but coeluted with an impurity characterized by LCMS as m/z 313.4. 
The impurity was removed after synthesizing peptide 8. 
eq.	2.1	
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Tryptophan was the remaining target. As a less abundant amino acid in nature, the 
ability to identify this side chain can be informative for determining the protein origin of 
peptides in proteomic studies.17 In synthetic peptide design, incorporating an additional site 
for derivatization increases the repertoire of side chains to modify. Therefore, devising a 
selective modification strategy incorporating modification of tryptophan was seen as 
important. Cysteine reacting with sulfenyl chlorides has been reported.18 As with the other 
modification steps, modification of cysteine prior to that of tryptophan was chosen. 
However, under acidic conditions the tryptophan could be selectively targeted in the 
presence of unprotected N-terminus and lysine. The advantage to modification of the 
tryptophan last was the relative ease of the reaction. Peptides 5 and 6 readily dissolved in 
glacial acetic acid, and the reaction occurred in 4 h at RT. 2,4-Dinitrobenzenesulfenyl 
chloride (DBSC) was a chromophore and the peptides could also be monitored at 330 nm. 
Yields were 32% and 49% for peptides 8 and 9, respectively.  
2.2.2 Solid-Phase Sequential, Selective Modification of KDYWE 
The ultimate application in single molecule sequencing of our derivatization 
protocol will employ immobilization of the peptides on solid supports, and subsequent 
attachment of the peptides to surfaces via the thiols on cysteine. Thus, in a protocol that 
employs solid supports for derivatization, cysteine residues do not need to be derivative, 
because they will be the points of attachment to the surface. Hence, we removed the 
cysteine of the peptide we studied in solution, resulting in KDYWE, for our solid-phase 
synthesis studies. 
Efforts to modify the amino acids on solid phase supports were explored after the 
sequence of targeting side chains had been successfully demonstrated in solution. Synthetic 
peptides have been commonly modified when immobilized on a solid support, usually at 
reactive side chains such as lysine.19 Requirements for successful solid-phase reactions 
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include making sure each step is highly selective. Further, the reagents must be able to 
diffuse into the resin to reach sites for reaction. A high concentration of starting material 
in the bulk solution ensures a concentration gradient is formed for reactants to diffuse.20 
Inherent in this study was devising an approach that selectively modified target side chains 
in a sequential fashion. Therefore, high specificity was required. Literature, and the work 
presented here, has demonstrated that excess reagent can be used while maintaining 
selectivity. The final requirement for solid-phase studies was using a resin that would not 
cleave with acid or base. 4-Fmoc-hydrazinobenzoyl resin AM was selected, because 
literature accounts describe the stability towards strong acids and bases. Peptides 
immobilized on this resin were isolated after oxidative cleavage with Cu(II) and base.21,22 
Fig. 3 summarizes the modification of reactions performed on the solid support for peptide 
KDYWE. The first side chain targeted was the lysine. Two changes were made from the 
solution approach. The reaction time was longer. The immobilized peptide was incubated 
overnight with MDI. A solution of MeOH/DIPEA/H2O (7 : 2 : 1) (v/v/v) was used instead 
of a solution of NH4OH. Overnight incubation and the use of DIPEA have been reported 
in the literature.23 The doubly modified peptide was not observed after an overnight 
reaction at RT, however, extending the reaction time to 48 h led to doubly modified peptide. 
Selectivity for the Ne-amine can be explained due to inductive and steric effects. The Nε 
amine in lysine is part of a hydrocarbon side chain and not adjacent to an electron-
withdrawing amide group, and thus, the lysine side chain amine is more nucleophilic than 
the a-amine. Furthermore, the N-terminal amine is closer to the amide backbone, impeding 
MDI due to sterics. The same inductive and steric effects played a role when modifying 
KDYWEC in solution phase. However, lowering the reaction temperature from 60 °C to 
RT made these effects more pronounced. A protection step of the N-terminus was not 
performed. One reason was to discover if in the presence of excess amine, the carboxylates 
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would be modified without concatenation to this terminal amine. A second goal was to 
check if the number of modification steps could be reduced, leaving the terminal-amine 
unmodified for future reactions. This approach could provide synthetic flexibility by 
diversifying the kinds of reactions performed at the N-terminus once the peptide is cleaved 
from the resin. The amine used in solid-phase synthesis differed from that of the solution-
phase studies. 1-Amino-3-butyne had an alkyne group that could also provide sites for 
derivatization via Huigen–Sharpless.24 The same coupling reactants PyAOP and NMM 
were employed for solid-phase studies. Two repetitions ensured all carboxylates were 
modified. Cleavage of the peptide was performed using a catalytic amount of Cu(II) and a 
mixture of MeCN/H2O/Pyr. To a different batch of resin, the lysine and carboxylates were 
also modified. Tryptophan was modified in a similar fashion as in solution, four hours at 
RT.25 Two different cleavage conditions were tested for the model peptide after the target 
side chains were modified. The first condition was water, liberating a carboxylate at the C-
terminus. Peptide 11 was thereby isolated with a HPLC purified yield of 4%. Additionally, 
a nonaqueous condition in the presence of a nucleophile could also be employed to cleave 
the peptide. 1-Amino-3-butyne was the nucleophile used, liberating peptide 12 with an 
HPLC purified yield of 5%. The peptide could also have been cleaved with a different 
nucleophile diversifying the functional groups, further differentiating between the C-
terminus and carboxylate side chains. Isolating peptide 12 required extra washes with 
DMF, because solubility in H2O/MeCN was reduced once an alkyne was introduced at the 
C-terminus. Initially, the peptide was rinsed with MeCN, and LCMS data of the extract did 
not indicate the presence of desired product. Once rinsed with DMF and the solvent 





A sequential and selective scheme using common mass modifications was 
developed for derivatizing peptides as a model for ultimate use in single-molecule 
sequencing studies, helping to overcome a key barrier identified by previous computational 
models of single molecule protein sequencing.1,2 Selective targeting of side chains in 
KDYWEC was achieved in solution-phase. Most of the side chains, as well as the N-
terminus and C-terminus were modified. No heating was required to target N-terminal 
amine with 4,4-dimethyl-2,6-dioxocyclohex-1-ylidene when using Phos-DOD. Selective 
modification also occurred in solid-phase studies for KDYWE. Modification of all the 
target side chains was possible while omitting any reaction at the a-amine. Oxidative 
cleavage of the resin provided flexibility to choose between releasing modified or 
unmodified C-terminus. The use of 1-amino-3-butyne as the carboxylate-modification of 
reagent introduced further functionality that could be exploited in future reactions. Such an 
approach can also have applications for peptide modification studies and novel synthetic 
peptide design. Other tags, like fluorescent probes, can be designed to have the same 
functional handles presented in this paper. Work on the design, synthesis, and selective 
modification of peptides using these dyes will be discussed in future publications. 
2.4 Experimental 
2.4.1 General Materials 
For automated, Fmoc amino solid-phase peptide synthesis, OtBu (Asp, Glu), Boc (Lys, 
Trp), tBu (Tyr) were used. Fmoc protected amino acids were purchased from Novabiochem 
(USA) and AAPPTec (USA). Fmoc-Cys(Trt)-Wang resin (100–200 mesh) and 4-Fmoc-
hydrazinobenzoyl resins AM NovagelTM were purchased from Novabiochem (USA). Other 
chemicals used for automated, solid-phase peptide synthesis were purchased from Fisher 
Scientific and Sigma-Aldrich. Reagents used for selective modification of studies were 
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iodoacetamide (IA), 2-methylthio-2-imadazoline hydroiodide (MDI), sodium methoxide, 
diethylchlorophosphate, 2-(3-methylbutyryl)-5,5-dimethyl-1,3-cyclohexandione, 
benzylamine (BA), isobutylamine, 3-dimethylaminopropylamine (DMAPA), 1-amino-3-
butyne (AB), (7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate (PyAOP), N-methylmorpholine 
(NMM), and 2,4-dinitrobenzenesulfenyl chloride (DBSC). All chemicals were purchased 
from Sigma-Aldrich. 
2.4.2 General Instrumentation 
A Prelude peptide synthesizer (Protein Technologies, Inc.) was used for automated-
solid phase synthesis. Preparative HPLC purification of peptides was performed using an 
Agilent Zorbax SB-C18 Prep HT column 21.2 x 250 mm; 10 ml min-1, 5–95% MeCN (0.1% 
TFA) in 90 min. Analytical HPLC characterization of peptides was performed using an 
Agilent Zorbax column 4.6 x 250 mm; 1 ml min-1, 5–95% MeCN (0.1% TFA) in 40 min 
(RT). An Agilent Technologies 6530 Accurate Mass 
QTofLC/MS was used for high-resolution mass spectra of purified peptides. Solvents used 
were HPLC grade. 
2.4.3 General Solid-Phase Model Peptide Synthesis 
KDYWEC was synthesized using Fmoc-Cys(Trt)-Wang resin (0.57 mmole g-1, 100 
mmole) by sequential coupling of Nα-Fmoc-amino acid (0.1 M, 1.5 ml) in DMF in the 
presence of N,N,N,N-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate 
(HBTU, 0.15 M, 1.0 ml) and DIPEA (0.2 M, 0.5 ml) with a reaction time of 30 minutes at 
room temperature. A total of three repetitions were performed for each amino acid building 
block. DMF (3 ml, 3 min, 3x) and DCM (3 ml, 3 min, 3x) washes were done before each 
repetition.  After incorporation of the third amino acid, a 0.8 M LiCl wash step was 
performed after swelling with DCM (3 ml, 3 min, 3x). Post synthesis, resin was washed 
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with glacial AcOH (5 ml, 3x), DCM (5 ml, 3x), and MeOH (5 ml, 3x). The resin was placed 
under vacuum overnight. The peptide was cleaved from the resin using trifluoroacetic acid 
(TFA), triisopropylsilane (TIS), 1,2-ethanedithiol (EDT), and nanopure water (94 : 1.0 : 
2.5 : 2.5), and precipitated with diethyl ether at 0 °C. No HPLC purification of the crude 
peptide was necessary. KDYWE was synthesized using 4-Fmoc-hydrazinobenzoyl resin 
AM Novagelt. TFA, TIS, and nanopure water were used (95 : 2.5 : 2.5) to deprotect the 
side chains, and the peptide remained immobilized on the solid support. 
2.4.4 Solution-Phase Modification Studies of KDYWEC 
Modification of Cysteine with iodoacetamide. Peptide 1 (75 mmole) was 
dissolved in 0.4 ml of nanopure water. A solution consisting of 0.37 ml of 
MeOH/Pyr/TEA/nanopore H2O (7/1/1/1) (v/v/v/v) was introduced (adjusting to pH 8), 
followed by addition of iodoacetamide (97 mmole). The reaction was incubated for 2 h at 
RT. Modification of lysine with 2-methoxy-4,5-dihydro-1Himidazole (3). In the same pot, 
0.5 ml of a 7 N solution of NH4OH was added, followed by introduction of MDI (750 
mmole). The reaction mixture was incubated for 24 min at 65 °C, followed by introduction 
of TFA (0.3 ml) at 0 °C. The crude peptide was prepared for preparative HPLC using an 
Extract Clean C18 500 mg/4 ml solid phase extraction column (SI). The peptide was 
purified using preparative HPLC, and the organic solvent in the peptide fraction was 
removed via rotary evaporation. Aqueous remnants were frozen at -78 °C and lyophilized 
overnight. Purified yield: (29 mmole) 38%. High-res MS: found m/z 968.39360, calcd 
968.39310 (M + H)+; found m/z 966.37880, calcd 966.37850 (M - H)-. 
Modification of the N-terminus with 5,5-dimethyl-2-(3-methylbutanoyl)-3-
oxocyclohex-1-en-1-yl diethyl phosphate (Phos-DOD) (4). Peptide 3 (12 mmole) was 
dissolved in 0.1 ml of nanopure water, followed by dilution with 0.2 ml of MeCN. To the 
solution, 0.12 ml of 7/2/1 MeOH/TEA/H2O (v/v/v) was introduced. A solution of Phos-
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DOD (SI) (18 mmole) was introduced. The solution was incubated overnight at RT. The 
peptide was purified using preparative HPLC. Organic solvent in peptide fraction was 
removed via rotary evaporator. Aqueous remnants were frozen at -78 °C and lyophilized 
overnight. Purified yield: (8 mmole) 67%. High-res MS: found m/z 1174.52380, calcd 
1174.52380 (M + H)+; found m/z 1172.50750, calcd 1172.50920 (M - H)-. 
Modification of the carboxylate side chains and C-terminus with benzylamine 
(BA) (5). Peptide 4 (51 mmole) was dissolved in 0.2 ml of 3/1 MeOH/H2O (v/v). In a 
separate vial, benzylamine (1.3 mmole) was dissolved in 0.1 ml of MeCN, followed by 
addition of NMM (1.0 mmole). The BA/NMM solution was introduced to the peptide 
solution, followed by addition of solid PyAOP (0.51 mmole) and anhydrous HOBt (0.56 
mmole). 0.1 ml of MeCN was introduced to improve the solubility of PyAOP/HOBt. The 
solution was incubated for a total of 4 h at RT. The peptide was purified using preparative 
HPLC. The organic solvent in the peptide fraction was removed via rotary 
evaporation. Aqueous remnants were frozen at -78 °C and lyophilized overnight. Purified 
yield: (15 mmole) 29%. High-res MS: found m/z 1441.71230, calcd 1441.71260 (M + H)+; 
found m/z 1439.69600, calcd 1439.69800 (M - H)-. 
Modification of the carboxylate side chains and C-terminus with 3-
dimethylaminopropylamine (6). Peptide 4 (11 mmole) was dissolved in 0.2 ml of dry 
DMF. DMAPA (1.6 mmole) and NMM (1.4 mmole) were combined in a separate vial. The 
amine/NMM solution was introduced to the peptide solution, followed by addition of solid 
PyAOP (1.9 mmole). The solution was incubated for 24 h at RT. The sample was placed 
in a centrifugal evaporator for 21 h at 35 1 °C. The resulting oil was dissolved in 1.5 ml of 
2/1 H2O/DMF (v/v), and purified by prep HPLC. The organic solvent in the peptide fraction 
was removed via rotary evaporation. Aqueous remnants were frozen at -78 °C and 
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lyophilized overnight. Purified yield: (2.4 mmole) 23%. High-res MS: found m/z 
1426.83900, calcd 1426.83920 (M + H)+.  
Modification of the carboxylate side chains and C-terminus with 
isobutylamine (7). Isobutylamine (60 mmole) and NMM (excess) were combined in a 
separate vial to make 0.1 ml solution in DMF. Amine/NMM solution was introduced to 
peptide 4 (20 mmole), followed by introduction of solid PyAOP. The solution was 
incubated for 3 h at RT, followed by quenching with 1 ml of H2O. The solution was placed 
in centrifugal evaporator for 14 h at 35 °C. The residual oil was dissolved in 1.5 ml of 1/1 
H2O/MeCN (v/v) and purified via prep HPLC. An impurity and the desired compound both 
eluted at the same time. The peptide was therefore taken directly to the subsequent 
modification of tryptophan without further purification. 
Modification of tryptophan in peptide 6 (8). Peptide 6 (19 mmole) was dissolved 
in 1 ml of glacial acetic acid, followed by introduction of 2,4-dinitrobenzenesulfenyl 
chloride (57 mmole). The reaction was shaken for 4 h at RT. Glacial acetic acid was 
removed by rotary evaporation. The residual film was dissolved in 1/1 MeCN/H2O (v/v), 
and purified via preparative HPLC. The organic solvent in the peptide fraction was 
removed via rotary evaporation. Aqueous remnants were frozen at  
-78 °C and lyophilized overnight. Purified yield: (6.4 mmole) 32%. High-res MS: found 
m/z 812.91050, calcd 812.91000 (M + 2H)2+; found m/z 1622.79650, calcd 1622.79810 (M 
- H)-. 
Modification of tryptophan in peptide 7 (9). Peptide 7 (6.2 mmole) was dissolved 
in 1 ml of glacial acetic acid, followed by introduction of 2,4-dinitrobenzenesulfenyl 
chloride (19 mmole). The reaction was shaken for 4 h at RT. The peptide was purified 
using preparative HPLC. The organic solvent in the peptide fraction was removed via 
rotary evaporator. Aqueous remnants were frozen at -78 1 °C and lyophilized overnight. 
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Purified yield: (6.4 mmole) 49%. High-res MS: found m/z 769.37050, calcd 769.37020 (M 
+ 2H)2+; found m/z 1535.71420, calcd 1535.71850 (M - H)-. 
2.4.5 Solid-Phase modification studies of KDYWE 
Before and after each modification step, the resin was washed with DMF and DCM 
(3 ml, 3 min, 3x). Resins were placed under high vacuum overnight before cleavage at each 
step. Cu(II)Ac (0.3 mmole) was dissolved in 3 ml 45/45/10 MeCN/H2O/ Pyr (v/v/v). The 
copper acetate solution was introduced to the dried resin and incubated for 4 h at RT to 
cleave peptide. This solution was removed from the resin and collected, followed by 
washing with 1/1 MeCN/H2O (v/v) (1 ml, 3 min, 3x); washes were collected. 
Modification of the lysine with 2-methoxy-4,5-dihydro-1Himidazole in 2. To 
the swollen resin (130 mg, 0.66 mmole g-1), 3 ml of a 200 mM solution of 2-methoxy-4,5-
dihydro-1H-imidazole in 7/2/1 MeOH/DIPEA/H2O (v/v/v) was added. The resin was 
incubated overnight at RT. 
Modification of the carboxylates and C-terminus (10). 1-Amino-3-butyne 
(0.61mmole) was dissolved in NMM (0.45mmole), and the mixture was diluted with 1ml 
of DMF. PyAOP (0.40 mmole) was separately dissolved in 2 ml DMF. The amine/NMM 
solution was introduced to the resin, followed by introduction of the PyAOP solution. The 
resin was incubated overnight at RT, followed by rinsing with MeOH (3 ml, 3min, 3x). 
The peptide was cleaved with 55 mmole of Cu(OAc)2, and the MeCN and Pyr were 
removed by rotary evaporation. The remaining aqueous solution was frozen at -78 °C and 
lyophilized overnight. The solid was dissolved in 1.5 ml of 1/1 MeCN/H2O (v/v) and 
purified by prep HPLC. The organic solvent in the peptide fraction was removed via rotary 
evaporation, and aqueous remnants were frozen at -78 °C and lyophilized overnight. 
Purified yield: (1.4 mmole) 2%. High-res MS: found m/z 910.45740, calcd 910.45700 (M 
+ H)+; found m/z 908.44300, calcd 908.44240 (M - H)-. 
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Tryptophan modification of immobilized peptide (11). Immobilized peptide 10 
was prepared as described using 193 mg of the same resin. 2,4-Dinitrobenzenesulfenyl 
chloride (0.30 mmole) was dissolved in 3 ml of glacial acetic acid. This solution was 
introduced to the swollen resin, and incubated for 4 h at RT. The solution was removed 
from the resin and 6 ml of DMF was passed through the resin. Cleavage of peptide 11 from 
hydrazinobenzoyl resin using H2O. Cleavage of the peptide was performed as described 
with copper acetate (0.3 mmole) dissolved in 3 ml of 45/45/10 MeCN/ H2O/Pyr (v/v/v). 
MeCN and pyr were removed by rotary evaporation, and the remaining aqueous solution 
was frozen at -78 °C and lyophilized overnight. The solid was dissolved in 1.5 ml of 1/1/ 
MeCN/H2O (v/v) and purified by prep HPLC. The organic solvent in the peptide fraction 
was removed via rotary evaporation. Aqueous remnants were frozen at  
-78 °C and lyophilized overnight. Purified yield: (5.4 mmole) 4%. High-res MS: found m/z 
1108.42840, calcd 1108.43050 (M + H)+; found m/z 1106.41400, calcd 1106.41600 (M - 
H)-. 
Cleavage of peptide 12 from hydrazinobenzoyl resin using 1-amino-3-butyne. 
Copper acetate (0.33 mmole) was dissolved in 3 ml of 9/8.3/1.6 MeCN/Pyr/1-amino-3-
butyne (v/v/v). Subsequently, the solution was introduced to swollen resin. The resin was 
incubated for 4 h at RT, followed by filtration to collect the solution, and the MeCN and 
pyridine were removed by rotary evaporation. Collected washes of the resin with DMF (3 
ml, 3 min, 3x) were used to improve the solubility of the peptide. The solvent was removed 
by centrifugal evaporation (35 °C, 24 h). The solid was dissolved in 1.5 ml of 1/1 MeCN/ 
H2O (v/v) and purified by prep HPLC. The organic solvent in the peptide fraction was 
removed via rotary evaporation and the aqueous remnants were frozen at -78 °C and 
lyophilized overnight. Purified yield: (5 mmole) 5%. High-res MS: found m/z 1159.47250, 
calcd 1159.47780 (M + H)+; found m/z 1157.46220, calcd 1157.46330 (M - H)-. 
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2.6 Experimental Characterization 
 




Preparation of Modifying Reagents 
 
2-Methoxy-4,5-dihydro-1H-imidazole was prepared following a literature protocol. 
(Peters EC, Horn DM, Tully DC, Brock A. A novel multifunctional modifying reagent for 
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enhanced protein characterization with mass spectrometry. Rapid Commun. Mass 
Spectrom. 2001; 15: 2387-2392.) 
 
1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl diethyl phosphate was 
prepared by dissolving of 2-(3-methylbutyryl)-5,5-dimethyl-1,3-cyclohexandione (17 
µmole) in 0.5 ml of dry MeCN under argon. Solution was placed in ice bath. DIPEA (20 
µmole) was introduced, followed by slow introduction of diethylchlorophosphate (22 
µmole). Reaction was stirred overnight at RT. Yield: quantitative. 1H NMR (500 MHz, 
Acetonitrile-d3) δ 4.12 (dq, J = 8.3, 7.1 Hz, 4H), 2.67 (d, J = 1.6 Hz, 2H), 2.45 (d, J = 6.8 
Hz, 2H), 2.26 (s, 2H), 2.09 – 2.00 (m, 1H), 1.30 – 1.27 (m, 6H), 1.06 (s, 6H), 0.89 (d, J = 
6.7 Hz, 6H). 13C NMR (126 MHz, cd3cn) δ 197.70, 164.75, 66.22, 66.17, 53.74, 51.03, 
42.23, 33.22, 28.06, 24.81, 22.92, 16.42, 16.37. HR-res MS: found m/z 383.15970, calcd. 
383.15940 (M+Na+)+; found m/z 359.16290, calcd. 359.16290 (M-H)- (Adapted from 
Zhang, H. A process for the preparation of the intermediate of β-methyl carbapenem. WO 
2007104219 A1, September 20, 2007.) 
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Figure 2.5: 1Proton NMR of 5,5-dimethyl-2-(3-methylbutanoyl)-3-oxocyclohex-1-en-1-yl 
diethyl phosphate (Phos-DOD). 
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Figure 2.6: 13Carbon NMR of phos-DOD.  
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Figure 2.8: 2-D NMR for phos-DOD. 2-D NMR for phos-DOD.(a) HMBC NMR of phos-
DOD. (b) Region shown demonstrated doublet attributed to position a in 
phos-DOD correlated with a carbon in the carbonyl region, instead of an 
alkene as shown in 1. 
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Figure 2.11.: HPLC trace for purified peptide 3. 
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Desalting of peptide 4 
 
Crude peptide was prepared for preparative HPLC using an Extract CleanTM C18 500 
mg /4 ml solid phase extraction column. Column was flushed with 6 ml of 90/10 
MeOH/H2O with 0.1% TFA (v/v/v) at a flow rate of 1 drop sec-1 (RT), followed by 
equilibration with 3 ml of 0.1% TFA in water (v/v) at a flow rate of 1 drop sec-1. Acidified 
peptide solution was loaded on the column 1 drop sec-1 (RT). Peptide was eluted with 1 ml 
5% MeOH/Water with 0.1% TFA (v/v/v). Residually bound peptide was eluted with 50/50 
































































































Figure 2.27: HPLC trace for purified peptide 12. 
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Chapter 3: Fluorescently Labeled Model Peptides for a New Single-
Molecule Peptide Sequencing Platform Using Edman Degradation and 
Total Internal Reflection Fluorescence (TIRF) Microscopy3 
3.1 INTRODUCTION 
 
3.1.1 Mass Spectrometry: Current Peptide Sequencing Approach and Limitations 
 
 Proteomics focuses on studying the structure and function of proteins.1, 2 
Understanding the proteins present in a cell at biological states is a key goal in the field. 
Knowing which proteins are expressed or under expressed at certain conditions allows for 
a more detailed description of an organism. Current technologies, such as mass 
spectrometry, have revolutionized the field by increasing the level of sensitivity and 
throughput when analyzing complex mixtures of protein digests. However, there are still 
limitations with this technology. One important barrier is the difficulty in resolving lower 
abundant proteins from more prevalent ones. Several biomarkers for diseases like prostate 
cancer or Alzheimer’s could be better detected if key proteins, which are found at smaller 
concentrations, can be identified.3, 4 
Mass spectrometry uses reverse-phase column separation methods to increase 
resolution. Yet, it does not guarantee that peptide digests reach the detector a single 
compound at a time. Short peptides (15-20 residues) with similar hydrophobic/hydrophilic 
content usually elute at similar times.5 For instance, if one lower-abundant peptide elutes 
closely to a more abundant one, the signal of the less prevalent peptide will be obscured. 
In addition, depending on the side chains present on a protein digest, some peptides will 
																																																						
3 Swaminathan, Jagannath†; Boulgakov, Alexander A.†; Hernandez, Erik T.†; Bardo, Angela M.†; Bachman, 
Logan; Johnson, Amber; Marotta, Joseph; Anslyn, Eric V.; Marcotte, Edward M. “Peptide Sequence 
Information can be Obtained at the Level of a Single Molecule.” Manuscript submitted to Nature 
Biotechnology. Prepared model peptides and surface chemistries. 
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inherently ionize more efficiently. A more efficient ionization of a peptide increases the 
signal intensity, and could exacerbate the ability to detect peptides if they lack residues that 
ionize.6 For example, peptides rich in arginine, histidine, or lysine can be protonated 
forming a positive charge.7 Peptides with these residues will be observed more readily in 
the positive mode than those without them. So, if a peptide at smaller concentrations that 
elutes closely with a more abundant peptide and if both these peptides do not ionize well, 
observing the less concentrated peptide becomes less likely. Efforts have been made to 
improve ionization of peptides by chemical modifications of proteins, enrichment 
protocols, and instrument tuning, but these approaches add to the time required for sample 
preparation and the amount of sample needed.8 
3.1.2 Higher Sensitivity Required 
 A more effective technique is required for observing less abundant proteins. 
Although mass spectrometry can detect at picamole concentrations, issues that arise with 
complex mixtures and ionization efficiencies obstruct that sensitivity. Therefore, new 
sequencing platforms that can overcome these challenges are needed to improve upon the 
current effective sensitivity available. The Marcotte group at the University of Texas at 
Austin has been working on a new platform that seeks to solve current challenges in 
peptide/protein sequencing.9 
3.1.3 Single-Molecule DNA Sequencing 
 Unlike next-generation DNA sequencing technologies, which increased the 
throughput and level of detection for identifying oligonucleotides, protein sequencing did 
not experience the same technology advancement. In the early 2000’s, several technologies 
emerged aimed at improving from the Sanger method for sequencing DNA.10, 11 One such 
method was based on based single-stranded DNA (ssDNA) and the detection of the 
complementary strand using Förster Resonance Energy Transfer (FRET).12 Other 
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technologies took advantage of DNA polymerase and fluorescently labeled 
oligonucleotides. Total Internal Reflection Fluorescence (TIRF) microscopy was used for 
ssDNA immobilized on a glass surface. As the DNA polymerase incorporated a 
fluorescently labeled base, the emission associated with one of the bases was detected. The 
read out was a series of fluorescence emissions that coupled together to provide a sequence 
of the ssDNA.13, 14 Many of these technologies rely on the use of fluorescent probes and 
imaging technologies to identify sequences.15 The use of TIRF microscopy and fluorescent 
probes serves as the inspiration for the protein/peptide-sequencing platform presented in 
this work. 
3.1.4 Marcotte Single-Molecule Protein Sequencing (Marcotte Sequencing) 
 TIRF microscopy provides a level of sensitivity that exceeds mass spectrometry. 
This increased sensitivity is due to the TIRF platform using an evanescent wave of 
electromagnetic energy that radiates from the interphase between the glass slip and oil-
phase. Only molecules within 200 nm from the interphase will only be excited. Thus, any 
fluorescent impurities that may be found in the bulk solution do not interfere with the 
compounds to be sequenced. Unlike DNA proteins do not have the machinery available to 
amplify the sequence, limiting the ability to improve signal detection by amplifications like 
PCR. Therefore, in order to extract sequence information, biochemists have traditionally 
relied on Edman degradation (Figure 3.1). This chemistry removes the N-terminal amino 
acid residue in a step-wise fashion. Usually, reverse-phase separation and detection of 
elution times by UV-Vis is required to identify the residue removed. This method for 
sequencing proteins predated the use of mass spectrometry, and like mass spectrometry 





Figure 3.1: Edman Degradation Cycle. Only-N-terminal amino acid is removed. (Image 
credit: Angela M. Bardo (Marcotte). 
 
 Edman degradation combined with TIRF microscopy is the pivotal feature of the 
Marcotte sequencing platform. As described in Figure 3.2, the overall aim is to extract 
proteins from a sample: tissue, blood, saliva, etc. The proteins will be digested using site-
specific proteases. These peptide digests will be labeled with amino acid-residue specific 
fluorophores from the side-chain selective functional handles described in Chapter 2. After 
being labeled, these peptides will be immobilized by covalent attachment on a glass slip. 
Edman degradation will be performed on these peptides. The loss of fluorescence 
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Figure 3.2: Schematic for the overall goal for the Marcotte sequencing approach. (Image 
credit: Angel Syrett).9 
 
intensity after these degradation cycles (Edman cycles) will be monitored. For every 
residue labeled, a different emission wavelength will be monitored. When the intensity for 
a particular wavelength is observed, the identity along with the position of an amino acid 
can be determined, resulting in a partial sequence. 
 This partial sequence can be searched against protein databases to assign the protein 
origin of the peptide fragment. Since this is a single-molecule technique, this approach is 
order of magnitudes more sensitive than mass spectrometry, because it is a single-molecule 
approach. Furthermore, the technology described is also a massively parallel approach, 





Figure 3.3: Fluorescently labeled peptides on a glass surface. Yellow spots are gold 
nanorods that serve as fudicial markers. Magenta spots are peptides visible in 
the red channel. Cyan spots are a peptide visible in the red channel. This figure 
is a composite of 4000 fields stitched together containing 1.7 million spots. 
(Image credit: Jagannath Swaminathan (Marcotte)) 
 
3.1.5 Theoretical Justification for Marcotte Sequencing 
 The Marcotte group recently published work explaining the justification for this 
approach.9 In the most ideal case, 98% of the human proteome is possible within ten Edman 
cycles. This high coverage was possible despite not labeling all naturally occurring 
residues. Factors, such as choice of side chains to label, site-specific cleavage, and 
anchoring of the peptide on the glass cover slip also play an important role when identifying 
a protein. Even introducing errors introduced into the modeling, such as inefficient Edman 
degradation, blinking events, and photobleaching, reasonable coverage of the human 









Figure 3.4: Ideal coverage of the human proteome under different cleavage conditions, 
peptide immobilization anchoring points, and side chains targeted. (Image 
credit: Alexander M. Boulgakov (Marcotte)).9 
 
3.1.6 Competing Single-Molecule Protein Sequencing Approaches 
 Other groups are currently working on their version of single-molecule protein 
sequencing, most notably the Joo group at the Delft University of Technology. Theoretical 
work justifying their technology was recently published.17 Their approach focuses on the 
translocation of fluorescently labeled proteins through a fluorescently labeled nanopore. 
FRET occurs as the labeled side chain exits the pore, and this event is used to identify the 
residue and its position along the protein. Unlike Marcotte sequencing, there is no need to 
digest the proteins, but the method does rely on the labeling of cysteine and lysine residues, 
as described in Chapter 1. In addition, the Joo approach to sequencing lacks the massively 
parallelize component emphasized in this work. Despite these limitations, this alternative 
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technology is also seen as a strong contender in the demand for new protein sequencing 
technologies. 
3.1.7 Model Peptides Required for Sequencing 
 In this chapter, the design, synthesis, and sequencing of fluorescently labeled model 
peptides for proof-of-concept studies is described. First, peptides used for sequencing in 
bulk fluorescence experiments were made to evaluate if Edman degradation chemistry was 
possible in the presence of sterically large side chains. A screening process for dyes that 
survive the stringent conditions of the Emdan cycles was performed to identify robust 
fluorophores. Different fluorophores appended to peptides were synthesized, and 
tetramethyl rhodamine (TMR) (Figure 3.5a) was the dye of choice due to its stability, 
relative inexpensiveness, and ease to use during synthesis. After completing these bulk 
studies, peptides for single molecule sequencing were required. Atto 647N (Figure 3.5b) 
labeled peptides were preferred due to improve signal to noise and photostability relative 
to TMR. Natural peptides were synthesized to demonstrate that proteins in nature can be 
labeled, and a partial sequence can be derived from Marcotte sequencing, followed by 
mapping that partial sequence back to its protein origin.  A synthetic digest of insulin, 
simulating cleavage with Glu-C, was made and labeled with Atto 647N.  Also, 
Somatostatin-14 and a cellulomonas peptide fragment were made to demonstrate that 
enough sequence information was available to identify uniquely the protein origin for these 
simple and naturally occurring peptides. Currently, modification of recombinant insulin is 
being pursued as our first protein target to sequence using this platform. 
 Finally, in our efforts to find suitable dyes for Edman degradation, a silicone-based 




Figure 3.5: Rhodamine Dyes. a) Tetramethyl Rhodamine (TMR). b) Atto 647 N in both 
NHS and iodacetamide form. 
 
dye was used to modify the N-termini of model peptides for binding studies of peptides to 
DNA. 
3.2 Results and Discussion 
3.2.1 Description of Instrumentation and Data Analysis 
 The microscopy, flow cell, fluidic/pump solvent delivery, automation, and image 
data analysis was developed by the Marcotte group (Figure 3.6).17 Collaboration with the 
Anslyn group was geared towards labeling peptides with fluorescent probes and 
optimization of surface Edman degradation chemistries. For model studies, peptides were 
immobilized at the C-terminus on an amino-silane coated glass surface via amide coupling. 
A four-wavelength laser source was used to excite at four distinct wavelengths. Peptides 
attached on the surface of the glass were excited by the evanescent wave of energy emitted 
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camera and were represented as small white dots on a screen. Each white spot represented 




Figure 3.6: Marcotte Sequencing Platform. a) Fluidic pumps that dispense Edman 
degradation reagents and reactants. b) Flow cell composed of organic 
compound resistant materials. c) Glass slipcover functionalized with amino 
silanes. Peptide immobilization and Edman degradation occurs here. d) The 
inverted objective used to focus laser light and collect fluorescence emission 
captured by the camera. (Image credit: Jagannath Swaminathan) 
 
 Initially, phenyl isothiocynate (PITC) was omitted to perform three “mock” Edman 
cycles. These cycles were controls for fluorescence loss due to solvents and bases used for 
degradation. These cycles also helped to remove any fluorescent impurities and non-
specifically bound peptide at the surface. After these mock runs, Edman cycles were 
performed as required to go through the model peptide. Images were taken after each cycle 
to monitor fluorescence loss. Once  the experiment was completed, these images were 
aligned against inert reference points, such as gold nanoparticles located at the surface, to 
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ensure the same spot was correctly identified for each cycle. Once the images were aligned 
properly, the data analysis tracked the changes in fluorescence intensity for each spot. 
 Fluorescence intensity loss at different Edman cycles, is displayed as histograms 
(Figure 3.9) or heat maps (Figure 3.10). These plots counted the spots that experience 
significant fluorescence loss after an Edman cycle.  
3.2.2 Bulk Fluorescence Studies 
 Before performing single-molecule experiments, a bead assay was developed to test 
if sequencing was possible by Edman degradation and monitoring fluorescence loss. These 
studies were referred to as bulk studies, since individual molecules were not imaged. 
Instead, the fluorescence was observed on a tentagel polystyrene bead functionalized with 
amines. Model peptides were immobilized on the bead via the C-terminal end using EDC 
coupling conditions. Peptides 3.1-3.12 (SI) were synthesized for these preliminary studies. 
Similar to the description provided in section 3.2.1, beads were placed under a TIRF 
microscope and the fluorescence was imaged after each Edman cycle. Unlike section 3.2.1, 
Edman chemistry was performed manually with fritted syringes. Portions of the beads were 
removed and imaged after each degradation. 
3.2.3 N-terminal Protecting Group and Dye Selection for Bulk Fluorescence Studies 
 Initially, peptide 3.1 was synthesized for the bead assay. This peptide was made 
using a similar N-terminal protecting group from Chapter 1, known as 1-(4,4-Dimethyl-
2,6-dioxocyclohex-1-ylidene)-3-methylbutyl (ivDde). A Lys building block was 
commercially available with this protecting group. However, upon the deprotection of the 
N-terminus, with 2% vol. hydrazine in DMF, loss of fluorescence happened. Although 
characterization of the degraded fluorescent peptide was not performed, attack of the 1’ 
position on the TMR by the hydrazine was seen as a likely starting point. Attempts to 
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reverse this loss by acidifying the beads with TFA were not fruitful, suggesting conjugation 
of peptide may have been lost due to the hydrazine. 
 As an alternative, peptide 3.2 was synthesized with a boc protecting group with Rh. 
Rhodamine B was used to decrease the cost of making fluorescently labeled peptides; Rh 
B is available in larger quantities at a cheaper price. The dye was stable to TFA 
deprotection required for boc removal. Keeping concentrations consistent between Peptide 
3.1 and 3.2 when immobilizing peptide on the bead, peptide 3.2 consistently led to a less 
bright bead.  
 To improve brightness of peptides, peptides 3.3 and 3.4 were synthesized. Rh 101 
dyes are known for their higher quantum yields relative to TMR and other rhodamine- 
based dyes.18 Structural constraints of this fluorophore are due to the julolidine moiety 
present, which contributes to this dyes improved quantum yield. Again, despite the 
literature precedent for improved brightness, at similar concentration for bead 
immobilization, this peptide was not bright enough. An argument about the steric size of 
the peptides was hypothesized. Since these peptides were relatively short, and the steric 
size increased with Rh B and Rh 101, coupling efficiency contributed to decrease in the 
brightness of beads. 
 Since loss of fluorescence was caused by hydrazine, TMR was tested against TFA 
and piperidine. The dyes appeared to be stable after treatment with these solvents and 
considered suitable for removing boc or Fmoc protecting groups post immobilizing model 
peptides on beads. Therefore, Fmoc-K*A, Fmoc-GK*A and Fmoc-K*AK*A ( Peptides 
3.5-3.7 where * = TMR) were used for the bead assay. Fmoc was chosen as the protecting 
group, because the N-terminal amino acid can be left unprotected during solid-phase 
peptide synthesis. Placing the boc group would add an additional synthetic and purification 
step. 
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3.2.4 Bead Assay Results 
 As shown in Figure 3.8, peptides 3.5 -3.7 (SI; Fmoc-K*A, Fmoc-GK*A, and Fmoc-
K*AK*A, respectively, where * = TMR) were used to demonstrate the feasibility of 
sequencing by monitoring fluorescence loss after Edman degradation. These three peptides 
were synthesized to demonstrate degradation at the N-terminal position (first position), 
degradation at the second position, and degradation at the second and fourth position. The 
fluorescence data suggested peptides could be deprotected with piperidine with no adverse 
affect on the fluorophores. To control for fluorescence loss due to Edman degradation 
solvents, a mock cycle was performed. Fluorescence remained the same after this cycle. 
Fmoc-K*A after the first Edman cycle demonstrated fluorescence loss, and Fmoc-GK*A 
showed loss after the second Edman cycle. Fmoc-K*AK*A, losses were observed after the 
second and third Edman cycle. 
3.2.5 Solution-Phase Confirmation of Edman Degradation with Fluorescent Side 
Chains 
 After successfully completing these bead assays, solution-phase Edman 
degradation was performed as further proof that Edman occurred with sterically large, 
fluorescent side chains. Peptide 3.8 (SI) was synthesized and isolated as the uncyclized, 
thiourea intermediate before degradation, proving N-terminal modification was possible. 
The isolated peptide was subjected to a solution of TFA (90% vol. in H2O). The TFA was 
removed by rotary evaporation and remaining solution was submitted for high-resolution 
mass spectrometry (HRMS). The phenylthiohydantoin (PTH) derivative (peptide 3.8) was 
observed with the expected fluorescent side chain. These results served as further evidence 






Figure 3.7: Bead Peptide Sequencing Study. a) Histogram representation of cycles 
performed on peptides. b) Images taken after each cycle and respective radial 
fluorescence intensity profile across beads. (Image credit: Jagannath 
Swaminathan) 
 
3.2.6 Miscellaneous Fluorescent Peptides 
 Peptides 3.10-3.12 were synthesized taking into consideration what sequences can 
be used in future bead assays. For example, peptide 3.10 was synthesized to see if 
immobilization on amine surfaces was possible if cleavage of proteins were to be done 
with cyanogen bromide, which is site-specific for methionine.19 Thus, all peptides were 
terminated with a methionine. Exploring the stability of this residue at the C-terminus when 
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performing Edman degradation should be done. Stability studies are important since 
cleavage at this residue provided the best coverage of the human proteome.  
 Peptide 3.11 was synthesized implementing only solid-phase chemistries. The 
Anslyn group synthesized a boc-protected lysine building block with a RhB. The peptide 
had a free cysteine as an alternate cite for immobilization. However, due the dubious 
quality in the brightness of RhB, further exploration of this peptide was not pursued. 
  Finally, peptide 3.12 was designed as a preliminary attempt to begin sequencing 
peptides with unnatural side chain residues. 4-ethynylbenzohydrazide (compound provided 
by the Anslyn group) was clicked onto an azido lysine peptide in the solid-phase. Upon 
cleavage and isolation, the hydrazide peptide was labeled similarly to lysine residues. 
Efforts to sequence this unnatural peptide are ongoing. 
3.2.7 Smaller Scale Reactions 
 As experiments transitioned towards single-molecule sequencing, the need for Atto 
647 N peptides became more important. Relative to TMR, Atto 647 N demonstrated better 
photostability. Also, since this dye absorbed and emitted at longer wavelengths, fewer 
fluorescent impurities were observed, improving the signal to noise. Atto 647 N and its 
derivatives were synthetically challenging to make and expensive. Therefore, minimizing 
the starting material required to make model peptides was an important goal. During HPLC 
purification the peptide was readily detected at 0.1mg/mL concentrations. 
3.2.8 Atto 647 N Model Peptides Single-Molecule sequencing: Single Dye 
 Peptides 3.13 and 3.14 (boc-GK**AGAG and Ac-GK**AGAG, respectively, 
where ** = Atto 647N) were made to study sequencing of a peptide with a single dye. The 
peptide was labeled at the second position to ensure degradation was the cause for desired 
loss of fluorescence. In addition, glycine and alanine residues were selected to minimize 
any potential issues that arose from any steric hindrance from bulkier side chains. An 
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acetylated version of the GK**AGAG was synthesized to act as a control. The N-terminal 
amino acid was permanently protected degradation. This peptide was subjected to the same 
experimental run as the free amine peptide on a separate glass cover slip to take into 
account losses in fluorescence intensity due to boc-deprotection, non-specific solvent-
induced degradation, non-specific binding to glass surface, poor glass surface quality, 
photobleaching, and photoblinking events. Like the bead assays, both the sequence-capable 
peptide and the control peptide underwent a series of mock cycles as further controls to 
ensure true sequencing events were identified.  
 Shown in Figure 3.9 is a histogram of the peptides tracked over the sequencing run. 
After three mock cycles, only a small percentage of the peptides tracked had complete loss 
of fluorescence. Losses for Ac-GK**AGAG and GK**AGAG were the same. Once the 
first Edman cycle was performed, no appreciable loss was observed as expected. However, 
after the second Edman cycle, GK**AGAG had significant fluorescence loss. In contrast, 
the acytelated peptide had a loss of fluorescence similar to previous cycles. Two additional 
Edman cycles were performed to see if more significant losses occurred. GK**AGAG did 





Figure 3.8: Single-molecule sequencing results for peptides 3.13 and 3.14. (Image credit: 
Jagannath Swaminathan) 
 
3.2.9 Atto 647 N Model Peptides Single-Molecule sequencing: Two Dyes 
 Peptides with two dyes along the sequence were synthesized to study if two probes 
of the same fluorescence, incorporated into same peptide, could be resolved. Peptides 3.15 
and 3.16 (Boc-GC**AGC**AGAG and Ac- GC**AGC**AGAG, respectively, where ** 
= Atto 647 N) were synthesized to monitor if the thioether linkage was able to survive 
Edman degradation, and to facilitate the synthesis of model peptides using the chemistries 









Figure 3.9: Single-molecule sequencing results for peptides 3.15 and 3.16. (Image credit: 
Angela Bardo). 
 
 Figure 3.9 tallies the spots monitored over one mock and six Edman cycles. The 
number located at the intersection of E2 (first drop) and E5 (second drop) represents the 
number of spots with fluorescence losses that occurred at degradation cycles 2 and 5. In 
other words, after the fifth Edman cycle, of the total number of spots tracked throughout 
the experiment, 1568 were no longer observed. The same number of spots was observed 
after the second cycle, but at a lower intensity. As expected, the position on the heat map 
with the greatest intensity is at E2 and E5, showing that true sequencing events were 
observed. The results also demonstrated that losses at other junctures could be identified. 
The sequence heat map for Ac-GC**AGC**AGAG also showed losses in fluorescence 
intensity. However, the number of fluorescence loss compared to GC**AGC**AGAG are 
still fewer, suggesting inefficiencies in Edman degradation also misidentified sequencing 









events. Despite these issues, the Marcotte platform was able to identify the sequence of a 
doubly labeled model peptide. 
3.2.10 Future Sequencing Studies: Spacing Limitation for Fluorescently Labeled Side 
Chains 
Peptides 3.17-3.31 (SI) were synthesized as future models to explore the ability of 
this sequencing platform. For example, peptides 3.17-3.18 will be used for determining at 
what distance fluorophores on doubly labeled peptides can be distinguished. These include 
a peptide with two adjacent fluorescently labeled peptides (peptide 3.17) and one with two 
residues spaced between labeled side chains (peptide 3.18). 
3.2.11 Future Sequencing Studies: Naturally Occurring Peptides 
 Peptides 3.20-3.21 were synthesized to simulate Somatostatin-14 (peptide 3.20) 
and a peptide found in the bacteria cellulomonas.  Somatostatin-14 contains two cysteine 
residues and two lysine residues. However, cysteine was not labeled with a fluorescent 
probe, because models showed that it can still be identified uniquely against the human 
proteome with only Lysine residues labeled.  
3.2.12 Future Sequencing Studies: Synthetic Insulin Digests 
 Peptides 3.22-3.29 were synthesized to simulate insulin digested with Glu-C, which 
cleaves specifically after carboxylate residues, and resulted in 6 peptide fragments. Four 
can be labeled with iodoacetamide dyes (Figure 3.11). Along with their acetylated 
counterparts, these peptides will be used to determine if insulin can be uniquely identified 




Figure 3.10: Insulin (ins) fragments post Glu-C digestion. From chains A and B, four 
peptides can be labeled at cysteine. Each peptide gives a unique partial 
sequence which can be uniquely identified to insulin when searched against 
the human proteome.20  
 
3.2.13 Labeling of Cysteine Residues in Recombinant Human Insulin 
 The ultimate application for the Marcotte sequencing technology will be to identify 
proteins and peptides from biological samples. Thus, our focus is aimed towards 
recombinant insulin. This serves as a next step in labeling studies inching closer to our 
ability to label protein and peptide mixtures with fluorophores. Insulin was selected 
because of its commercial availability and cost. 
 In our efforts to digest insulin, reduction of the disulfide bonds joining chains A 
and B was performed by addition of TCEP. Insulin was difficult to dissolve at the 
concentrations used, but it was possible with 14 N NH4OH. The stoichiometry of the 
reducing agent was also controlled during reduction, three equivalents for each disulfide 
bond present. Excess TCEP would react with the iodoacetamide dye introduced. TMR was 
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used instead of Atto 647 N because of the cheaper cost. In future studies, chemistries to 
optimize the labeling of insulin with Atto 647 N will be pursued. 
 HPLC purification was first attempted to isolate the peptides from the hydrolyzed 
dye. The run proved unsuccessful since colored fractions did not contain desired products. 
The samples were difficult to isolate, because the peptides were quite large and 
hydrophobic. These two factors contributed to the difficulty in solubilizing modified 
compounds in aqueous mixtures. Sodium dodecyl sulfate (SDS) was used to promote 
solubility prior to purification. Product also was filtered from the solution when passed 
through a 0.2 micron syringe filter. Washes with H2O and MeCN did not entirely remove 
chains A and B. Peptides were washed off using DCM. No further purification was 
attempted. The filtering unintentionally served as crude and effective means to remove 














Figure 3.12: Insulin Chain B labeled with TMR isolated by syringe filter. 
 
3.2.14 Digestion of TMR Labeled Insulin Fragments 
 After modification to the procedure, studies to see if peptides could be digested 
with bulky fluorescent probes were pursued. The labeled A and B chains were dissolved in 
a 1:1 MeCN:H2O aqueous mixture. Ammonium bicarbonate (100mM) was the buffer used 
to selectively cleave the glutamates residues.21 Glu-C was introduced and incubated at RT 
at 37 °C overnight, and submitted for LCMS. Fragments from chain B were seen more 
readily, because of protonatable sites such as histidine and smaller masses that increased 
the ionization efficiencies compared to the more hydrophobic, heavier insulin A fragments. 
















 Current aims will be to transition this labeling chemistry to Atto 647 N and 
digestion with Glu-C followed by sequencing of recombinant insulin. Obstacles include 
the hydrolysis of the dye, which happens more readily than TMR. Attempts to decrease the 
pH and increasing the amount of organic solvent for solubilizing are expected to mitigate 
hydrolysis. As with the TMR, labeling protein digests with Atto 647 N increased their 
hydrophobicity. Increasingly hydrophobic peptides create difficulty when trying to 
dissolve both Glu-C and peptides. Proteases, like Glu-C, at most tolerate 20% v MeCN. 
Solubility should be optimized when labeling before continuing to label mixtures of 
proteins. 
3.2.15 Silicone-based Rhodamine for N-Terminal Modification (Si-Rh) 
 During the screening of dyes, the Anslyn group provided a silicone-based 
Rhodamine (Si-Rh) dye as a cheaper alternative to Atto 647 N (Figure 13.15). 
Unfortunately, this Rhodamine dye was not stable to Edman degradation conditions. The 
Si-C bond was presumed to be too labile to the conditions required for sequencing. 








the dye.22 A series of peptides modified at the N-terminus incorporating Si-Rh were 
synthesized for binding studies to DNA. A general template was followed when 
synthesizing peptides: Si-Rh–DYKDDDDKXAXAXA, where X = one of the 20 naturally 
occurring amino acids. Changing the residue will help determine what sequences of DNA 
bind preferentially to these amino acids. DYKDDDDK, known as Flag Tag, was included 
as an anchoring point to isolate these peptides via antibodies. These experiments are 
ongoing and no data is available.23 
Conclusions 3.3 
 Single-molecule peptide sequencing studies were conducted by monitoring 
fluorescence loss of labeled peptides undergoing Edman degradation. Model peptides 
labeled with Rhodamine dyes were first synthesized to confirm that sequence information 
could be obtained by bulk fluorescence studies on beads. Atto 647 N peptides were 
subsequently synthesized for single-molecule proof-of-concept studies. Studies sequencing 
these model peptides are ongoing. Efforts are also directed to label insulin as the first 
protein target to be modified, digested, and immobilized on the Marcotte platform. Future 
directions will include the incorporation of two colors to differentiate between amino acid 
residues. From these studies, Si-Rh and was synthesized and incorporated to N-termini in 
peptides that will be used for DNA binding studies. 
3.4. Experimental 
3.4.1 General Materials 
For automated, Fmoc amino solid-phase peptide synthesis, Ala, Ile, Leu, Met, Phe, 
Pro, Val, Pbf (Arg), OtBu (Asp, Glu), Boc (Lys, Trp), tBu (Ser, Thr, Tyr), Trt (Asn, Cys, 
His), and ivDde-Lys(boc)-OH were purchased from Novabiochem (USA), AAPPTec 




ylidene)-N-ethylethanaminium was provided by James Logan Bachman from the Anslyn 
group. Fmoc-Ala-Wang resin (0.62 mmol g-1), Fmoc-Met-Wang resin (0.30 mmol g-1), 
Fmoc-Asp(OtBu)-Wang resin (0.69 mmole g-1), Fmoc-Gln-Wang resin (0.47 mmol g-1), 
Fmoc-Asn-Wang resin (0.57 mmol g-1), and Fmoc-Gly-Wang resin (0.62 mmol g-1)  were 
purchased from Novabiochem (USA) and P3 Biosystems. Other chemicals used for 
automated, solid-phase peptide synthesis were purchased from Fisher Scientific and 
Sigma-Aldrich. N,N′-Diisopropylcarbodiimide (DIC) and Oxyma and (ethyl 
cyano(hydroxyimino)acetate) was purchased from Chem-Impex.  N-hydroxy-succinimide 
tetramehtyl rhodamine (NHS-TMR), tetrmethylrhodamine-5-iodoacetamide dihydroiodide 
(5-TMRIA) was purchased from Pierce. Rhodamine B (RhB) and Rhodamine 101 (Rh101) 
were purchased from Sigma-Aldrich. N-(7-(dimethylamino)-10-(5-(((2,5-dioxopyrrolidin-
1-yl)oxy)carbonyl)-2-methylphenyl)-5,5-dimethyldibenzo[b,e]silin-3(5H)-ylidene)-N-
methylmethanaminium (Si-Rh) was provided by Anslyn group member James Logan 
Bachman. N-hydroxysuccinimide boc was purchased from ACROS organics. Boc 
anhydride was purchased from Fisher. Recombinant insulin, Tris-(2-
Carboxyethyl)phosphine, Hydrochloride (TCEP) was purchased from Sigma-Aldrich. 
3.4.2 General Instrumentation 
A Prelude peptide synthesizer (Protein Technologies, Inc.) was used for automated-
solid phase synthesis. For longer sequences, a Liberty Blue microwave peptide synthesizer 
was used for solid-phase peptide synthesis. Preparative HPLC purification of peptides was 
performed using an Agilent Zorbax SB-C18 Prep HT column 21.2 250 mm; 10 mL min1 , 
5–95% MeOH (0.1% FA) in 90 min. Analytical HPLC characterization of peptides was 
performed using an Agilent Zorbax column 4.6 250 mm; 1 mL min1 , 5–95% MeCN (0.1% 
TFA) in 35 min (RT). A Gemini C18 3.5 micron 2.1 50 mm was used for online separation; 
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0.7 mL min1 , 5–95% MeCN (0.1% formic acid) in 12 min (RT) for LCMS 
characterization. An Agilent Technologies 6530 Accurate Mass QTofLC/MS mass spectra 
of purified peptides. 
3.4.3 General Solid-Phase Model Peptide Synthesis 
Peptides were synthesized using their respective resin with sequential coupling of 
Nα-Fmoc-amino acid (0.1 M, 1.5 ml) in DMF in the presence of N,N,N,N-tetramethyl-O-
(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 0.15 M, 1.0 ml) and DIPEA 
(0.2 M, 0.5 ml) with a reaction time of 30 minutes at room temperature. A total of three 
repetitions were performed for each amino acid building block. DMF (3 ml, 3 min, 3x) and 
DCM (3 ml, 3 min, 3x) washes were done before each repetition.  After incorporation of 
the third amino acid, a 0.8 M LiCl wash step was performed after swelling with DCM (3 
ml, 3 min, 3x). Standard settings for Liberty Blue microwave peptide synthesizer were used 
to make longer peptides. Post synthesis, resins were washed with glacial AcOH (5 ml, 3x), 
DCM (5 ml, 3x), and MeOH (5 ml, 3x). The resins were placed under vacuum overnight. 
If cysteine was present, the peptide was cleaved using trifluoroacetic acid (TFA), 
triisopropylsilane (TIS), 1,2-ethanedithiol (EDT), and nanopure water (94 : 1.0 : 2.5 : 2.5), 
and precipitated with diethyl ether at 0 °C. No HPLC purification of the crude peptide was 
necessary. If cysteine was not present, TFA, TIS, and nanopure water were used (95 : 2.5 
: 2.5) to cleave peptides. 
Peptides labeled with hydrzinobenzoyl resins were first synthesized on the solid 
support as described previously. 100 mM (1.5 mL) dye of choice, 1.2 M of DIPEA (0.5 
mL), and 300 mM (1.0 mL) in DMF were introduced to resin. Afterwards, resin was 
washed and placed under vacuum. Copper acetate (0.33 mmole) was dissolved in 3 ml of 
9/8.3/1.6 MeCN/Pyr/1-amino-3-butyne (v/v/v). Subsequently, the solution was introduced 
to swollen resin. The resin was incubated for 4 h at RT, followed by filtration to collect the 
 89 
solution, and the MeCN and pyridine were removed by rotary evaporation. Crude product 
was purified via preparative HPLC. Organic solvent was removed via rotary evaporation, 
and aqueous remnants were frozen and lyophilized overnight at -70 °C. 
3.4.4 Labeling of N-terminal ivDde/Fmoc-protected peptides with Cysteine or  Lysine 
Residues 
 Peptides were dissolved in DMF 50-100 µL. To this solution, 50-100 µL of DIPEA 
was added. Iodoacetmaide (IAc) (for Cysteine) or N-hydroxysuccinimide (NHS) activated 
dye (for Lysine) was added to the solution and incubated at RT overnight. Compound was 
purified by preparative HPLC. Fractions were collected and organic solvent was removed 
by rotary evaporation. Aqueous remnant were collected and frozen. Sample was 
lyophilized overnight at -78 °C. 
3.4.5 Synthesis N-terminal boc-protected peptides with Cysteine or Lysine Residues. 
 Peptides were first modified with NHS-dyes as described in 4.4.4, followed by 
deprotection with introduction of piperidine (20% the volume of DMF present in reaction). 
Compound was purified and isolated by preparative HPLC and lyophilization. Purified 
peptide was dissolved in DMF 50-100 µL, followed by 50-100 µL of DIPEA. NHS-boc 
was introduced in 10 eqs. The solution was incubated overnight at RT overnight. Peptide 
was purified via preparative HPLC and lyophilization. 
3.4.6 Solid-phase N-terminal Labeling of Peptides with NHS-Si-Rh 
N-terminal protecting group for the last amino acid incorporated into the sequence 
was manually removed with piperidine (20% vol. in DMF, 3 mL, 3 min, 3 x). 57.5 mg of 
dye were dissolved in 1000 μL of DMF to make a 100 mM stock dye solution in DMF. 
100 μL of a 1.2 M DIPEA solution and 300 μL of stock dye solution were mixed with 20 
mg of resin overnight (16 hours) in the dark. Excess labeling solution was washed from the 
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resin with DMF until the filtrate ran clear. Resin was treated similarly as described in 4.4.3 
post solid-phase synthesis. Peptide was isolated via preparative HPLC and lyophilization. 
3.4.7 Acetylation of Peptides 
Peptides were generally acetylated at the N-terminus manually by introducing 2 mL 
of DCM, 1 mL of 1.2 M N-methyl morphiline, and 1 mL of boc anhydride to resin with a 
peptide with a deported N-terminus. Mixture was incubated at RT for 2 hrs, and the solution 
was removed. The resin was subjected to the same reaction conditions a second time. The 
resin was treated post-synthesis as described in 4.4.3. Alternatively, boc anhydride could 
be introduced to the peptide synthesizer and treated as an additional building block in the 
sequence. 
3.4.8 Labeling of Human Recombinant Insulin 
4 mg of recombinant insulin was dissolved in 500 µL of 14 N NH4OH, and 3 eqs. 
of TCEP were introduced into the solution. The solution was incubated at RT for 15 min. 
(5-TMRIA) was introduced at 6 eqs and incubated at RT for 3 hrs. Crude isolation of 
peptide was performed by passing solution through a Fisherbrand 13 mm syringe filter 
(0.22 µm, PVDF). 1000 µL of 1:1 H2O/MeCN was passed through filter, followed by 1000 
µL of DCM.  Organic solvent was removed by rotary evaporation. 
3.4.9 Glu-C Digestion TMR Labeled Chain A and Chain B 
Crude sample isolated from section 4.4.8 was dissolved in 500 µL of 1:1 
(H2O/MeCN). 2000 µL of an ammonium bicarbonate solution was introduced, followed 
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3.6 Experimental Characterization 
 





















Figure 3.16: (top) Analytical trace for peptide 3.1 at 254 nm; Retention time: 32.736 min. 










































































m/z: 845.42 (100.0%), 846.43 (51.9%), 847.43 (13.2%), 846.42 (2.2%), 847.43 (1.6%), 



















m/z: 847.44 (100.0%), 848.44 (51.9%), 849.45 (13.2%), 848.44 (2.2%), 849.44 (1.6%), 
850.45 (1.4%), 849.44 (1.2%) 
 
 































Figure 3.23: (top) Analytical trace for peptide 3.4 at 254 nm; Retention time: 29.92 min., 

































































































Figure 3.28: (top) Analytical trace for peptide 3.6 at 254 nm: Retention times: 27.81867 
min., 28.448 min. (bottom) Analytical trace at 550 nm; Retention time: 








































m/z: 732.32 (100.0%), 732.82 (89.8%), 733.32 (39.8%), 733.83 (10.8%), 732.82 (3.7%), 





























m/z: 1461.62 (100.0%), 1462.62 (89.8%), 1463.63 (39.8%), 1464.63 (10.8%), 1462.62 
(3.7%), 1463.62 (3.3%), 1463.62 (3.1%), 1464.63 (2.8%), 1465.63 (2.1%), 1464.62 





































Figure 3.31: (top) Analytical trace for peptide 3.8 at 254 nm; Retention time: 5.10933 
min., 18.03733 min., 23.52 min. (bottom) Analytical trace at 550 nm; 









































m/z: 832.39 (100.0%), 833.39 (49.8%), 834.39 (12.1%), 834.38 (4.5%), 833.38 (2.6%), 


















m/z: 416.70 (100.0%), 417.20 (49.8%), 417.70 (12.1%), 417.69 (4.5%), 417.19 (2.6%), 
418.20 (2.2%), 417.70 (1.3%), 417.70 (1.2%), 418.20 (1.1%) 
 
 















Figure 3.34: (top) Analytical trace for peptide 3.10 at 254 nm; Retention time: 32.416 min. 



































m/z: 745.35 (100.0%), 746.36 (46.5%), 747.36 (10.6%), 747.35 (4.5%), 746.35 (2.2%), 
748.35 (2.1%), 747.35 (1.0%) 
 
 


































m/z: 981.39 (100.0%), 982.39 (58.4%), 983.39 (16.7%), 983.38 (4.5%), 984.39 (2.6%), 
984.40 (2.3%), 982.38 (2.2%), 983.39 (2.1%), 983.39 (1.3%), 984.39 (1.2%) 
 
 





















m/z: 514.19 (100.0%), 514.69 (58.4%), 515.19 (16.7%), 515.18 (4.5%), 515.69 (2.6%), 


























Figure 3.39: (top) Analytical trace for peptide 3.12 at 254 nm; Retention time: 29.16267 























































Figure 3.42: (top) Analytical trace for peptide 3.13 at 254 nm; Retention time: 25.78133 




































(25.9%), 1186.48 (5.3%), 1184.47 (3.7%), 1185.47 (2.7%), 1185.47 (2.3%), 1186.48 






























m/z: 604.24 (100.0%), 604.74 (72.5%), 605.24 (25.9%), 605.74 (5.3%), 604.73 (3.7%), 
605.24 (2.7%), 605.24 (2.3%), 605.74 (1.6%), 606.24 (1.0%) 
 
 





























Figure 3.45: (top) Analytical trace for peptide 3.14 at 254 nm; Retention time: 30.61333 
min., 31.02933 min. (bottom) Analytical trace at 550 nm; Retention time: 









































m/z: 594.35 (100.0%), 594.85 (70.3%), 595.35 (24.3%), 595.85 (5.5%), 594.85 (3.7%), 










































































m/z: 1111.59 (100.0%), 1111.09 (77.0%), 1112.10 (32.9%), 1112.10 (31.4%), 1112.60 (22.1%), 1112.59 
(9.0%), 1113.10 (8.1%), 1112.09 (7.0%), 1112.09 (7.0%), 1111.59 (5.4%), 1112.60 (5.3%), 1112.59 (4.5%), 
1113.09 (3.0%), 1113.09 (2.8%), 1112.60 (2.3%), 1113.60 (2.1%), 1113.60 (2.0%), 1112.10 (1.9%), 
1112.09 (1.7%), 1112.09 (1.6%), 1111.60 (1.4%), 1112.60 (1.4%), 1113.10 (1.3%), 1111.59 (1.2%), 1113.10 




m/z: 1082.57 (100.0%), 1082.07 (79.0%), 1083.08 (62.7%), 1083.58 (16.8%), 1083.58 



















































Figure 3.49: (top) Analytical trace for peptide 3.17 at 254 nm; Retention times: 32.0933 
min., 32.24533 min. (bottom) Analytical trace at 640 nm; Retention times: 


































m/z: 1176.12 (100.0%), 1175.61 (74.0%), 1176.62 (67.1%), 1177.12 (21.1%), 1177.62 
(9.8%), 1177.11 (9.0%), 1177.12 (8.6%), 1176.61 (7.4%), 1176.61 (6.7%), 1177.62 
(6.1%), 1176.11 (5.5%), 1177.12 (5.0%), 1177.12 (4.3%), 1176.62 (3.2%), 1177.62 




















































m/z: 829.75 (100.0%), 829.42 (71.7%), 830.09 (69.2%), 830.42 (31.7%), 830.42 (9.0%), 
























































m/z: 803.08 (100.0%), 802.75 (73.4%), 803.41 (67.6%), 803.75 (23.1%), 804.08 (9.1%), 
803.75 (9.0%), 803.41 (8.1%), 803.75 (7.1%), 803.41 (6.6%), 803.08 (6.0%), 803.75 























































































m/z: 1017.86 (100.0%), 1018.19 (65.4%), 1017.52 (55.7%), 1018.53 (46.2%), 1018.19 (23.8%), 
1018.86 (16.7%), 1018.19 (9.6%), 1018.52 (9.0%), 1018.86 (6.6%), 1018.53 (6.5%), 1018.53 





































































m/z: 605.85 (100.0%), 606.10 (73.0%), 605.60 (68.0%), 606.35 (27.3%), 606.60 (12.7%), 606.35 
(7.9%), 606.10 (7.8%), 606.35 (5.7%), 605.84 (5.3%), 606.35 (4.5%), 606.60 (3.3%), 606.35 
(3.3%), 606.09 (3.1%), 606.85 (2.5%), 606.60 (2.4%), 606.10 (2.2%), 606.10 (2.1%), 606.60 















































m/z: 1338.66 (100.0%), 1339.66 (76.8%), 1340.67 (29.1%), 1341.67 (6.4%), 1340.66 
(4.5%), 1339.66 (4.1%), 1341.66 (3.5%), 1340.66 (2.8%), 1340.66 (2.7%), 1341.67 
(2.1%), 1342.67 (1.3%), 1342.66 (1.3%), 1341.66 (1.2%), 1339.67 (1.1%) 
 
 



























m/z: 1340.67 (100.0%), 1341.68 (76.8%), 1342.68 (29.1%), 1343.68 (6.4%), 1342.67 
(4.5%), 1341.67 (4.1%), 1343.67 (3.5%), 1342.68 (2.8%), 1342.68 (2.7%), 1343.68 

































m/z: 641.82 (100.0%), 642.32 (73.5%), 642.82 (26.6%), 643.33 (6.3%), 642.82 (4.5%), 
642.32 (3.7%), 643.32 (3.3%), 642.82 (3.0%), 642.82 (2.5%), 643.32 (1.8%), 643.82 









Figure 3.60: (top) Analytical trace for peptide 3.25 at 254 nm; Retention time: 30.41067 
















































































































m/z: 1859.00 (100.0%), 1858.50 (92.5%), 1859.50 (71.7%), 1857.99 (42.5%), 1860.00 












































































Figure 3.63: (top) Analytical trace for peptide 3.27 at 254 nm; Retention times: 29.504 
min., 29.952 min. (bottom) Analytical trace at 640 nm; Retention times: 







































m/z: 847.97 (100.0%), 848.47 (97.3%), 848.97 (42.8%), 849.47 (11.7%), 848.47 (4.8%), 








































m/z: 818.95 (100.0%), 819.45 (94.1%), 819.95 (42.8%), 820.45 (11.7%), 819.44 (4.8%), 











































Figure 3.66: (top) Analytical trace for peptide 3.29 at 254 nm; Retention times: 34.51733 
min., 35.08267 min. (bottom) Analytical trace at 640 nm; Retention times: 









































m/z: 771.08 (100.0%), 770.74 (79.7%), 771.41 (34.1%), 771.41 (28.1%), 771.75 
(21.4%), 771.41 (8.9%), 772.08 (7.4%), 771.08 (7.1%), 771.74 (5.5%), 771.75 (4.9%), 
771.74 (4.5%), 771.75 (4.2%), 771.41 (3.9%), 771.41 (3.6%), 772.08 (3.1%), 771.41 























































m/z: 751.73 (100.0%), 751.40 (81.8%), 752.06 (35.0%), 752.06 (25.6%), 752.40 























































Figure 3.69: (top) Analytical trace for peptide 3.31 at 254 nm. Retention times: 28.68267 
min., 28.992 min. (bottom) Analytical trace at 640 nm; Retention times: 




































m/z: 1156.11 (100.0%), 1155.61 (79.7%), 1156.61 (62.2%), 1157.12 (16.2%), 1157.12 
(9.3%), 1156.61 (8.9%), 1156.11 (7.1%), 1157.62 (5.3%), 1157.11 (4.9%), 1157.11 
(4.5%), 1156.61 (3.9%), 1156.61 (3.6%), 1157.62 (3.1%), 1157.11 (3.0%), 1157.61 
(2.8%), 1157.11 (2.5%), 1157.62 (2.5%), 1156.62 (1.9%), 1157.61 (1.9%), 1158.12 























































































































Figure 3.72: (top) Analytical trace for peptide 3.33 at 254 nm; Retention times: 19.57333 
min., 26.77333 min., 35.59467 min. (bottom) Analytical trace at 640 nm; 




















































































































Figure 3. 74: (top) Analytical trace for peptide 3.34 at 254 nm; Retention times: 21.866 
min., 21.952 min., 22.99733 min., 24.512 min., 25.792 min. (bottom) 









































































































Figure 3.76: (top) Analytical trace for peptide 3.35 at 254 nm. (bottom) Analytical trace at 















































































































Figure 3.78: (top) Analytical trace for peptide 3.36 at 254 nm; Retention time: 22.85867 






































































































Figure 3.80: (top) Analytical trace for peptide 3.37 at 254 nm. (bottom) Analytical trace 













































































































Figure 3.82: (top) Analytical trace for peptide 3.38 at 254 nm; Retention time: 19.91467 








































































































Figure 3.84: (top) Analytical trace for peptide 3.39 at 254 nm; Retention time: 22.96533 






































































































Figure 3.86: (top) Analytical trace for peptide 3.40 at 254 nm; Retention time: 20.16 min. 







































































































Figure 3.88: (top) Analytical trace for peptide 3.41 at 254 nm. (bottom) Analytical trace 

































































































Figure 3.90: (top) Analytical trace for peptide 3.42 at 254 nm. (bottom) Analytical trace 



































































































Figure 3.92: (top) Analytical trace for peptide 3.43 at 254 nm. (bottom) Analytical trace 











































































































Figure 3.94: (top) Analytical trace for peptide 3.44 at 254 nm; Retention time: 25.472 min. 








































































































Figure 3.96: (top) Analytical trace for peptide 3.45 at 254 nm. (bottom) Analytical trace 































































































Figure 3.98: (top) Analytical trace for peptide 3.46 at 254 nm; Retention time: 21.93067 


































































































Figure 3.100: (top) Analytical trace for peptide 3.47 at 254 nm; Retention times: 3.09333 
min., 19.53067 min., 26.79467 min., 35.56267 min. (bottom) Analytical 




































































































Figure 3.102: (top) Analytical trace for peptide 3.48 at 254 nm; Retention time: 3.70133 
min., 3.78667 min. (bottom) Analytical trace at 640 nm; Retention time: 







































































































Figure 3.104: (top) Analytical trace for peptide 3.49 at 254 nm; Retention time: 19.616 




































































































Figure 3.106: (top) Analytical trace for peptide 3.51 at 254 nm. (bottom) Analytical trace 











































































































Figure 3.108: (top) Analytical trace for peptide 3.52 at 254 nm. (bottom) Analytical trace 






































































































Figure 3.110: (top) Analytical trace for peptide 3.53 at 254 nm. (bottom) Analytical trace 


























































































Figure 3.112: (top) Analytical trace for peptide 3.54 at 254 nm; Retention time: 24.05333 
























































































Figure 3.114: (top) Analytical trace for peptide 3.55 at 254 nm; Retention times: 
21.26933 min., 22.85867 min. (bottom) Analytical trace at 640 nm; 
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Chapter 4: An Efficient Methodology to Introduce o-




4.1.1 Need for Facile Incorporation of o-(aminomethyl)phenyl-boronic Acids into 
Peptides 
Boronic acid containing compounds continue to gain interest in the areas of 
chemosensing, materials chemistry, fluorescence imaging, mass spectrometry, and 
biomedical engineering.1-22 From the sensing of sugars to the formation of dynamic 
covalent structures, or serving as probes for the enrichment of analytes, boronic acid 
compounds are seen as an important organic moiety for developing novel analytical and in 
vivo applications. Continued growth in the biological sciences has sparked interest for 
synthesizing boronic acid containing peptides. These are attractive synthetic targets 
because peptides are versatile platforms for incorporating binding specificity to a target of 
interest. Boronic acid peptides could also be used in the design of combinatorial libraries. 
A method for incorporating a boronic acid into the side chains at controllable positions 
increases the diversity of compounds accessible. 
4.1.2 Current Approaches to Incorporate Boronic Acids into Peptides 
Common approaches for synthesizing boronic acid containing peptides include the 
use of building blocks with a boronate ester side chain, amidation of boronic acid 
compounds, or reductive amination of residues with 2-formylphenyl boronic acid.23-31 The 
most common approach is incorporating a building block during solid-phase synthesis. 
																																																						
4 Hernandez, Erik; Kolesnichenko, Igor; Reuther, James F. “Secondary-Amine Introduction to Peptides 
and Subsequent Derivatization with 2-(Bromomethyl)phenylboronic acid.” New Journal of Chemistry. 2017, 
41, 126-133. Designed and synthesized peptides demonstrating chemistries to append boronic acids. 
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However, long synthetic routes to non-commercially available boronic acid reactants are 
required (Figure 4.1a). To derivatize the C-terminus, amidation of amino boronic acids  
is usually used (Figure 4.1b). Peptides with aspartates or glutamates have to be avoided. If 
carboxylate side chains are used, no site-	 specific reactivity can be achieved.  Such a 
limitation decreases the diversity of peptides available. Lastly, reductive amination, 





Figure 4.1: Boronic Acids. a) Synthesized building block. Requires a total of five synthetic 
steps. b) Boronate ester moieties introduced at the C-terminus via coupling 
conditions. c) Polypeptide with ortho-aminomethyl boronic acid, synthesized 
by reductive amination of 2-formylphenyl boronic acid. 
 
4.1.3 Limitations with Current Approaches 
Most boronic acids do not bind saccharides efficiently at neutral pH. While electron 
withdrawing groups on the phenyl ring, such as in m-nitrophenylboronic acid, can act to 
promote boronate ester formation at neutral pH, the most common structural feature that 
promotes binding is an o-aminomethyl group.32, 33 This structural feature is often 
overlooked when incorporating a boronic acid into a receptor meant to be used in a 
biological setting. The only previously published strategy that allows for easy 


































be feasible to incorporate the o-aminomethyl moiety into an amino acid building block in 
advance of peptide synthesis, but this would further increase the number of synthetic steps. 
The methods we present in this paper were devised to be synthetically simple and afford 
the critical o-aminomethyl group. 
4.1.4 Scientific Aim: Use Alkylation Strategies and Secondary Amines to Incorporate 
o-(aminomethyl)phenyl-boronic Acids 
To increase the number of targetable sites on peptides while minimizing the 
difficulty and time required to synthesize o-(aminomethyl)phenylboronic acid building 
blocks, we developed chemistries for functionalizing peptides with secondary amines. 
Primary amines are present in the side chains of natural amino acids such as lysine. 
However, alkylation of primary amines typically suffers from over-alkylation. If secondary 
amines residues are present, then alkylation approaches become a viable alternative. The 
commercial availability of o-(bromomethyl) phenylboronic acid is an additional benefit to 
an alkylation approach.  
Herein, we report three methods that introduce secondary amines and subsequent 
o-(aminomethyl) phenylboronic acids to peptides. The methods include both solid-phase 
and solution-phase approaches. The first approach was the selective modification of 
cysteine residues in solution using an iodoacetamide linker with a boc-protected secondary 
amine. In the second approach, a cysteamine resin and an azido lysine building block was 
used in the solid-phase synthesis of peptides with a secondary amine. The third approach, 
using the commercially available Nε-methyl lysine, was the most direct way for making 
our desired peptides. Once a secondary amine was incorporated, a reaction with o-
(bromomethyl)phenylboronic acid afforded the o-aminomethyl moiety on all our peptides.  
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Finally, to demonstrate the usefulness of our chemistry for making complex 
structures, seven peptides containing Nε-methyl lysine amino acids and derivatized at the 
N-terminus with a pegylated biotin were synthesized. 
 
4.2. Strategies to Incorporate Secondary Amines into Peptides 
4.2.1 Solution-Phase Incorporation of Secondary Amines and Alkylation 
 To first test if an alkylation strategy would be successful, N, N’-
dimethylethylenediamine (DMEDA) was used as a model (Scheme 4.1). The alkylation 
occurred with a purified yield of 16% (1). As is well recognized by the boronic acid 
community34, boronic acids are notoriously difficult to isolate in pure form due to streaking 
on almost all chromatographic methods. Due to this, pinacol-protected boronate esters are 
more commonly used due to ease of handling and isolation of boronic acid compounds. 
However, the reaction conditions needed for deprotection of the boronic ester were 
considered to be too harsh for peptides, and thus unprotected boronic acids were chosen.  
Irrespective of the low yield of this model reaction we pushed forward with peptide 
derivatization because of the ease of the technique. Mass spectrometry and 1H- NMR 
confirmed the presence of the desired product. The mass spectra of this product and many 


















 After successful functionalization of DMEDA as a proof of concept experiment, 
we set out to devise a linker approach to place secondary amines on peptides. Cysteine 
residues are reported to be selectively modified with iodoacetamides, therefore a linker 
with this functional handle provided a method for selectively introducing a secondary 
amine.35 The synthesis of this linker involved a single Boc protection of DMEDA (Scheme 
4.2). Literature accounts regularly describe mono-protection with diamine compounds by 
using an excess of the amino compound relative to boc-anhydride..36 A mixture of products 
was observed: unreacted starting material, singly protected product, and doubly protected 
product. Aqueous washes removed unreacted starting material. No further purification was 
performed because the doubly protected product was inert in the following step. Mono-boc 
DMEDA was modified with chloroacetyl chloride, and the desired product was isolated. A 
Finklestein reaction afforded iodoacetamide linker 4.2. Once made, cysteine in Fmoc-
CysAla-OH was modified with the linker (Scheme 4.3). Deprotection with TFA solution 
occurred quantitatively, followed by alkylation with o-(bromomethyl)phenylboronic acid 
(BMPBA)(4.3). Linker 2 should prove widely useful to selectively modify peptides with 






















Scheme 4.3: a) MeCN, MeOH, TEA, Pyr, H2O, RT, 4 hrs. b) TFA, TIS, H2O, RT, 4hrs. 
c) MeCN, H2O, RT, overnight. 
 
4.2.2 Solid-phase Incorporation of Secondary Amines and Alkylation  
To expand the utility of the alkylation approach, we sought to develop solid-phase 
reactions for the incorporation of secondary amines. A cysteamine resin and an azido lysine 
building block also allowed incorporation of a secondary amine (Scheme 4.4). The 
unnatural azido residue can be modified via click chemistry while immobilized on the solid 
support.37 We used N-methyl propargylamine (NMPA) to click on a secondary amine. To 
ensure the Fmoc protecting group did not get deprotected by the basic amine, repetitions 
of the click reaction were performed. Three one-hour repetitions were the maximum 






















































Scheme 4.4: Synthesis of compound 4. a) DMF, CuI, TBTA, Sodium Ascorbate, RT, 1 
hr. (3 repetitions). b) MeCN, H2O, overnight. c) TFA, TIS, H2O, RT, 4 hrs. 
 
   Interestingly, Wang resin did not yield the desired product. However, “clicking” 
did occur with a cysteamine resin. Upon cleavage, the product (4.4) contained a thiol 
functional group as the c-terminus, which could be used for solution-phase derivatization 
if desired. 
4.2.3 Building-block Incorporation of Secondary Amines and Alkylation 
Using commercially available and synthetically accessible Nε-methyl lysine as a 
building block proved to be the most straightforward method for introducing secondary 
amines. This building block ensured the placement of multiple secondary amines along a 
sequence with high reliability. Fmoc-Lys(Nε, Me)A-OH gave the highest purified yield 
(60%; Scheme 4.5). Only a single modification step post-solid phase synthesis was 


















































at each reaction step in the former two approaches. Using this approach, seven complex 




Scheme 4.5: Synthesis of compound 6. a) DMF, DIPEA, RT, 2 hrs (2 repetitions) b) 
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 Of the seven biotinylated peptides, 9 had the highest purified yield (45%). The 
purified yields of peptides with two or three boronic acids ranged from 8%-22%. We 
attributed the lower yield to the more difficult purification with increasing number of 
boronic acids on a peptide due to streaking in the purification steps. 
The HPLC analytical trace for 9 gave a relatively sharp peak as the product eluted. 
However, when two or three boronic side chains were present, the elution peak was 
broadened, suggesting again that the phenyl boronic acid moieties interact with the column. 
Higher percentages of organic solvent were needed to elute the peptide. The broadening of 
the elution peak led to low signal intensity during HPLC purification. This broadening led 
to a low signal intensity during HPLC purification, which made identification of the peaks 
challenging, and hence poor detection of sample elution was hypothesized to contribute to 
the lower yields for peptides with more than one boronic acid.  
4.3 Conclusions 
 We developed three different approaches for derivatizing peptides with secondary 
amines, followed by modification with o-(bromomethyl)phenylboronic acid. Unlike most 
previously published methods for incorporation of boronic acids into peptides, this 
alkylation strategy allows for easy incorporation of an o-aminomethyl functionality on the 
aryl boronic acid, which has been previously shown to increase binding affinity of boronic 
acids to saccharides. The first approach involved the synthesis of a linker with an 
iodoacetamide at one side and boc protected secondary amine on the other end. Cysteine 
residues were selectively targeted in a model peptide. After deprotection, the secondary 
amine was alkylated with a boronic acid. In the second approach, N-methyl propargyl 
amine was used in click chemistry to introduce secondary amines followed by alkylation 
with a boronic acid in the solid phase. Post cleavage, a boronic acid peptide with a C-
terminal thiol group was isolated. Lastly, the commercially available Nε-methyl lysine 
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building block was used as the most direct method for making boronic acid peptides. It 
gave the highest yield and was the method of choice to make a set of seven biotinylated 
peptides. These peptides had up to three boronic acids, although purification became 
difficult and the associated yields decreased with increasing numbers of boronic acids.  
 
Compound Sequence Yield 
4.6 RTRX2LX2FX2Y 7.5% 
4.7 RTRX2LX2FGY 11% 
4.8 RTRX2LGFX2Y 19% 
4.9 RTRX2LGFGY 45% 
4.10 GTGX2LX2FX2Y 25% 
4.11 RTLX2RX2FX2Y 17% 
4.12 RTFX2LX2RX2Y 22% 
 
Table 4.1: Biotinylated peptide library sequences and yields. PEG4-Biotin was placed on 
the N-terminus. X2 = -CH2CH2CH2CH2(NH(CH3)(CH2C6H6B(OH)2)) 
 
Compounds such as 4.6 – 4.12 are currently being investigated as pull-down 
reagents for cell-surface saccharides. Due to the utility of the synthetic methodologies we 
report herein we anticipate that others can adopt them for site-specific incorporation of 
boronic acids in peptides and proteins. 
4.4 Experimental 
4.4.1 General Materials 
 For automated Fmoc amino solid-phase peptide synthesis, Ala, Pbf (Arg), Trt 
(Cys), Gly, Leu, Boc (Lys), Phe, and Boc (Thr) were purchased from P3 biosystems. Fmoc-
Lys(Nε, Me)-OH was purchased from Chem. Pep. Inc. Fmoc-Lys(N3)-OH was purchased 
from Chem-Impex, Inc. Cysteamine 2-ClTrt (0.95 mmol/g) resin and Fmoc-Tyr(tBu)-
Wang resin (0.46 mmol/g) were purchased from AnaSpec, Inc. Fmoc-Ala-Wang (100-200 
mesh, 0.72 mmol/g) was purchased NovaBiochem. DMF, DCM, piperidine used for 
automated solid-phase peptide synthesis were purchased from Fisher Scientific and Sigma-
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Aldrich. N, N’-dimethylethylenediamine, chloroacetyl chloride, and sodium iodide, N-
methyl propargyl amine, copper iodide, and sodium ascorbate were purchased from Sigma-
Aldrich. o-(bromomethyl) phenylboronic acid was purchased from Combi-Blocks. EZ-
LinkTM NHS-PEG4-Biotin was purchased from Thermo Scientific. 
4.4.2 General Instrumentation 
 A Prelude peptide synthesizer (Protein Technologies, Inc.) was used for automated-
solid phase synthesis of the peptides. For the longer peptides, a Liberty Blue microwave 
peptide synthesizer was used. Preparative HPLC purification of peptides was performed 
using an Agilent Zorbax SB-C18 Prep HT column 21.2 x 250 mm. Analytical HPLC 
characterization of peptides was performed using an Agilent Zorbax column 4.6 x 250 mm; 
1 ml/min., 5-95% MeCN (0.1 % TFA) in 35 min. (RT). A Gemini C18 3.5 micron 2.1 x 50 
mm was used for online separation; 0.7 ml/min., 5-95% MeCN (0.1 % formic acid) in 12 
min. (RT). An Agilent Technologies 6530 Accurate Mass QTofLC/MS was used for high-
resolution mass spectra of purified peptides. Solvents used were HPLC grade. For small 
molecule organic compounds, reverse-phase combi-flash was used for purification if 
necessary. 
4.4.3 General Procedure (A): synthesis of Dimeric Peptides and Nε-methyl Lysine 
Peptides 
 Fmoc-CysAla-Wang resin, Fmoc-Lys(N3)Ala-S-Resin, Fmoc- Lys(Nε, Me)Ala-
Wang, and biotinylated Nε-methyl lysine peptides resin (100 μmol) were synthesized by 
automated sequential coupling of Nα-Fmoc-amino acid (0.1 M) in DMF in the presence of 
N,N,N,N-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 
0.15 M) and Hunig’s base (0.2 M) with gentle nitrogen bubbling for 30 mins. at room 
temperature. A total of three repetitions were performed for each amino acid building block 
incorporated, followed by DMF (3 ml, 3 min., 3x) and DCM (3 ml, 3 min., 3x) washes. 
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For peptides longer than three amino acid residues, a 0.8 M LiCl wash (3 ml, 3 min., 3x) 
was included after swelling with DCM. After the synthesis, resin was washed with glacial 
AcOH (5 mL, 3x), DCM (5 mL, 3x), and MeOH (5 mL, 3x). Resins were placed under 
vacuum overnight. Fmoc-Cys Ala was cleaved from the resin using trifluoroacetic acid 
(TFA), triisopropylsilane, 1,2-ethanedithiol (EDT), and nanopure water (94: 1.0: 2.5: 2.5) 
(4 hrs.) for Fmoc-CysAla-OH. TFA was evaporated and the remaining oil was precipitated 
with diethyl ether at 0 °C. No further purification of the crude peptide was performed.  
4.4.4 General Procedure (B): solution-phase alkylation with o-
(bromomethyl)phenylboronic acid.  
Peptides were dissolved in a mixture of H2O and MeCN (0.6 mL, 1:1 v/v). To this 
solution, 0.1 mL of Hunig’s base was added. If the peptide precipitated, 0.15 mL of MeOH 
was added. The solution was further diluted with 0.2 mL of MeCN, followed by addition 
of 3.5 equivalents of o-(bromomethyl)phenylboronic acid. The reaction was allowed to stir 
overnight at RT. The following day, additional boronic acid (3.5 equivalents) was added, 
followed by addition of 0.05 mL of Hunig’s base. The reaction was incubated at room 
temperature for an additional 2 hrs. Preparative HPLC was used to purify the peptides. 
Purified samples were placed on the rotary evaporator to remove MeOH. The aqueous 
remnants were frozen and lyophilized overnight. 
 
 
4.4.5 General Procedure (C): solid-phase modification of the N-terminus with EZ-
LinkTM NHS-PEG4-Biotin: Post automated solid phase synthesis.  
Fmoc group was removed with 3 mL of piperidine (20% v. in DMF, 3 min., 3x) 
followed by washes with DMF (3 mL, 3 min., 3x), DCM (3 mL, 3 min., 3x), and 0.8 M 
LiCl (3 mL, 3 min., 3x). A 1.5 mL solution of EZ-LinkTM NHS-PEG4-Biotin was introduced 
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with 0.5 mL solution of 1.2 M Hunig’s base. Gentle stirring under nitrogen was performed 
for 1 hr. at RT, followed by washes with DMF (3 ml, 3 min, 3x), DCM (3 ml, 3 min., 3x), 
and 0.8 M LiCl (3 ml, 3 min., 3x). Coupling of biotin to peptide was repeated a total of 
three times. Resins were washed with glacial AcOH (5 mL, 3x), DCM (5 mL, 3x), and 
MeOH (5 mL, 3x), and resins were placed under vacuum overnight. Peptides were cleaved 
with trifluoroacetic acid (TFA), triisopropylsilane, and nanopure water (95: 2.5: 2.5) (4 
hrs.), followed by removal of TFA, and precipitated with diethyl ether at 0°C. No further 
purification of the crude peptide was performed. 
4.4.6 Synthesis of (((ethane-1,2-diylbis(methylazanediyl))bis(methylene))bis(2,1-
phenylene))diboronic acid (4.1). 
N, N’-dimethylethylenediamine (2.0 mmol) was dissolved in a solution of MeCN, 
MeOH, DMF (1.4 mL, 71/14/14 (v/v/v)), followed by addition of 2-
bromomethyl)phenylboronic (4.0 mmol).  The reaction was stirred overnight at RT. The 
compound was purified via reverse-phase combi-flash. Purified yield: 16%. HRMS-ESI+ 
(MeOH/H2O): calcd.: m/z = 319.20310; found: m/z = 319.20060 [M-2H2O+H]+. 1H NMR 
(400 MHz, Acetonitrile-d3) δ 7.72 (dt, J = 7.4, 1.0 Hz, 1H), 7.66 – 7.63 (m, 1H), 7.61 – 
7.58 (m, 1H), 7.38 – 7.23 (m, 6H), 5.00 (d, J = 0.8 Hz, 1H), 4.86 (s, 2H), 4.52 (s, 1H), 3.89 
(s, 7H), 3.30 (d, J = 0.8 Hz, 2H), 2.78 – 2.70 (m, 1H). 
Synthesis of tert-butyl (2-(2-iodo-N-
methylacetamido)ethyl)(methyl)carbamate (4.2)— Boc-anhydride (0.011 mol) was 
dissolved in 20 mL of DCM and added dropwise to a solution of N, N’ 
dimethylethylenediamine (0.034 mol) in 30 mL of DCM under N2. The reaction was stirred 
overnight at RT. The DCM was removed via rotary evaporation. The residual oil was 
washed with EtOAc, with water, and brine. Ethyl acetate was evaporated and a colorless 
oil remained. No further purification was performed. The crude product (1g) was dissolved 
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in 20 mL of dry DCM and placed in an ice bath, and chloroacetyl chloride (0.0058 mmol) 
was introduced slowly under N2. The solution turned dark brown. The reaction was allowed 
to come to RT and stirred overnight. DCM was removed via rotary evaporation. The 
remaining oil was dissolved in EtOAc and washed with distilled water and brine (3x). The 
organic layer was dried with Na2SO4.  After filtration, EtOAc was removed by rotary 
evaporation. The compound was purified by normal-phase combi-flash (SI). Isolated 
product (0.11 mol) was dissolved in 1 mL of acetone followed by the introduction of NaI 
(0.22 mol). Precipitate formed after ten minutes. The reaction was stirred overnight at RT. 
The acetone was removed via rotary evaporation, followed by three washes with brine. No 
further purification was required. Yield 73%. LRMS-ESI/APC+/- (MeOH/H2O): calcd.: m/z 
= 379.2; found m/z = 379.05 [M+Na]+. 
Synthesis of Fmoc-C(B)A (4.3)—Fmoc-CA-OH (0.07 mmol) was dissolved in 
0.3 mL of H2O, followed by addition of 0.1 mL of MeOH:TEA:Pyr:H2O (7:1 :1:1) (v/v/v). 
A solution of compound 3 (0.07 mmol) in 0.5 mL MeCN:H2O  (69:31) (v/v) was 
introduced. The boc protecting group was removed using trifluoroacetic acid (TFA), 
triisopropylsilane, and nanopure water (95: 2.5: 2.5) (4 hrs.). TFA was removed, and the 
product was precipitated with diethyl ether at 0°C. No further purification of the peptide 
was performed. The peptide was alkylated with o-(bromomethyl)phenylboronic acid 
following general procedure B. The peptide was purified via preparative HPLC. MeOH 
was removed by rotary evaporation, followed by freezing and lyophilization of aqueous 
remnants. Purified yield: 6%. HRMS-ESI+ (MeOH/H2O): calcd.: m/z = 658.27420; found: 
m/z = 658.27390 [M-2H2O+H]+. 1H NMR (500 MHz, DMSO-d6) δ 8.30 (s, 1H), 7.82 (d, J 
= 7.6 Hz, 2H), 7.65 (t, J = 6.8 Hz, 2H), 7.38 (t, J = 7.4 Hz, 2H), 7.33 – 7.25 (m, 3H), 7.16 
(d, J = 7.3 Hz, 1H), 4.25 (t, J = 6.6 Hz, 2H), 4.20 – 4.11 (m, 1H), 3.94 (d, J = 7.0 Hz, 1H), 
3.88 (s, 4H), 3.72 (d, J = 10.9 Hz, 1H), 3.57 – 3.39 (m, 2H), 3.40 – 3.30 (m, 1H), 2.91 (dd, 
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J = 13.8, 5.2 Hz, 1H), 2.71 (d, J = 14.0 Hz, 3H), 2.68 – 2.58 (m, 4H), 2.24 (s, 2H), 2.16 (s, 
1H), 1.18 (dd, J = 7.0, 1.7 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) δ 170.31, 156.90, 
144.37, 144.36, 144.25, 141.36, 135.41, 135.40, 130.34, 130.14, 128.60, 128.02, 126.00, 
120.83, 66.76, 63.25, 63.23, 54.97, 54.97, 52.75, 50.19, 47.26, 47.26, 44.12, 41.44, 40.45, 
40.45, 40.06, 40.02, 39.90, 39.87, 39.84, 39.73, 39.70, 39.67, 39.56, 39.53, 39.51, 39.40, 
39.37, 39.34, 39.23, 39.20, 39.17, 39.04, 39.01, 35.87, 34.48, 34.12, 18.92, 18.91. 
Synthesis of Fmoc-Lys(N3,B)Ala-SH (4.4). Fmoc-Lys(N3)Ala-S-Resin. Mixing 
of solvents, preparation of click solutions, and click reaction was done under N2. Resin 
(100 μmol) and alkyne (1 eq) were combined with 1 mL of DMF followed by the addition 
of 0.2 mL solution of CuI (0.5 eq), tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine 
(TBTA) (1 eq), and sodium ascorbate (1 eq) in DMF and stirred for 1 hr. at RT. The 
reaction solution was drained from the resin and fresh reaction solution was introduced two 
more times. The resin was washed with DMF (3 mL, 3 min., 3x), DCM (3 mL, 3 min., 3x), 
glacial AcOH (5 mL, 3x), DCM (5 mL, 3x), and MeOH (5 mL, 3x). The resin was then 
placed under vacuum overnight, followed by cleavage using trifluoroacetic acid (TFA), 
triisopropylsilane, 1,2-ethanedithiol (EDT), and nanopure water (94: 1.0: 2.5: 2.5) (4 hrs.). 
TFA was evaporated and remaining oil was precipitated with diethyl ether at 0°C. Peptide 
was purified via preparative HPLC. MeOH was removed by rotary evaporation, followed 
by freezing and lyophilization of aqueous remnants. Purified yield: 14%. HRMS-ESI+ 
(MeOH/H2O): calcd.: m/z = 749.32520; found: m/z = 749.32680 [M+Na]+. 1H NMR (500 
MHz, DMSO-d6) δ 8.30 (s, 1H), 7.97 (d, J = 6.7 Hz, 1H), 7.84 (t, J = 6.8 Hz, 2H), 7.65 (q, 
J = 6.2 Hz, 2H), 7.58 (d, J = 7.1 Hz, 1H), 7.39 (q, J = 7.0 Hz, 2H), 7.29 (q, J = 7.5, 7.0 Hz, 
2H), 7.22 (dd, J = 8.7, 6.6 Hz, 1H), 7.15 (q, J = 6.8 Hz, 1H), 4.30 (t, J = 6.8 Hz, 2H), 4.22 
(dd, J = 7.4, 4.0 Hz, 2H), 4.16 (td, J = 6.9, 3.3 Hz, 2H), 3.93 (dd, J = 9.4, 4.9 Hz, 1H), 3.65 
(d, J = 4.4 Hz, 2H), 3.47 (d, J = 5.2 Hz, 0H), 3.33 (dt, J = 13.5, 6.8 Hz, 1H), 3.25 (dt, J = 
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13.4, 6.6 Hz, 1H), 2.78 – 2.63 (m, 2H), 2.03 (d, J = 4.5 Hz, 3H), 1.77 (d, J = 9.3 Hz, 3H), 
1.64 (s, 1H), 1.52 (d, J = 11.8 Hz, 1H), 1.35 – 1.19 (m, 4H), 1.16 (d, J = 7.1 Hz, 3H). 13C 
NMR (126 MHz, DMSO-d6) δ 172.78, 172.08, 156.53, 144.13, 144.03, 143.25, 141.86, 
141.07, 134.48, 129.44, 129.21, 129.09, 128.16, 127.57, 127.19, 125.65, 124.80, 121.78, 
120.51, 72.44, 66.14, 61.71, 60.55, 54.72, 49.83, 49.70, 48.63, 47.02, 42.26, 40.28, 40.11, 
40.02, 39.94,	235.31, 175.67, 174.39, 173.56, 173.06, 172.72, 172.43, 171.79, 171.67, 
171.22, 167.42, 164.16, 160.27, 160.01, 157.35, 157.30, 155.95, 142.27, 138.02, 135.25, 
134.31, 131.05, 130.22, 129.87, 129.81, 129.19, 128.94, 128.54, 127.66, 127.24, 127.23, 
118.79, 116.42, 115.59, 110.38, 74.96, 70.39, 70.37, 70.31, 70.18, 69.57, 67.28, 67.03, 
62.00, 60.24, 60.13, 58.19, 56.29, 56.15, 54.43, 53.62, 52.39, 49.34, 42.70, 41.00, 40.48, 
40.28, 40.17, 39.25, 37.84, 37.10, 36.54, 35.91, 31.41, 29.10, 29.08, 28.92, 28.67, 25.97, 
25.43, 24.87, 24.21, 23.63, 23.47, 23.47, 23.34, 23.33, 22.07, 20.17. 
Fmoc-Lys(Nε,Me,B)A-OH (4.5). General procedure B was used for 0.054 mmol 
of starting material. Purified yield: 60%. Positive HRMS-ESI+ (MeOH/H2O): calcd: m/z 
= 610.27010; found: m/z = 610.2685 [M + Na]+. Negative HRMS-ESI (MeOH/H2O): 
calcd: m/z = 586.2736; found: m/z = 586.2727 [M H]. 1H NMR (400 MHz, DMSO-d6) d 
8.23 (s, 1H), 7.84 (dd, J = 7.6, 3.1 Hz, 2H), 7.68–7.61 (m, 2H), 7.50 (dt, J = 7.1, 1.1 Hz, 
1H), 7.39 (tt, J = 7.5, 1.6 Hz, 2H), 7.35–7.30 (m, 2H), 7.30–7.26 (m, 1H), 7.23 (ddd, J = 
7.2, 5.3, 3.4 Hz, 1H), 7.18 (d, J = 7.2 Hz, 1H), 4.63 (s, 2H), 4.28–4.15 (m, 3H), 4.04 (q, J 
= 7.2 Hz, 1H), 3.93 (dd, J = 9.0, 5.1 Hz, 1H), 3.66 (q, J = 7.3 Hz, 2H), 3.50–3.45 (m, 1H), 
3.43–3.37 (m, 1H), 2.19–2.12 (m, 3H), 1.61 (dt, J = 13.8, 7.0 Hz, 1H), 1.49 (h, J = 7.6 Hz, 
2H), 1.20 (dd, J = 9.4, 7.1 Hz, 4H).  
Biotin-ArgThrArgLys(Nε,Me,B)LeuLys(Nε,Me,B)PheLys(Nε,Me,B)- Tyr-OH 
(4.6). General procedure B was used for 0.022 mmol of starting material. Purified yield: 
7.5%. HRMS-ESI+ (MeOH/H2O): calcd: 701.0625; found: m/z = 701.0638 [M - 3H2O + 
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3H]3+ . 1 H NMR (500 MHz, DMSO-d6) d 8.29 (s, 8H), 7.65–7.50 (m, 3H), 7.33–7.03 (m, 
18H), 6.93 (d, J = 7.8 Hz, 3H), 6.58 (d, J = 7.9 Hz, 3H), 4.51–4.30 (m, 2H), 3.57 (q, J = 
8.5, 7.5 Hz, 5H), 3.46 (d, J = 8.9 Hz, 9H), 3.37 (t, J = 5.7 Hz, 2H), 3.24 (s, 1H), 3.20–3.11 
(m, 2H), 3.04 (dt, J = 26.2, 7.3 Hz, 6H), 2.91 (s, 5H), 2.83–2.63 (m, 7H), 2.42–2.24 (m, 
10H), 2.23–2.00 (m, 12H), 1.70–1.32 (m, 29H), 1.29–1.05 (m, 14H), 1.04–0.90 (m, 3H), 
0.78 (dtd, J = 33.8, 18.2, 17.3, 5.5 Hz, 9H).  
Biotin-ArgThrArgLys(Nε,Me,B)LeuLys(Nε,Me,B)PheGlyTyr-OH (4.7). 
General procedure B was used for 0.021 mmol of starting material. Purified yield: 11%. 
HRMS-ESI+ (MeOH/H2O): calcd: m/z = 951.0221; found: m/z = 951.0258 [M - 3H2O + 
2H]2+. HRMS-ESI (MeOH/H2O): calcd: m/z = 949.0075; found: m/z = 949.0051 [M - 
2H2O 2H]2. 1 H NMR (499 MHz, DMSO-d6) d 8.35 (s, 8H), 8.16 (s, 4H), 7.59 (s, 3H), 
7.20–7.05 (m, 4H), 6.94 (q, J = 8.8 Hz, 2H), 6.54 (d, J = 8.3 Hz, 1H), 4.34–4.27 (m, 1H), 
4.13 (dd, J = 7.9, 4.3 Hz, 1H), 3.42–3.35 (m, 3H), 2.91 (s, 1H), 2.81–2.65 (m, 1H), 2.57 (d, 
J = 12.6 Hz, 2H), 2.45–2.17 (m, 1H), 2.12–1.99 (m, 13H), 1.69 (d, J = 17.0 Hz, 1H), 1.63–
1.55 (m, 1H), 1.54–1.34 (m, 18H), 1.33–1.22 (m, 1H), 1.18 (d, J = 7.1 Hz, 5H), 1.00 (td, J 
= 14.0, 12.8, 6.7 Hz, 4H), 0.86 (d, J = 6.1 Hz, 1H), 0.80 (t, J = 5.6 Hz, 4H), 0.74 (dd, J = 
10.5, 4.6 Hz, 1H). 13C NMR (126 MHz, DMSO-d6) d 142.07, 133.86, 129.20, 129.17, 
127.81, 127.04, 74.53, 57.89.  
Biotin-ArgThrArgLys(Nε,Me,B)LeuGlyPheLys(Nε,Me,B)Tyr-OH (4.8). 
General procedure B was used for 0.015 mmol of starting material. Purified yield: 19%. 
HRMS-ESI+ (MeOH/H2O): calcd: m/z = 634.6855; found: m/z = 634.6832 [M - 2H2O + 
3H]3+. 1H NMR (500 MHz, DMSO-d6) d 8.34 (s, 9H), 7.84 (t, J = 5.5 Hz, 1H), 7.66 (s, 1H), 
7.37–6.87 (m, 3H), 6.58 (d, J = 8.4 Hz, 3H), 6.41 (s, 1H), 6.36 (s, 1H), 4.32–4.28 (m, 1H), 
4.12 (d, J = 7.2 Hz, 1H), 3.99 (d, J = 24.1 Hz, 1H), 3.21–3.14 (m, 2H), 3.10–2.89 (m, 1H), 
2.85–2.78 (m, 2H), 2.39–2.29 (m, 1H), 2.21 (q, J = 0.5 Hz, 2H), 1.63–1.35 (m, 6H), 1.33–
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1.09 (m, 3H), 1.01 (dd, J = 15.0, 6.0 Hz, 4H), 0.84 (ddd, J = 23.6, 11.2, 5.7 Hz, 8H). 13C 
NMR (126 MHz, DMSO-d6) d 179.31, 172.13, 165.36, 162.71, 157.24, 129.20, 127.96, 
69.75, 63.36, 61.04, 59.20, 55.40, 39.12, 35.09, 30.67, 30.65, 28.17, 28.02, 25.24. 
Biotin-ArgThrArgLys(Nε,Me,B)LeuGlyPheGlyTyr-OH (4.9). General 
procedure B was used for 0.015 mmol of starting material. Purified yield: 45%. HRMS-
ESI+ (MeOH/H2O): calcd: m/z = 567.6386; found: m/z = found 567.6403 [M - H2O + 3H]3+. 
HRMS-ESI (MeOH/H2O): calcd: m/z = 848.9370; found: m/z = 848.9370 [M - H2O + 
2H]2+. 1 H NMR (500 MHz, DMSO-d6) d 8.35 (s, 8H), 8.13 (s, 1H), 7.92–7.57 (m, 2H), 
7.55 (d, J = 7.2 Hz, 1H), 7.38 (d, J = 7.6 Hz, 1H), 7.34 (d, J = 5.8 Hz, 0H), 7.32–7.26 (m, 
3H), 7.26–7.18 (m, 7H), 7.18–7.02 (m, 2H), 6.94 (d, J = 8.3 Hz, 3H), 6.59 (d, J = 7.9 Hz, 
3H), 6.39 (d, J = 28.5 Hz, 2H), 4.88 (s, 1H), 4.76 (s, 1H), 4.64 (d, J = 4.2 Hz, 1H), 4.58 (s, 
2H), 4.44 (s, 0H), 4.36 (s, 1H), 4.32–4.27 (m, 1H), 4.20 (s, 3H), 4.13 (s, 2H), 4.02 (s, 2H), 
3.88–3.70 (m, 3H), 3.59 (d, J = 6.4 Hz, 2H), 3.49 (d, J = 2.6 Hz, 10H), 3.39 (t, J = 6.0 Hz, 
2H), 3.31 (s, 1H), 3.28 (d, J = 5.1 Hz, 5H), 3.22–3.15 (m, 3H), 3.04 (s, 6H), 2.94 (d, J = 
12.8 Hz, 1H), 2.82 (dd, J = 12.5, 5.1 Hz, 2H), 2.74 (s, 2H), 2.58 (d, J = 12.4 Hz, 1H), 2.46–
2.28 (m, 2H), 2.22–2.20 (m, 2H), 1.47 (d, J = 25.5 Hz, 20H), 1.35–1.16 (m, 2H), 1.02 (d, 
J = 8.1 Hz, 4H), 0.83 (d, J = 22.7 Hz, 8H). 13C NMR (126 MHz, DMSO-d6) d 172.45, 
172.13, 171.90, 171.66, 171.53, 171.15, 170.33, 170.15, 168.71, 168.71, 167.56, 166.37, 
162.73, 157.29, 157.29, 155.45, 143.52, 142.89, 142.27, 138.01, 137.98, 134.00, 133.99, 
133.73, 133.25, 130.13, 129.09, 128.93, 128.56, 128.33, 128.05, 127.37, 126.95, 126.81, 
126.19, 126.04, 125.72, 125.63, 125.35, 114.66, 73.89, 73.37, 73.33, 73.24, 73.20, 69.76, 
69.70, 69.67, 69.55, 69.45, 69.15, 66.76, 66.34, 61.05, 59.22, 58.44, 57.64, 57.59, 57.52, 
57.49, 57.47, 55.88, 55.40, 51.87, 40.78, 40.34, 39.45, 39.13,38.45, 37.19, 35.85, 35.09, 
30.97, 30.79, 30.65, 30.47, 28.66, 28.18, 28.03, 25.25, 24.73, 24.12, 22.97, 21.60, 21.47, 
20.08, 19.76, 18.69. 
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Biotin-GlyThrGlyLys(Nε,Me,B)LeuLys(Nε,Me,B)PheLys(Nε,Me,B)-Tyr-OH 
(4.10). General procedure B was used for 0.015 mmol ofstarting material. Purified yield: 
25%. HRMS-ESI+ (MeOH/H2O): calcd: m/z = 635.3418; found: m/z = 635.3437 [M - H2O 
+ 3H]3+.HRMS-ESI (MeOH/H2O): calcd: m/z = 950.9938; found: m/z =949.9907 [M - 
3H2O + 2H]2+. 1H NMR (500 MHz, DMSO-d6) d 8.30 (s, 6H), 7.64 (d, J = 7.2 Hz, 3H), 
7.34–7.19 (m, 4H), 7.15 (d,J = 8.8 Hz, 12H), 6.94 (d, J = 7.5 Hz, 3H), 6.59 (d, J = 7.8 Hz, 
3H), 4.96 (s, 0H), 4.52 (d, J = 1.8 Hz, 1H), 4.49–4.39 (m, 1H), 4.31 (t, J = 6.4 Hz, 1H), 
4.13 (dd, J = 7.8, 4.3 Hz, 2H), 4.00 (t, J = 5.3 Hz, 1H), 3.38 (t, J = 5.9 Hz, 2H), 3.25 (d, J 
= 1.7 Hz, 1H), 3.20–3.13 (m, 2H), 3.11–2.98 (m, 1H), 2.93 (d, J = 9.7 Hz, 1H), 2.83–2.67 
(m, 2H), 2.57 (d, J = 12.5 Hz, 1H), 2.50 (p, J = 1.8 Hz, 11H), 2.45–2.31 (m, 6H), 2.30–
2.21 (m, 0H), 2.21–2.17 (m, 1H), 1.94 (s, 1H), 1.66–1.56 (m, 1H), 1.55–1.33 (m, 13H), 
1.27 (q, J = 7.8 Hz, 1H), 1.22 (dd, J = 6.6, 2.2 Hz, 9H), 1.12 (d, J = 19.8 Hz, 0H), 1.07–
0.94 (m, 4H), 0.93–0.68 (m, 6H). 13C NMR (126 MHz, DMSO-d6) d 234.84, 234.82, 
180.21, 172.94, 171.36, 170.97, 169.88, 169.35, 165.77, 163.23, 155.70, 142.16, 141.70, 
135.07, 133.88, 130.93, 130.55, 129.64, 129.64, 129.41, 129.07, 129.07, 128.30, 127.61, 
127.16, 126.84, 115.00, 109.87, 74.38, 72.40, 70.05, 69.99, 69.93,69.84, 69.81, 69.32, 
69.32, 66.89, 66.72, 63.79, 62.93, 61.35,60.46, 59.50, 57.78, 55.79, 55.72, 53.45, 42.42, 
41.85, 40.32, 40.14,38.71, 36.16, 35.40, 31.77, 31.29, 31.11, 30.97, 30.95, 30.91, 30.87, 
30.84, 30.80, 30.77, 30.71, 30.61, 30.46, 28.51, 28.31, 25.55, 25.15, 24.43, 23.26, 21.79, 
19.82, 17.80, 12.84, 4.89, 15.08, 15.08. 
Biotin-ArgThrLeuLys(Nε,Me,B)ArgLys(Nε,Me,B)PheLys(Nε,Me,B)-Tyr-OH 
(4.11). General procedure B was used for 0.022 mmol of starting material. Purified yield: 
17%. HRMS-ESI+ (MeOH/H2O): calcd: m/z = 701.3950; found: m/z = 701.3926 [M - H2O 
+ 3H]3+. HRMS-ESI (MeOH/H2O): calcd: m/z = 1050.0735; found: m/z = 1050.0684 [M - 
3H2O + 2H]2+. 1H NMR (500 MHz, DMSO-d6) d 8.28 (s, 5H), 7.64 (dt, J = 19.1, 8.7 Hz, 
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3H), 7.41–6.99 (m, 18H), 6.94 (d, J = 8.0 Hz, 2H), 6.60 (d, J = 8.0 Hz, 2H), 4.59–4.41 (m, 
2H), 4.39–4.28 (m, 1H), 4.11 (d, J = 14.8 Hz, 97H), 3.56 (q, J = 14.4, 10.9 Hz, 2H), 3.45 
(d, J = 7.9 Hz, 12H), 3.38 (d, J = 6.0 Hz, 2H), 3.16 (t, J = 6.3 Hz, 2H), 3.10–2.96 (m, 6H), 
2.84–2.61 (m, 7H), 2.57 (d, J = 12.7 Hz, 1H), 2.45–2.10 (m, 10H), 2.05 (t, J = 7.4 Hz, 2H), 
1.79–1.30 
 Synthesis of Biotin-ArgThrPheLys(Nε, Me, B)LeuLys(Nε, Me, B)ArgLys(Nε, 
Me, B)Tyr-OH (4.12). General procedure B was used for 0.022 mmol of starting material. 
Purified yield: 22 %. Positive HRMS-ESI+ (MeOH/H2O): calcd.: m/z = 700.73010; found: 
m/z = found 700.73090 [M - H2O + 3H]3+. HRMS-ESI- (MeOH/H2O): calcd.: m/z = calcd. 
1048.57700; found: m/z = 1048.56120 [M-3H2O-2H]2-. 1H NMR (500 MHz, DMSO-d6) δ 
8.28 (s, 8H), 7.65 – 7.57 (m, 3H), 7.31 – 7.20 (m, 11H), 7.15 (t, J = 11.0 Hz, 16H), 6.90 
(d, J = 8.1 Hz, 0H), 6.85 (d, J = 8.1 Hz, 2H), 6.62 – 6.50 (m, 3H), 6.37 (d, J = 19.1 Hz, 
0H), 4.51 (s, 1H), 4.49 (s, 1H), 4.31 (dd, J = 7.8, 5.0 Hz, 2H), 4.29 – 4.22 (m, 0H), 4.22 – 
4.09 (m, 2H), 3.98 (s, 2H), 3.65 – 3.51 (m, 4H), 3.50 – 3.46 (m, 12H), 3.44 (s, 4H), 3.37 
(t, J = 5.8 Hz, 3H), 3.24 (d, J = 1.3 Hz, 1H), 3.16 (t, J = 5.9 Hz, 3H), 3.11 – 2.87 (m, 4H), 
2.79 (dd, J = 12.6, 5.2 Hz, 3H), 2.20 – 2.17 (m, 1H), 1.95 – 1.91 (m, 1H), 1.82 – 1.73 (m, 
0H), 1.59 (s, 7H), 1.54 – 1.32 (m, 26H), 1.28 (p, J = 7.1 Hz, 1H), 1.18 (d, J = 18.2 Hz, 8H), 
0.95 (d, J = 6.3 Hz, 4H), 0.81 (dd, J = 22.7, 6.6 Hz, 9H). 
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4.6 Experimental Characterization Data 
 
















































































































































































































































































































































































































































































































































Figure 4.26: HRMS data for compound 4.8. 
 
 
































































































































































































































































































































































































































































Figure 4.43: Purity check for compound 4.12. Retention time: 18.251 min. 
 
4.7 References 
1. S. Abdellaoui, B. C. Corgier, C. A. Mandon, B. Doumeche, C. A. Marquette and 
L. J. Blum, Electroanal, 2013, 25. 
2. R. Amin and S. A. Elfeky, Spectrochim Acta A, 2013, 108. 
3. S. Arimori, S. Ushiroda, L. M. Peter, A. T. A. Jenkins and T. D. James, Chem. 
Commun., 2002, 20. 
4. J. B. Crumpton, W. Zhang and W. L. Santos, Anal. Chem., 2011, 83, 3548-3554. 
5. W. W. Bachovchin, W. Y. L. Wong, S. Farr-Jones, A. B. Shenvi and C. A. Kettner, 
Biochemistry (Mosc.), 1988, 27, 7689-7697. 
6. W. L. A. Brooks and B. S. Sumerlin, Chem. Rev., 2016, 116, 1375-1397. 
7. J. N. Cambre and B. S. Sumerlin, Polymer, 2011, 52, 4631-4643. 
8. T. M. El Dine, J. Rouden and J. Blanchet, Chem. Commun., 2015, 51, 16084-16087. 
9. T. D. James, K. R. A. S. Sandanayake and S. Shinkai, Angew Chem Int Edit, 1994, 
33. 
10. S. Kotha, K. Lahiri and D. Kashinath, Tetrahedron, 2002, 58. 
11. K. Lacina and P. Skládal, Electrochim Acta, 2011, 56. 
12. K. Lacina, P. Skládal and T. D. James, Chem. Cent. J., 2014, 8, 1-17. 
13. J. Langen, U. Fischer, M. Cavalar, C. Coetzee, P. Wegmann-Herr and H.-G. 
Schmarr, Anal. Bioanal. Chem., 2016, 408, 2425-2439. 
14. J. Li, A. S. Grillo and M. D. Burke, Accounts of Chemical Research, 2015, 48, 
2297-2307. 
15. M. Li, W. Zhu, F. Marken and T. D. James, Chem. Commun., 2015, 51, 14562-
14573. 





















17. L. Rocard, A. Berezin, F. De Leo and D. Bonifazi, Angew. Chem. Int. Ed., 2015, 
54, 15739-15743. 
18. G. Springsteen and B. Wang, Chem. Commun., 2001, 17. 
19. X. Sun, W. Zhai, J. S. Fossey and T. D. James, Chem. Commun., 2016, 52, 3456-
3469. 
20. Q. Zhang, N. Tang, J. W. C. Brock, H. M. Mottaz, J. M. Ames, J. W. Baynes, R. 
D. Smith and T. O. Metz, J. Proteome Res., 2007, 6, 2323-2330. 
21. W. Zhang, D. I. Bryson, J. B. Crumpton, J. Wynn and W. L. Santos, Chem. 
Commun., 2013, 49, 2436-2438. 
22. X. Sun and T. D. James, Chem. Rev., 2015, 115, 8001-8037. 
23. S.-H. Chung, T.-J. Lin, Q.-Y. Hu, C.-H. Tsai and P.-S. Pan, Molecules, 2013, 18, 
12346. 
24. J. J. Deadman, S. Elgendy, C. A. Goodwin, D. Green, J. A. Baban, G. Patel, E. 
Skordalakes, N. Chino and G. Claeson, J. Med. Chem., 1995, 38, 1511-1522. 
25. P. J. Duggan and D. A. Offermann, Aust. J. Chem., 2007, 60, 829-834. 
26. N. Y. Edwards, T. W. Sager, J. T. McDevitt and E. V. Anslyn, J. Am. Chem. Soc., 
2007, 129, 13575-13583. 
27. G. A. Ellis, M. J. Palte and R. T. Raines, J. Am. Chem. Soc., 2012, 134, 3631-3634. 
28. O. V. Gozhina, J. S. Svendsen and T. Lejon, J. Pep. Sci., 2014, 20, 20-24. 
29. M. Kita, J. Yamamoto, T. Morisaki, C. Komiya, T. Inokuma, L. Miyamoto, K. 
Tsuchiya, A. Shigenaga and A. Otaka, Tet. Lett., 2015, 56, 4228-4231. 
30. C.-H. Tsai, C.-H. Lin, C.-T. Hsieh, C.-C. Cai, T.-J. Lin, P.-Y. Liu, M.-H. Lin, M.-
J. Wu, C.-C. Fu, Y.-C. Wu, F.-R. Chang and P.-S. Pan, Res. Chem. Intermed., 2014, 
40, 2187-2198. 
31. K. L. Bicker, J. Sun, J. J. Lavigne and P. R. Thompson, ACS Comb. Sci., 2011, 13, 
232-243. 
32. B. E. Collins and E. V. Anslyn, Chem. European J., 2007, 13, 4700-4708. 
33. B. E. Collins, S. Sorey, A. E. Hargrove, S. H. Shabbir, V. M. Lynch and E. V. 
Anslyn, J. Org. Chem., 2009, 74, 4055-4060. 
34. D. G. Hall, in Boronic Acids, Wiley-VCH Verlag GmbH & Co. KGaA, 2006, pp. 
1-99. 
35. J. M. Chalker, G. J. L. Bernardes, Y. A. Lin and B. G. Davis, Chem. .Asian J., 2009, 
4, 630-640. 
36. N. Fomina, C. McFearin, M. Sermsakdi, O. Edigin and A. Almutairi, J. Am. Chem. 
Soc., 2010, 132, 9540-9542. 
37. V. Castro, H. Rodríguez and F. Albericio, ACS Comb. Sci., 2016, 18, 1-14. 
 
 253 
Chapter 5: The Synthesis of Bipyridine Peptides via Alkylation with 5- 
and 6-(bromomethyl)-2,2’-bipyridine for Metal-based Cyclization 
Studies in the Presence of Hydrazone Forming Peptides 
5.1 INTRODUCTION 
 
5.1.1 Metals and Ligands in Forming Higher-Order Organic Structures 
 Self-assembly of small organic molecules or oligomers into large complex 
structures resemble biomolecule folding in nature. Thus, when chemists observe such 
processes in synthetic systems, these higher order structures are called “biomimetic.” 
Common metal ligands in coordination chemistry are studied for folding into structures. 
These ligands garner interest because of the ability to control their arrangement in space 
by a metal. If conformational changes are made at will, using externally applied stimuli, 
parallels to metal based protein structuring and aggregation in nature can be made.1 
5.1.2 Facilitating Incorporation of Ligands into Peptides 
 As described in Chapters 2-4, the chemistries presented so far aimed at the selective 
modification of amino acids for protein sequencing can also be applied.2 Alkylation of 
secondary amine residues was the method chosen for incorporation of boronic acids.3 Use 
of similar methodology to modify peptides with 2-2’-bipyridines is presented here. 
Including N-methyl Lysine via solid-phase peptide synthesis (SPPS) remained the manner 
in which secondary amines were introduced. Brominated compounds 5.1 and 5.2 were 
synthesized for this purpose. To our knowledge, alkylation is not a reported method for 
functionalizing peptides with bipyridines. However, it is for the synthesis of small 
molecule ligands.  
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Figure 5.1: Brominated bipyridines. a) 5-(bromomethyl)-2,2’-bipyridine b) 6-
(bromomethyl)-2,2’-bipyridine 
 
5.1.3 Bipyridine Ligands 
 The use of one pyridine ring, in conjunction with complimentary natural/ metal 
binder, has led to interesting folding properties. Thus, increasing the number of pyridines 
for formation of different ligands is part of the reason terpyridines and other multi-dentate, 
heterocyclic aromatic structures are also employed. Bipyridine is one of the most widely 
used metal ligands. Synthesis of small molecules, polymers, and peptides containing this 
functional group has been reported.4, 5 These moieties facilitate helical formation of organic 
compounds, act as materials in photovoltaic/electronic devices, serve as achiral molecular 
sensors, and are applied in luminescent devices.4 Peptide chemists have found their utility 
quite desirable and amino acid building blocks with this moiety have been made.6 The need 
to synthesize building blocks adds to the onerous task of synthesizing large amounts of 
starting material, mostly which is discarded during peptide synthesis. Nevertheless, 
methods to incorporate bipyridines has been extensively studied and analyzed for their 
peptide folding properties.7 These moieties are regarded as an integral part in the chemist’s 
effort to materialize protein-like properties from unnatural functionalities.8  
5.1.4 Relevance for Unnatural Metal-Based Peptides 
 Proteins and peptides are polymers that nature uses as a scaffold for the modular 
synthesis of macromolecules numbering conservatively ~ 20, 000 proteins before post-










inside the body and are composed of a relatively simple set of organic side chain moieties 
and functionalities. Nearly one-third of proteins have metal coordination sites to execute 
regulatory or enzymatic processes.7 Therefore, peptide chemists have tried to replicate 
metal ligand coordination with both naturally occurring residues and non-canonical metal 
binders. Bipyridines are extensively reported as unnatural metal ligands coordinating to 
metals such as Cu2+, Zn2+, and Fe2+, ions of biological relevance.4 More interesting are the 
changes in properties and function that occur when these peptides bind to metals. Inducing 
helical formation and/or nanoscale aggregation of metallo-peptides is described as how 
these subset entities differ in structure and function once assembled. 
5.1.5 The Synthesis of Metal-Binding Peptides 
 Solid-phase peptide synthesis (SPPS) is a well-established chemistry, serving as a 
facile means for making these diverse set of compounds by a controlled step-wise 
incorporation of monomers. Natural amino acids building blocks are commercially 
available at relatively cheap costs. The relative inexpensiveness of this compound mitigates 
the inefficient consumption of the starting material to make peptides. However, when it 
comes to designing, synthesizing, and scaling up production of commercially unavailable, 
synthetically challenging building blocks, SPPS becomes a less attractive method for the 
introduction of unnatural residues. Amidation between the N-termini and/or Lysine residue 
with carboxylate-substituted bipyridines are used to overcome this challenge.  
In addition, incorporation of a metal ligand does not guarantee that spontaneous 
folding will occur.7 Therefore, devoting time and resources in the design of building blocks 
for solid-phase incorporation of unnatural residues may not be preferable when screening 
which functionalities cause peptides to fold. In fact, building block design of non-canonical 
side chains that can lead to peptide folding is regarded as an ongoing challenge in the field.7 
The alkylation approach previously described is seen as an alternative to building block 
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approaches when screening metal binding synthetic and folding of synthetic peptides. The 
commercial availability of alkyl bromide precursors as well as the synthetic ease to acquire 
brominated compounds makes alkylation strategies an attractive approach. From one 
sequence containing mono-methylated Lysine residues, different compounds can be 
incorporated, isolated, and studied for binding/folding properties. Once a side chain is 
found, building block design and synthesis for SPPS can be implemented as a means for 
expeditious synthesis of metal binding peptides, followed by optimization studies for 
improving folding, biological activity, etc. 
The same precursor-based screening approach can be said of bipyridines with 
carboxylate functionalities. Lysine residues could be amide-coupled to different 
derivatives of bipyridine. However, isolation of the peptide may be more challenging due 
to the excess amount of coupling reagents required. Commonly reported solution-phase 
coupling conditions require the excess of EDC and NHS. Furthermore, selective 
modification is an additional complicating feature for solution-phase amidation. Unless the 
C-terminus is protected, concatenation will occur. In addition, the heterocyclic compounds 
like pyridine in the process may participate in unanticipated side reactions during the 
coupling.10 In contrast, alkylation with bromide-containing precursors leaves impurities 
that can be readily removed with desalting or HPLC purifications. 
5.1.6 Rationale for Alkylating Peptide with Bipyridine 
 Disordered peptides and proteins are induced to form folded structures upon 
coordination. Research points towards these common phenomena in nature to bring 
structurally disordered segments of protein, known as intrinsically disordered proteins 
(IDPs), into controlled folded patterns. This disorder-to-order transition key roles for 
diseases such as neurodegenerative disorders.11 This served as inspiration for the work 
presented here. The hypothesis that the amine from the methylated Lysine would 
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preferentially bind to a metal as the third site of a tridentate ligand, further justifying the 
alkylation strategy. Particularly, bipyridine compound 3.2 would be best suited for this 
purpose (Figure 5.2). Compound 3.1 was the control to prove that positioning the 
methylated lysine on the ligand played a critical role. In other words, controlled folding of 
peptides would not readily occur, because the residue would not be preorganized to bind 
as a tridentate ligand. 
 
 
Figure 5.2: Proposed N-methyl Lysine modification with bipyridines. a) Compound 3.2 
modified with methylated Lysine considered to bind and form a tridentate 
ligand binding around a metal center in a 2:1 stoichiometry. b) Compound 3.1 
modified with methylated Lysine considered not to form a tridentate ligand. 
 In addition, bipyridines prefer coordination stoichiometries of 3:1 (ligand to metal 
center). Therefore, a peptide with only two ligands modified at position 6 (Figure 5.3) 
would favor cyclization. Peptide with ligands modified at position 5 (Figure 5.3) would not 
properly cyclize but participate in non-specific biding arrangements. A third ligand from 
an adjacent peptide would have to act as the third coordinating site, leading to a 
combination of different structures difficult to determine. These two peptides will be 






















Figure 5.3: Metallo-peptides (MPs) used for cyclization studies. 
 
5.1.7 Introduction of Dynamic Reversible Covalent Bonds  
 Once cyclization is confirmed, combining peptides with other unnatural 
functionalities that can participate in dynamic reversible covalent bonds is considered to 
mitigate issues that may arise when trying to induce folding of synthetic peptides with non-
canonical functionalities. Recently, the Anslyn group reported a series of NMR studies 
confirming no cross-reactivity between four highly reversible covalent bonds: boronic acid 
esterification, thiol-conjugate addition, hydrazone formation, including supramolecular 














































































the ligand studied previously, and the other three reactions can be incorporated as part of 
an ensemble to promote folding. 
 It is the dynamic reversibility of these covalent bonds formed that make the from 
these reactions attractive in the studies presented here. These kinds of reactions can be 
considered as an intermediate between the strong covalent bond, which usually locks 
precursors into a specific arrangement, and of non-covalent interactions, which tend to be 
too dynamic. If they are not biased by the principles of preorganization or complementarity, 
these kinds of supramolecular interactions tend to be form disordered entities within 
themselves or their immediate surroundings.13 The work presented here focuses on peptides 
with aldehydes and hydrazides as the orthogonal functional groups combined with our 
bipyridine peptide cyclization studies. 
 So, these kinds of bonds are regarded to act as useful unnatural moieties when 
included in peptides. These will promote higher order rearrangement of simple peptide 
precursors. Because of their dynamic character, definitive targets are not envisioned. 
Instead, a set of simple components are mixed and the thermodynamically favored entity 
or entities are believed to form. In other words, like a wind-up toy, the mixing of 
components is the turning of the crank. The trajectory taken by the toy once it is released 
can be regarded as the products formed. The same can be said of proteins settling into their 
preferred conformational state.14 In a broader sense, these biomolecules and organic 
synthetic structures can be referred to as “dynamers,” because they are responsive to their 
environments and can change accordingly.15 Interest for these kinds of bonds are a strong 
focus for accessing macroscopically responsive and dynamic polymers.16 Such compounds 
can have potential pharmacological applications for introducing readily degradable 
compounds and minimizing toxic effects.17 
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5.1.8 Induce Cyclization of Bipyridine Peptides in the Presence of Aldehyde and 
Hydrazide Peptides and the Characterization of Higher-Ordered Structures 
 Therefore, this study’s aim was to induce cyclization of MP-6 and MP-5 in the 
presence of an aldehyde peptide (AldPep) and hydrazide peptide (HydPep-1 and HydPep-
2) shown in Figure 5.4. These peptides condensed upon [2,2'-bipyridine]-5,5'-
dicarbaldehyde, and thus provided another ligand that could coordinate around a metal 
center. Although the formation of a thermodynamically favorable higher-order structure 
was not the goal, these studies were seen as preliminary ones that could serve as a basis for 
future work focused on the design and characterization of peptide libraries composed of 
these two orthogonal reactions. 
 


































































































































































































5.2 Results and Discussion 
5.2.1 Rationale for MP-6 and MP-5 
 The sequence selected for MP-6 and MP-5 came from previously studied peptides 
from the Anslyn group that were used for cyclization. The peptides also contained a 
Tyrosine residue easy to identify at 280 nm during HPLC purification. The combination of 
Serine and Glycine increased hydrophilicity and minimized the steric repulsion from 
bulkier residues. Acetylated N-termini facilitated alkylation of secondary amine residues 
in solution. Acetylation also served as a precaution by removing basic sites that could 
compete to bind metals. As a result, residues such as Histidine and Arginine, known to 
bind to metal ions, were avoided.18, 19 Length also played an important role. Peptides with 
short sequences were seen to bring residues in close contact with each other, disfavoring 
cyclization. Particularly, when non-covalent interactions were being used, such as metal 
complexation, bulkier residues on shorter peptides could impede desired folding. 
5.2.2 Methods to Characterize Cyclization 
 Herein, we relied on UV-Vis and proton NMR titrations to characterize metal 
induced cyclization. After reaching saturation, the concentration of the titrant was most 
sensitive where complexation, was calculated. This value helped determine the correct 
stoichiometry for preferred folding. The Anslyn group previously has reported the use of 
these techniques for other assemblies.20 
5.2.3 Titration Studies with Small Molecule Bipyridines 
 Initially, to validate our characterization methods, we performed titrations with 2-
2’-bipyridine (5.3), 5-(bromomethyl)-2,2'-bipyridine (5.1), 6-methyl-2,2'-bipyridine (5.4), 
[2,2'-bipyridine]-5,5'-dicarbaldehyde (5.5),  and [2,2'-bipyridine]-5,5'-diyldimethanethiol 





Figure 5.5: Small molecule bipyridines used for titration studies. 
 
compatible in these studies. Compounds 5.1, 5.3, and 5.5 coordinated with Fe2+ in a 3:1 
stoichiometry. Compound 5.6 also bound similarly with zinc, and compound 5.4, however, 
did not show any binding. The methyl group substituted at the 6-postion suggested that 
steric hindrance inhibited complexation. In addition, to observe any metal dependence for 
binding, Zn2+ was titrated into a solution of compound 5.4. Still, binding did not occur. At 
first glance, this result was potentially problematic. However, we believed possible 
substitution with peptides would allow greater flexibility for bipyridine arrangement 
around a metal. The hypothesis that incorporation of an amine from the methylated Lysine 
could act as the third member of a tridentate ligand would allowing for metal binding even 




























































Figure 5.7: Binding isotherm for 5.5 at 530 nm. 
 
Figure 5.8: Proton NMR for Zn2+ titrated to a solution of 5.6. Red box indicates saturation 
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 The binding of compound 5.1 demonstrated that bulkier substituents, like bromide, 
could be tolerated for ligands substituted at the 5-position. As a result, MP-5 was expected 
to bind readily.  
5.2.4 MP-6 and MP-5 Binding with Fe2+ and Zn2+ 
 Titration studies for our peptides were initially characterized with proton NMR. To 
a solution of peptides, increasing amounts of metal were added. After each addition, 
successive NMR acquisitions tracked the alterations in the aromatic region, which is most 
sensitive to changes upon metal binding. Titrating Fe2+ to MP-6 led to a color change to a 
rusty red, but no notable changes were observed in the NMR spectra. Weakening of the 
signal intensity, however, was observed happened as the sample became more dilute 
(Figure 5.9). This suggested no metal was observed. 
 
 
Figure 5.9: Proton NMR titration of Fe2+ to MP-6. Saturation was not reached. 
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 In contrast, MP-5 was quite sensitive to the addition of Fe2+ (Figure 5.10). The 
signal, however, remained difficult to interpret in terms of the species formed. The NMR 
signals remained constant and were at their broadest at 1 equivalent of metal added. As the 
concentration of metal increased, additional peaks became prevalent, suggesting peptides 
were at their most oligomeric form. The more metal added, the more peptides began 
breaking apart into singly bound residues. 
 
 
Figure 5.10: Proton NMR titration of Fe2+ to MP-5. Red box indicates 1 eq. of metal. 
 
 Zn2+ was also titrated and monitored by UV-Vis spectrophotometry into a solution 
of MP-5. No absorption change occurred, confirming steric hindrance at the sixth position 
maybe contributing to the lack of binding. Therefore, despite a potential coordination site 
introduced via N-methyl lysine, a 1:1 metal to peptide stoichiometry proved elusive. UV-
Vis well-plate titration studies also demonstrated no response with iron (Figure 5.11). 
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Substitution at the 6-position colorimetric methylamine pendant increased the steric 




Figure 5.11: UV-Vis well-plate titration of MP-6 to Fe2+. No colorimetric response was 
observed. 
 
5.2.5 Ensuring Cyclization of MP-5 
 Since MP-6 did not bind as expected, further studies were not pursued. In contrast, 
MP-5 did respond to iron, as observed by UV-Vis spectrophotometry with an increase in 
absorbance. Literature accounts describing binding around metal centers with 
functionalized bipyridines and free 2-2’-bipyridine have been described, especially in the 
context of DNA binding studies with ruthenium centers.21 So, well-plate titration studies 
with an equivalent amount of metal, peptide, and compound 5.3 took place. As shown in 
Figure 5.12, a well-behaved binding isotherm was acquired with this three-component 
ensemble, suggesting a more ordered and non-oligomeric folding in MP-5.. These titrations 









titration studies. A total of three bipyridines were complexing around the cation. Two of 
the bipyridines came from the peptide and one from 2-2’-bipyridine in solution. 
 
 
Figure 5.12: Binding isotherm for Fe2+ and compound 5.3 titrated with MP-5 at 530 nm. 
 
5.2.6 Alternate Structure with Free Bipy: Oligomer 
 Because of the dilute concentrations, and the proximity of adjacent bipyridines on 
the peptide, cyclization was the most likely folding arrangement. Low concentrations tend 
to favor cyclic versus linear structures.22 If oligomerization, or the association of multiple 
MP-5s, was occurring, proton NMR studies would have shown broadening of peaks in a 
similar manner to NMR studies done only with iron and MP-5. High-resolution mass 
spectrometry (HRMS) also corroborated cyclization. The fragmentation pattern revealed 
MP-5 bound to iron and in the presence of compound 5.3. Oligomeric usually indicated by 
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5.2.7 MP Control Study 
 Peptide without bipyridine (MP) served as a control to rule out unintended binding. 
Aside from the binding occurring between the free bipyridine and, when increasing the 
concentration of MP, no change in absorption was observed, confirming that MP-5 indeed 
participated in complication. 
5.2.8 Alternative Small-Molecules Bipyridines and MP-5 
 Since compound 5.3 successfully contributed to peptide folding, compounds 5.5 
and 5.6 were also used for UV-Vis titration studies (Figure 5.13 & 5.14). From these 
studies, the desired 1:1:1 stoichiometry values were again confirmed, suggesting aldehydes 
and thiols do not interfere with complication. 
 
 



















Figure 5.14: Proton NMR titration of Fe2+ to MP-5 and compound 5.6. Red box 
indicates1 eq. of metal. 
 
5.2.9 Condensing HydPep-1 on Compound 5.5 and Complexation with MP-5 
 In our efforts to explore higher-order structure formation with orthogonal 
functionalities attached to small peptides, compound 5.5 served as an entry point. HydPep-
1 readily complexed with the bipyridine-peptide derivative. The Anslyn group previously 
has studied this kind of peptide cyclization via hydrazone formation about a dialdehyde 
small molecule. These molecules readily form in aqueous mixtures at nuetral pH, making 
them ideal peptide partners with MP-5. The hydrazone cyclization formed readily in the 
presence of MP-5 with no observed cross-reactivity. Once cyclized HydPep-1 formed, the 




Figure 5.15: Binding isotherm for MP-5, cyclic HydPep-1, and Fe2+ at 545 nm. 
 
 Figure 5.17 is a representative structure proposed from these titration studies. 
Although the exact orientations of the peptides remained unconfirmed, mixtures of 
isomeric structures were believed to have formed. 
 
 































































































5.2.10 Condensing HydPep-2 on AldPep Followed by Condensing on Compound 5.5 
 To increase the level of complexity, HydPep-2 was condensed on AldPep. One 
hydrazide side chain remained unmodified upon reaction to further condense compound 
5.5 onto the assembly. As with section 5.2.7, we did not determine the exact isomeric 
structure, however a mixture of products could have formed. These include structures with 
different C-termini orientations. Figure 5.18 is one possible structure that could form 
(compound 5.7). An attempt to condense two of these hydrazone peptide dimers did was 
not successful. In its place, a Tyrosine hydrazide served as an alternative. Further 
characterization is required to confirm this structure. 
 
 
Figure 5.17: Representative structure formed with HydPep-2/AldPep dimer, hydrazide 
Tyrosine, and compound 5.5 (compound 5.7). 
 
5.2.11 Complexation of Compound 5.7 with MP-5. 
 Although compound 5.7 was not confirmed, complexation appeared to occur with 


















































































































































it remained unclear if compound 5.7 formed part of the complex. A stoichiometry of 1:1:1 
did prove promising, but a number of species could have been present. For example, only 
compound 5.5 may have participated. To relieve any strain, portions of AldPep could have 
dissociated to accommodate MP-5. Or, the hydrazide Tyrosine may have easily 
dissociated. Nevertheless, compound 5.8 was shown in Figure 5.20 to visualize the 
possibility of MP-5 being accommodated. MP-5 and the residue containing the hydrazone 
bipyridine oriented away from the bulky assembly, suggested the feasibility of this 
compound being formed. 
 
 
Figure 5.18: Binding isotherm for MP-5, Compound 5.7, and Fe2+ at 545 nm. 





















Figure 5.19: Possible structure formed when MP-5 and compound 5.7 bind around an Fe2+. 
 
5.3 Conclusions 
 Cyclization studies for MP-6 and MP-5 using proton NMR and UV-Vis titrations 
demonstrated that a free bipyridine was required for cyclic folding to occur. MP-5 readily 
folded, but MP-6 showed no affinity to iron or zinc. This suggested that steric hindrance at 
the 6-position from the methyl group impeded complexation. Compound 5.5 served as the 
necessary third bipyridine ligand that incorporated further complexity to higher order 
structures. HydPep-1 and HydPep-2 condensed to form novel bipyridine ligands that, when 
mixed with MP-5, suggested complexation in a 1:1:1 stoichiometry. Future studies will 
include determining molecular weights of these complexes via gel electrophoresis to 
confirm these large structures remain intact. Future studies will also include increasing the 
diversity of compounds formed by including other orthogonal reactions reported by the 
Anslyn group. Identifying the thermodynamically favored compound, or compounds, and 
their stereochemistry/regiochemistry will be the next challenge to solve in order to control 















































































































































































5.4.1 General Materials 
For automated Fmoc amino solid-phase peptide synthesis, Gly, Thr(tBu), and 
Tyr(tBu) were purchased from P3 Biosystems. Fmoc-Lys(Nε,Me)-OH was purchased from 
Chem. Pep. Inc. Fmoc-Lys(N3)-OH was purchased from Chem-Impex, Inc. Fmoc-Gly-
Wang resin (0.62 mmol g-1) was purchased from P3 Biosystems. N,N′-
Diisopropylcarbodiimide (DIC) and Oxyma and (ethyl cyano(hydroxyimino)acetate) was 
purchased from Chem-Impex. DMF and piperidine used for automated solid-phase peptide 
synthesis were purchased from Fisher Scientific and Sigma-Aldrich. Ammonium acetate 
and acetic anhydride was purchased from Fisher. Methacrolein and 1-[2-oxo-2-(2-
pyridinyl) ethyl] iodide, 6-Methyl-2,2′-dipyridyl, and [2,2'-bipyridine]-4,4'-
dicarbaldehyde, and [2,2'-bipyridine]-5,5'-diyldimethanethiol[2,2'-bipyridine]-5,5'-
diyldimethanethiol[2,2'-bipyridine]-5,5'-diyldimethanethiol were purchased from Sigma-
Aldrich. N-bromo succinimide (NBS) and azobisisobutyronitrile (AIBN) were purchased 
from Acros Organics. 
5.4.2 General Instrumentation 
A Liberty Blue microwave peptide synthesizer was used for solid-phase peptide 
synthesis. Preparative HPLC purification of peptides was performed using an Agilent 
Zorbax SB-C18 Prep HT column 21.2 250 mm; 10 mL min1 , 5–95% MeOH (0.1% FA) 
in 90 min. Analytical HPLC characterization of peptides was performed using an Agilent 
Zorbax column 4.6 250 mm; 1 mL min1 , 5–95% MeCN (0.1% TFA) in 35 min (RT). A 
Gemini C18 3.5 micron 2.1 50 mm was used for online separation; 0.7 mL min1 , 5–95% 
MeCN (0.1% formic acid) in 12 min (RT). An Agilent Technologies 6530 Accurate Mass 
QTofLC/MS and a AB Voyager-DE PRO MALDI-TOF were used for high-resolution 
mass spectra of purified peptides. Solvents used were HPLC grade. A BioTek Cytation3 
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well plate reader and an Agilent Carey series spectrophotometer were used for UV-Vis 
titrations. A PowerEase Life technologies electrophoretic setup was used for gel 
separations of peptides and metallo-peptide complexes. 
5.4.3 General Procedure for Peptide Synthesis of MP-5 and MP-6. 
Synthesis of peptides was performed using standard settings using Liberty Blue 
software, and using 1 M of DIC and 1 M oxyma used as coupling and bases, respectively. 
Amino acid solutions were prepared at 200 mM, except for Fmoc-Lys(Nε,Me)-OH which 
was prepared at 100 mM. Each peptide made was capped using acetic anhydride 
incorporated into the automated synthesis. After the synthesis, resin was washed with 
glacial AcOH (5 mL, 3x), DCM (5 mL, 3x), and MeOH (5 mL, 3x). Resins were placed 
under vacuum overnight. Peptides were cleaved from the resin using trifluoroacetic acid 
(TFA), triisopropylsilane, and nanopure water (95 : 2.5 : 2.5) (4 h). TFA was evaporated 
and the remaining oil was precipitated with diethyl ether at 0 °C. No further purification of 
the crude peptide was performed. 
 MP-6. Starting amount (0.016 mmole). Yield 38%. HRMS: (M+2H)2+; calcd. 
748.35390, obs. 748.35630. 
MP-5. Starting amount: (0.015 mmole). Yield 25%. HRMS: (M+2Na)2+; calcd.  
770.33580,  obs. 770.33800. 
5.4.4 AldPep, HydPep-1, and HydPep-2 
 Dr. James Fredrick Ruether provided aldehyde and hydrazide peptides from the 
Anslyn group. 
5.4.5 General Procedure for Alkylation of Peptides.  
Peptides (1 eq.) were alkylated with 5-(bromomethyl)-2,2'-bipyridine (4.4 eqs.) or 
6-(bromomethyl)-2,2'-bipyridine (4.4 eqs) in a MeCN, H2O, and MeOH (80:15:5) (v/v/v) 
solvent mixture, followed by addition of 100 µL of Hunig’s base (DIPEA). The reaction 
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was allowed to stir for 24 hrs at RT. The solution was purified by preparative HPLC. 
Purified samples were placed on the rotary evaporator to remove organic solvent. The 
aqueous remnants were frozen at -70 °C and lyophilized overnight. 
5.4.6 Synthesis Brominated Ligand Precursors 
Synthesis of 5-(bromomethyl)-2,2'-bipyridine was prepared using a protocol 
reported in the literature. 24 
Synthesis of 6-(bromomethyl)-2,2’-bipyridine was prepared using a protocol 
reported in the literature.5 
5.4.7 Well-plate Titration Experiments20 
Stock solutions of ligand peptides (0.6 mM), free bipyridine (0.2 mM), and Fe2+ 
(0.2 mM). 
15 data points (15 wells) were taken for each experiment. To each well 25 µL metal 
and 25 µL of free bipyridine was introduced. Increasing amounts of peptide solution were 
introduced in 10 µL increments. The minimum was 0 µL solution introduced and the 
maximum was 150 µL introduced with all wells were diluted to a total of 150 µL. Each 
well was scanned between 300-700 nm. Blanks were composed of the MeOH:H2O (1:1) 
(v/v). 
Changes at 530 nm were monitored for titrations. A plot of concentration vs. change 
in absorption was made. Stoichiometry was determined by plotting a line along the 
increasing changes in absorption and a different line where the data points plateaued. The 
intersection was used to determine the amount of peptide required for optimal binding. 
5.4.8 UV-Vis Titration for Hydrazone Peptides and MP-5 mixtures. 
 A titrant solution of Fe2+ (0.6 mM) was introduced prepared to a mixture of 0.2 mM 
hydrazone peptides and MP-5. This solution was titrated into a second solution of 
hydrazone peptide and MP-5 (0.2 mM) until saturation was reached. 
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5.4.9 NMR titration experiments. 
NMR titrations were performed for both Zn2+ and Fe2+ to confirm UV-Vis titration 
experiments. 
MP was dissolved to concentration in (2.3 µmole) 600 µL of. D2O:MeOD (1:1) 
(v/v). Zinc or iron triflate was dissolved 180 µL (4.6 µmole) of deuterated solvent. 600 µL 
of the peptide solution was introduced to the NMR tube. An NMR was taken initially before 
the incorporation of any metal. Increment additions were added of metal solution (15 µL, 
6x; 30 µL, 3x). After each addition, an NMR experiment was performed, immediately after. 
Titration of unreacted bipyridines was performed in a similar fashion. 
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5.6 Experimental Characterization Data 
 
Figure 5.20: HRMS for MP-5.  
 





































































Figure 5.25: Proton NMR titration of 2-2’ bipyridine with Fet2+.  Red box indicated 0.32 
eq. required of metal required for 3:1 stoichiometry.  
 
Figure 5.26: Proton NMR titration of [2,2'-bipyridine]-5,5'-dicarbaldehyde with Fe2+.  Red 
box indicated 0.32-0.42 eq. required of metal for 3:1 stoichiometry.  
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Figure 5.27: Proton NMR titration of [2,2'-bipyridine]-5,5'-dicarbaldehyde with Zn2+.  Red 
box indicated 0.33 eq. required of metal for 3:1 stoichiometry. 
 
 
Figure 5.28: Proton NMR titration of [2,2'-bipyridine]-5,5'-diyldimethanethiol with Zn2+.  






































































































Figure 5.33: Proton NMR titration for MP-5, 2,2'-bipyridine, and Fe2+. Red box indicates 
1.25 eqs of metal were required for cyclization. 
 
Figure 5.34: Binding plot at 530 nm for MP-5 (0.206 mM),  [2,2'-bipyridine]-5,5'-
dicarbaldehyde (0.195 mM), and Fe2+ (0,214 mM). Cyclization occurred 
with a 1.1:1:1.1 stoichiometry. 
y = 2473.3x + 0.2922
R² = 0.93276



















Figure 5.35: Proton NMR titration for MP-5, 2,2'-bipyridine, and Fe2+. Red box indicates 




Figure 5.36: (top) Well-plate titration for MP-6, 2,2'-bipyridine, and Fe2+ (trial 1). (bottom) 































Figure 5.37: UV-Vis titration of MP-5, PepHyd-1 Cyclic Bipyridine, and Fe2+. 
 
Figure 5.38: MALDI spectrum for MP-5, PepHyd-1 Cyclic Bipyridine, and Fe2+. m/z 



















Figure 5.39: UV-Vis titration of MP-5, AldPep/HydPep-2 Bipyridine, and Fe2+. 
 
Figure 5.40: MALDI spectrum for MP-5, PepHyd-1 Cyclic Bipyridine, and Fe2+. m/z 
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Chapter 6: Supramolecular Oligomer Formation of 1-([2,2':6',2''-
terpyridin]-4'-ylmethyl)guanidine with Zn2+, Thiophene-2,5-
diyldiboronic Acid, and 2,3-Butadione 
6.1 INTRODUCTION 
 
6.1.1 Unnatural, Synthetic Oligomer Design from a Peptide Chemist’s Perspective 
 In this final chapter, a new supramolecular oligomer will be discussed. The 
principles governing the design of this structure originate from peptide chemistry, but 
added to these principles is the integration of dynamic covalent bonds, as they have been 
applied to unnatural peptides and unnatural oligomers. These reversible reactions helped 
facilitate the folding of peptides as discussed in Chapter 5, but first the expertise on how to 
selectively modify side chains had to be developed. Those selective modification studies 
served as a foundation for incorporating new residue-specific fluorophores  into emerging 
single-molecule peptide sequencing technologies (Chapters 2 & 3). Selective-peptide 
modification chemistries also enabled the synthesis of peptides with unnatural residues, 
such as secondary amine side chains. N-methyl lysine was used for expedient introduction 
of unnatural functionalities, including boronic acids and bipyridines (Chapter 4 & 5). These 
groups form part of an effort led by the Anslyn group to use orthogonal, reversible covalent 
bonds in the synthesis of novel molecules capable of forming higher-order structures. 
 Peptide bonds rooted the studies described. Their utility demonstrated in nature, 
they are the backbone of choice for chemists seeking to induce folding of synthetic and 
unnatural structures.1 The commercial availability of building blocks, synthetic 
accessibility, instrumentation, and well-established protocols have made polypeptides a 
useful scaffold for appending desired functionalities. Usually, these functionalities extend 
beyond the availability of residues found in nature. For example, the Gehlman group has 
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extensively studied the use of α, β peptides to improve proteolytic resistance in vivo and 
to probe into the mechanisms of intermembrane processes.2  
Apart from oligomers with peptide backbones, other types of oligomers, known as 
foldamers, have been explored for folding studies.3, 4 These unnatural synthetic structures 
commonly fold and act as recognition molecules to mimic large molecules like DNA or 
proteins, which serve as the inspiration governing foldamer design and synthesis. 
Therefore, many groups have demonstrated formation of helices in their oligomers 
although other topologies like knots and spirals have been achieved.5  
Motivation for making these oligomers comes from biomolecule analogues capable 
of matching or exceeding a particular biological function. Usually, a common goal is to 
ensure a robust compound not prone to degrading. Therefore, a synthetic structure that can 
fold like protein or DNA and that is also resistant to degradation inside an organism could 
be of great biological value, thus the interest in foldamer research. Synthetic, unnatural 
structures that can resist degradation, remain as inert entities, and perform only their 
intended purpose remain a focus of research.6 Functions can include but are not limited to 
binding, or molecular recognition. From these binding studies, foldamers have also led 
chemists to study unique motions such as rotations and screwing motions.7 
6.1.2 Limitations of Unnatural, Oligomer Design and Synthesis 
 A current limitation when considering making biomimetic oligomer structures is 
the synthetic difficulty of the building blocks, especially when incorporating side chain 
functional groups. If these unnatural oligomers are to begin to resemble biomolecules like 
proteins, appending functionalities off the backbone should become part of the synthetic 
design. Many of the examples in the literature show building blocks that require an 
extensive and skillful execution of synthetic steps that deter from the intended goal of 
analyzing folding/binding properties. In addition, these building blocks tend to lack side 
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chain functionalities that expand the diversity of monomers that can be made from a set of 
common chemistries. Complicated building block synthesis is a bottleneck, but the 
oligomerization, or elongation, process is also a stumbling block. Oligomerization of 
peptides is not atom economical and produces large amounts of waste, but it remains 
widely used because of the automated instrumentation and commercial availability of 
building blocks and reagents. The prevalence of the amide bond in nature has also easily 
justified the synthesis of peptides, despite their costly and wasteful production. The same 
cannot be said for the unnatural oligomers that are conceived, produced, and studied by 
one or a few groups. 
 As a result, a facile means of producing, screening, and scaling up the synthesis of 
an application-worthy unnatural oligomer continues to be a slow process. Even when using 
well-established peptide chemistries, as described in Chapter 5, appending and identifying 
unnatural functionalities which are useful in a material or biological setting still present 
challenges. For example, designing expedient means of modifying residues and scaling up 
the synthesis of building blocks with these non-canonical residues can be a time-consuming 
process and an inefficient use of resources for peptides. This becomes a process that incurs 
considerable risk especially at the preliminary stages of proving the utility of an unnatural 
residue. Chapters 3 & 4 explored straightforward ways to modify peptides, using known 
building blocks, or solution-phase chemistries, that facilitated introduction of secondary 
amines. These secondary-amine peptides could be considered as simple screening peptide 
scaffolds that can be modified by alkylation with bromide compounds. If an unnatural 
functional group gave a positive result, the building block with that residue could be readily 
scaled up. The development of such a methodology was possible because of the extensive 
maturation of the area of synthetic peptide chemistry. Similar access to chemistries to 
modify unnatural oligomers for screening purposes is virtually non-existent. 
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6.1.3 Lessons from Peptide Chemistry that can be Applied to Unnatural Oligomers 
 The first lesson that can be taken from peptide chemistry is to have synthetically 
accessible, structurally simple, and easy to modify building blocks. The twenty amino acid 
residues are either commercially available or relatively synthetically accessible for solid-
phase synthesis. Unnatural oligomers should preferably be made of building blocks 
acquired commercially or easily scaled up in the lab. If not, it can limit the diversity of 
structures that can be screened in a timely fashion. Structurally these compounds should 
be simple in a way that the diversity of the compound originates from the side chains 
branching off the backbone. That the building block itself must serve as a scaffold 
underpins the design of an oligomer’s backbone. It should be readily modified to induce 
unique folding structures. The natural analogues are the residues in proteins that can 
hydrogen bond, aggregate due to hydrophobic effect, or participate in π-π interactions.8 
Unnatural building blocks with these moieties branching off the backbone should also 
promote folding. 
 The second lesson is to use a reliable “linking” chemistry. A host of amide coupling 
reagents, protocols, solution-phase, and solid-phase methods optimized for dependable 
polypeptide formation exist.9, 10 The elongation process must occur consistently and 
efficiently, ensuring the quality of the target sequences. Avoiding deletion products is at 
the root of these optimization efforts. Similarly, for unnatural oligomers to be made and 
reliably screened, there must be approaches that ensure unnatural oligomers are made with 
few deletions. 
 Lastly, it is important to form an oligomer that can be modified at a side chain along 
the backbone that can serve as a branching point from which more functionality can be 
introduced. In addition to building an alphabet of building blocks that share a common 
simple structure differing in side chains, another set of building blocks should be readily 
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modified, post-oligomer synthesis, especially if making a synthetically challenging or 
highly reactive building block. If the functionality to be added to the oligomer cannot 
survive the elongation process, it precludes the ability to make a building block. Having 
functionalities that can react post-oligomer synthesis provides a convenient entry to bring 
about a diverse set of oligomers from a common origin. 
6.1.4 Modular Oligomer Design 
 In a broad sense, the three principles discussed in 6.1.3 can be subsumed under the 
term of modular oligomer design. This term will be used when one of these three principles 
is addressed throughout the text. Modular oligomer design will also allude to the focus of 
reducing complex higher-order structuring of unnatural oligomers into simple, 
intellectually digestible forms based on the straightforward design and accessibility of the 
components required for oligomer formation. 
 This work does not argue that the new oligomer proposed here necessarily marks 
an improvement over unnatural oligomers in the literature. Nor, does it claim that our 
oligomer surpasses the form, function, and utility of polypeptides. The goal of this work 
focuses on applying modular oligomer design to make an oligomer from building blocks 
that are commercially available/or synthetically accessible, are linked by a simple reliable 
chemistry, and contain chains that are easily modified post-oligomer formation. More 
importantly, focusing on re-conceptualizing the design and synthesis of foldamers and 
building upon the disciplines encompassing supramolecular, dynamic, combinatorial, 
polymer, and biological chemistry are the goals of this work. As in all these fields, 
chemistry presented here takes inspiration from and strives to emulate what exists in nature. 





Figure 6.1: Proposed Oligomer Using Guanidinyl Terpyridine, Zn2+, Di-boronic acid, and 
Butadione. 
 
 Figure 6.1 is the generalized scheme envisioned for inducing oligomer formation 
of 1-([2,2':6',2''-terpyridin]-4'-ylmethyl)guanidine (compound 6.1). The  building block is 




The guanidinium group, at pH values greater than 4,(? Why 4?) can readily attack diketones 
like 6.2, forming a five-membered vicinal diol ring. If a boronic acid is also present, the 
five membered diol ring binds to the boron center, such that the dione bridges the boronic 
acid and the guanidinium. Such an interaction was developed in the 1970s and has been 
utilized to inhibit protein function in enzymatic mechanistic studies.11 Mass spectrometry 





















































residues as mass labels, helping resolve peptides with similar molecular weights.12 This 
reaction also enriches samples with arginine-rich peptides;13 solid supports with 
immobilized boronic acids are incubated in a peptide digest and butadione. Peptides with 
guanidinyl residues bind to the solid support. Those without remain in solution and are 
washed away from the solid support with buffer and butadione. Finally, incubating the 
resin at pH 4 reverses its reaction with arginine and dione, and so bound peptides come off 
the resin. 
 The pH-based reversibility of this three-component assembly makes it attractive in 
the proposed oligomer in Figure 6.1, which could be decomposed to its individual 
components by adjusting the acidity of the solution. The formation of the oligomer could 
be viewed as “clicking”, and its decomposition as “declicking”, with applications similar 
to conjugate acceptor declicking reported by the Anslyn group.14 
 The oligomerization and polymerization of terpyridines has been extensively 
studied.15 The well-known and robust metal-ligand complexation was therefore selected 
for modular oligomer design as the analogue to the amide bond in polypeptides (Figure 
6.2). The bicyclic junction resulting from the assembly of a dione, guanidinium, and 
boronic acid, from which side chains can emanate, can be considered the analogue to side 
chains that branch off the peptide backbone. Figure 6.2 demonstrates the side chains 
coming off the dione, and greater complexity can be added by using asymmetric diones. 
There are several forms of diversification that can be achieved by using an asymmetric 
dione. The side chain would be oriented in a randomized manner, but possibly 
stereoselective reactions could be devised to consistently direct the orientation of the side 
chain. A mixture of symmetric or asymmetric compounds would form complex mixtures 
of sequences in a straightforward fashion. By merely mixing simple components that are 
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either commercially available or easily synthetically accessible, a quite complex mixture 
of products may be achieved. 
 
 
Figure 6.2: Comparing Peptide Backbone to Proposed Oligomer Backbone. 
 
 High affinity metal complexation by two terpyridines is the dependable chemistry, 
much akin to amide bonds, that  provides a linker allowing for elongation of the oligomer. 
This linker was chosen based on previous work wherein oligomers were formed from 
terpyridine capped pegylated chains.16 However, the flexible pegylated chains caused the 
oligomer to be prone to cyclization. The design of oligomers resembling biomolecules 
requires semi-rigid backbones.4 Flexible homo-oligomers tend to form globules that lack a 
defined and rigid structure.4 Our linking strategy therefore incorporates moieties that are 
more constrained at the branching point. 
 The branching point is unique in this oligomer because it uses supramolecular 
linking chemistry. Without this three-component assembly between the guanidinium, 
dione, and boronic acid, metal complexation could not result in oligomerization, and vice 


















advantage for promoting oligomer formation or degradation by at more than one type of 
junction. Without the metal, the oligomer does not form at the terpyridines. Without the 
butadione, the oligomer cannot form at the guanidiniums and boronic acid junction. 
 Finally, the backbone follows the principle of oligomer modular design, because it 
has branching points capable of introducing functionalities that can be easily modified by 
other chemistries. Therefore, we propose our oligomer will serve as a convenient scaffold 
for the formation of a diverse array of supramolecular oligomer structures. The 
commercially available bromobutadione can be modified by alkylation, as shown in eqns. 





As long as functional groups are stable to alkylation conditions, we propose this will be a 
facile means for derivatizing butadiones and accessing a wide set of side chain 
functionalities.  
Another branching point for the oligomer derives from the boronic acid. Diformyl 





















functionality (equation. 6.4). Imine formation would be a viable way to expand side chains 
functionalities and their attachment could be made permanent by reducing the imines to 
amines. More importantly, the commercial availability of di-boronic acids possibilities the 
formation of novel structures that could arrange in different forms depending on the 
positioning of boronic acids on a small molecule, for example if they are positioned ortho, 
meta, or para to each other. This feature adds to the possible diverse structures envisioned 
to form with the oligomer. Furthermore, non-covalent functionalities known to polymerize 
can be appended to these branching points, which can cross link the proposed oligomer. 
All in all, according to the principles stipulated in previous sections, we claim the proposed 




6.1.7 Possible Improvements When Compared to Peptide Chemistry 
 One advantage the guanidinium-terpyridine oligomer structure may have over 
peptide chemistry is the improved atom economy. Foremost, solution-phase chemistries 
underpin the elongation process. Unlike solid-phase peptide synthesis (SPPS), which 
requires excess amount of starting material to diffuse throughout the solid support,19 our 
approach moves toward stoichiometric amounts. Therefore, cost and waste of material may 



































to its original components, so that the starting material may be theoretically recovered for 
future use. The only material used in excess is the dione, since excess is required for 
oligomers to form. However, the relative inexpensiveness of diones partially mitigates this 
drawback. 
  Although the number of units that can come together to form this oligomer remains 
to be determined, the number may possibly exceed that of SPPS. Currently, state-of-the-
art technologies push the limit of amino acid residues up to 40.20 Although impressive, that 
amount can be exceeded by the supramolecular interaction in metal complexation. Large 
molecular weights have been reported for terpyridines polymers, which provide literature 
precedent for linking a considerable number of building blocks in our oligomer synthesis. 
 Methods do exist to make high-molecular weight polyamides; however they tend 
to lack the ability to incorporate several side chain functionalities.20 Furthermore, if 
different side chain functionalities were to be added, a particular sequence would be 
difficult to replicate, due to the non-reversibility of the amide bonds. Thus, for polypeptides 
with diverse side chains,  SPPS remains the premier manner to reproduce desired 
sequences. 
 . 
6.1.8 Dynamic Covalent Bonds to Overcome Issues with Sequence Reproducibility 
 A similar argument can be made for our oligomer. How can we reproduce a desired 
sequence for a particular application? At the root of this work, is the exploitation of the 
dynamic covalent bonds described in Chapter 5. Much focus has been directed towards 
these reactions in the formation of novel higher-order structures.21 The ability for reactions 
like hydrazone formation, boron esterification, and thiol conjugate addition to form 
products but readily reverse, coupled with metal-ligand complexation of terpyridines, 
makes for attractive intermolecular interactions. They serve as an intermediate between the 
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rigid, highly irreversible covalent bond and the highly dynamic non-covalent bond. In other 
words, these dynamic covalent bonds are regarded as more stable, but prone to change in 
the presence of competing reactants with similar functional groups. Thus, manipulating the 
kinds of reactants and their proportions in dynamic covalent systems offers a degree of 
control over synthetic structures chemists seek. 
 These reactions become a directional driving force that allows for reliable means 
to form higher order structuring.4 Non-directional forces like those of the hydrophobic 
effect and van der Waals interactions can still be incorporated, along with directional ones 
such as hydrogen bonding. These dynamic, covalent bonds add to the tools available for 
improving folding of synthetic structures. 
 In the case of inducing folding based on the molecular recognition of a target 
analyte or a set of analytes, we hypothesize the oligomer described should display different 
kinds of sequences and structures. What governs the elongation process is not a covalent 
one, but a supramolecular one. Combined with the dynamic reactions mentioned, this 
oligomer should not be limited by the need to reproduce a target sequence, because inherent 
in this system will be the process where the oligomer will find its thermodynamically 
favored state; which can change in sequence and structure depending on the environment. 
Therefore, the means to control the sequence of the oligomer will not depend on the 
elongation process similar to SPPS, where building blocks are incorporated by a linear, 
step-wise process, but instead by controlling external conditions of solvent, reactant 
proportions, and analytes present in solution. 
6.1.9 The Dynamic/Orthogonal Nature of the Guanidinium-Dione-Boronic Acid 
Interaction 
 An important feature stressed here is the presumed dynamic nature of the reaction 
described in equation 6.1. From Chapter 5, we know that boronic acids are dynamic and 
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reactants with similar starting materials readily exchange. Part of the tri-component 
ensemble is boronic acid esterification and is therefore regarded as dynamic. The attack of 
the guanidinium on the dione is reversible, since binding by a boronic aid is needed to lock 
in the five membered ring. Currently, research in the Anslyn group focuses to confirm the 
dynamic nature of equation 6.1. If shown as dynamic, this tri-ensemble will be one of the 
first, to our knowledge, to be reported. Furthermore, the reaction between guanidinium and 
dione will be another reaction considered as dynamic that, to our knowledge, remains 
unreported. 
 As far as the orthogonality of this tri-component assembly, boronic acid binding to 
diols does not cross react with amines, thiols, terpyridines, and α,β unsaturated ketones.22 
Therefore, the boronic acid binding event will be quite inert. However, a little more 
difficult will be to assess the orthogonality of diones. At least when considering the 
dynamic reactions previously reported, diones should have little to no cross reactivity. 
Amines may condense readily, however, in aqueous conditions condensation reverses. 
Since, these diones may be selective under wet conditions, efforts will be aimed to form 
this oligomer in aqueous environments. Thiols may also condense; so further studies to 
determine the reversibility of these products in water are important. 
6.1.10 Scientific Aim: Order of Addition and Oligomer Formation Studies 
 In this chapter, experiments performed aimed to answer two questions. Does it 
matter in what order the components were added to form the oligomer? In other words, we 
wanted to explore if any cross reactivity within the tri-component assembly arose by doing 
a combination of different order of additions. Also, does an oligomer form when a 
terpyridine, metal, and the tri-component ensemble are present in an aqueous solution? To 
answer these two questions, proton NMR studies were carried out to determine if order of 
addition mattered. An extension of this study was determining how much dione promoted 
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assembly formation. Boron NMR became the method of choice to monitor the equivalence 
needed. Proton DOSY NMR was also used to try to establish the formation of oligomers 
from observed changes in diffusion that suggested formation of large molecules. Studying 
the oligomerization is the first step towards probing the presumed emergent properties 
described in previous sections. 
6.2 Results and Discussion 
6.2.1 Synthesis of Compound 6.1 
 
 
Scheme 6.1: Synthesis of Compound 6.1. 
 
Scheme 6.1 shows the synthesis of 6.1. Compound 6.5 was commercially 
purchased and converted to 6.6 following literature protocol. Reduction of this cyano 
derivative afforded compound 6.7, which was guanidinated with 6.8, also commercially 
available. Quantitative deprotection occurred with 20% v/v TFA in DCM. Leaving the 
compound in salt form facilitated dissolving guanidinyl terpyridine into aqueous mixtures. 
These ligands normally do not dissolve in water, and incorporation of pegylated chains 






















































literature, and can serve as an alternative to pegylated derivatives for solubilizing 
terpyridines in water. 
6.2.2 Order of Addition Studies 
 The boronic acid, guanidinium, and butadione react with each other to form the tri-
component assembly. However, the reactivity of compound 6.1 with any of these 
compounds had not been established.  and so order-of-addition studies were performed. In 
Figure 6.3, the different permutations along with the compounds used in the NMR 
experiments are listed. Compound 6.11, denoted “B” in this section, was provided  
 
 
Figure 6.3: Components Used in Order of Addition Studies and Orders Studied. 
 
by the Anslyn group. The improved binding of diols at neutral pH with ortho-
(aminomethyl) boronic acids was described in Chapter 4. This compound served as the 
simplest model available for boronic acids with ortho benzylic amines with minimal steric 
hindrance. Butadione was chosen for the same minimization of steric hindranceZn2+ is 
bound strongly by terpyridines and is compatible with NMR spectroscopy.. Fe2+ is also 
strongly bound by terpyridines, but its paramagnetic properties would broaden signals. 
Broadening or loss of fine structure was to be interpreted as part of assembly formation, 


















Figure 6.4: Proton NMR Studies for A, D, B, C Order of Addition. 
 
 A, D, B, C was the first order studied (Figure 6.4). The stoichiometry between the 
terpyridine and metal (A and D) required careful control, since excess zinc caused mixtures 
of mono and fully bound ligand. Binding the terpyridine ensured the pyridine rings did not 
cross react with butadione. Broadening of the boronic aromatic signals occurred when 
added the boronic acid was added to the fully bound ligand (ADB). This loss in fine 
structure only happened for the boronic acid and not the terpyridine rings, suggesting the 
possibility of the guanidinium interacting with the aromatic portion of the boronic acid. 
This broadened signal persisted after introducing one equivalent of butadiene (ADBC). 










structure. When a total of ten equivalents butadione were added, signals did broaden, but 
no peak could be identified as indicative of assembly forming. To see if further change 
occurred by adding more butadione, a total of 100 equivalents were added. Interestingly, 
the peaks did not further broaden, but instead fine structure for signals returned. A cluster 
of new peaks formed between 6.9 and 7.3 ppm, but remained unidentified. 
 Although a peak identifying assembly formation was not apparent in the spectra, 
studies continued. The rationale for continuing derived from the idea that if order did not 
matter, whether a peak proving assembly was found or not, the final spectra of all species 
combined should look the same. Thus, the next order (B, A, D, C) had the boronic acid as 
its starting point. The aromatic region for B again broadened, albeit with metal-free 
terpyridine ligand. As with bound ligand, unbound terpyridine still retained fine structure 
in the aromatic region. Adding zinc did not change the boronic acid, but complexation 
occurred readily. After adding 1 equivalent of dione C, signals broadened with the surging 
of peaks as described earlier. The final spectra looked the same as for A, D, B, C. Instead 
of adding more equivalents of butadione, the solution sat RT overnight. The following day 
the spectrum did not change, suggesting that equilibrium was had been reached within an 
hour of dione addition. 
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Figure 6.5: Proton NMR Studies for B, A, D, C Order of Addition. 
 
. As with the previous NMR study, broadening of peaks did not confirm assembly 
formation, but acquiring a final spectrum that did not differ from the one before suggested 
no dependence on addition order. 
 A third combination (C, A, D, B) aimed to determine if reactivity between pyridine 
and butadione existed. In the aromatic region, nothing was observed as expected. After 
adding A, some impurities were observed (Figure 6.6). Butadione could have reacted with 
the terpyridine rings to give a mixture of unintended byproducts.. Adding zinc did not 









Figure 6.6: Proton NMR Studies for C, A, D, B Order of Addition. 
 
We interpret that the order of addition in this particular case led to unintended side 
products. However, an alternative hypothesis is that these impurities come from non-zinc 
metals, such as Fe2+, picked up from the lab (spatulas, glassware, etc.)when handling 
compound 6.1 over time. However, further studies to test the hypothesis were not pursued. 
Aside from these impurities, the spectrum for CADB looked like those taken previously. 
 This sample was heated at 37 °C and 50 °C to see if the spectrum changed, but no 
differences were observed. However, some cooling occurred prior to taking an NMR, and 
there could have been a reversion to the same product mixture that existed at room 
temperature prior to heating. We propose to study temperature-dependent NMR in the 








Finally, order D, A, C, B (SI) completed the set. As with all three previous NMR 
studies, the final spectrum looked the same. Thus, despite the slight impurities observed 
for C, A, D, B, order did not play a large role in assembly formation. Components could 
be mixed together simultaneously with minimal concerns  for side products. 
6.2.3 Boron NMR Titration Studies 
 Since proton NMR studies alone failed to unambiguously confirm assembly 
formation, boron NMR studies became an alternative. Second to the carbonyl carbons, the 
boron should experience the greatest change between its unbound and bound state. 
Therefore a  titration was performed while monitoring boron to determine the equivalents 
of dione required for assembly in buffered aqueous mixtures. Literature accounts report the 
excess use of butadione to ensure efficiency without biasing results.12 However, if 
improving the atom economy of an unnatural oligomer formation were the aim, 
determining the minimum amount of butadione required would be important. We presumed 
that excess was not required, because of butadione’s reactivity. However, water could 
outcompete the resulting diol for binding by the boronic acid. Entropy should disfavor diol 
binding. In contrast, enthalpy should favor diol binding.  
Titration studies helped to settle these questions. Initially, the components in 
section 6.2.2 were used. Interestingly, the boron NMR signal disappeared after introducing 
the metal-ligand complex. Control spectra of compound 6.11 with only Zn2+ or only 6.1 
did not cause signal loss. The metal bound ligand complex broadened the signal to such an 
extent that it was not discernible from the baseline.. Upon the  addition of one equivalent 
of butadione, a new peak emerged at 9 ppm, which we interpreted as assembly formation. 
At 5 equivalents, the signal intensity once more decreased to the baseline. With 30 
equivalents butadione, a peak at 19.5 ppm became more prominent. Dilution of the sample 
with each addition of butadione certainly contributed to loss in signal intensity, but a 
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dilution factor of 1.7 could not solely account for the disappearance of signal. Thus, it 




Figure 6.7: Boron NMR Titration of Butadione into a Solution of Metal-Bound 6.1 and 
6.11. 
 
 With increasing excess of butadione in solution, we propose that reaction of the 
secondary amine in the ortho-aminomethyl phenylboronic acid with butadione became 
more prevalent, disrupting the pseudo tetrahedral, or sp3, arrangement of the boronic acid.24 
Chemical shifts between 19-20 indicate sp2 formation, not consistent with ortho-
aminomethyl phenylboronic acids binding to vicinal diols. In other words, compound 6.11 
was not useful in this type of experiment because of the secondary amine. A tertiary amine, 
such as that in compound 6.12, could react with butadione, but the ammonium product 





Figure 6.8: Reactions of Compounds 6.11 and 6.12 with Butadione. a) Secondary amine 
would attack the carbonyl carbon to form an iminium (resulting in an sp2 
boronate) or an alkoxide that can esterify the boronic acid (resulting in an sp3 
boronate). b) Tertiary amine cannot form the imminium, only the alcohol, but  
it is less prone to esterify to the resulting sp3 boronate due to steric repulsion 
between the five-membered ring and the carbonyl. 
 
 In fact, if the secondary amine in compound 6.11 attacked butadione as shown in 
Figure 6.8a, the broadening of the boron signal could be rationalized by unintended 
oligomerization or polymerization as another aminomethyl phenylboronic acid attacked 
the remaining carbonyl as neighboring boronic acids partially esterified. Thus, a vast 
mixture of products formed making the boron signal so broad and difficult to identify what 
occurred. In contrast, an attack by compound 6.12 on butadione should readily reverse, due 
to steric issues rising from the close interaction between the five-membered ring and the 
































Figure 6.9: Boron NMR Titration of Butadione into a Solution of Metal-Bound 6.1 and 
6.12. 
 
 The titration with compound 6.12 provided a more consistent change from a 
trigonal planar to a tetrahedral arrangement, consistent with boron binding to vicinal diols. 
Between 7 and 10 equivalents the NMR stopped changing considerably. Therefore, the 
minimal amount required for assembly formation in neutral conditions was set at 10 
equivalents. Although not ideal when improving atom economy and decreasing waste in 
oligomer production, ten equivalents was deemed acceptable. Interestingly, at 30 
equivalents, aside from dilution causing a decrease in signal intensity, the singlet peak at 
7.5 ppm broadened. The residual peak at 30 ppm, attributed to unreacted boronic acid, was 
not completely eliminated though. In addition, along with broadening some fine structure 









With butadione in great excess, more oligomeric species can form, possibly even with the 
esterified boron centers depicted in Figure 6.8b. High concentrations of the diketone might 
overcome the steric repulsion from the five-membered ring. Taking into consideration the 
order-of-addition studies and these 11B titration studies, the assembly formed readily in the 
presence of the metal-bound guanidinylmethyl terpyridine ligand.  LRMS also confirmed 
formation of the assembly (SI).  These promising results for the non-oligomerizing model 
spurred efforts to study oligomerization with a small molecule diboronic acid.  
6.2.4 Proton NMR of Oligomerization with Thiophene-2,5-diyldiboronic Acid (6.13) 
 
 
Figure 6.10: 1H NMR Titration of Butadione into a Solution of 6.13 and Metal-Bound 6.1. 
 
 Oligomerization studies were done with compound 6.13 because of its small size 







that could be helpful to our design.25 Figure 6.10, a 1H NMR titration of Zn2+-bound 6.1 
and 6.13 with butadione demonstrates that as the equivalents of butadione increased, the 
aromatic thiophene protons’ signal at 7.85 ppm decreased in intensity, and the decrease 
was attributed to boronic acid binding. Furthermore, a new singlet peak was not observed, 
perhaps because it disappeared under the other peaks. If discrete species had formed, a 
singlet should still have been observed. A small singlet did persist at 7.85 ppm, but it 
remains unclear if this was excess thiophene or partially bound 6.13. Nevertheless, these 
results suggest that the boronic acid electronic environment was changing.  
 
6.2.5 DOSY NMR Studies 
 
Figure 6.11: DOSY Experiment for a Mixture of Compounds 6.1, 6.13, and Butadione in 
DMSO. 
 To further probe if oligomerization occurred, DOSY experiments began with a 
control study in which metal-bound compound 6.7 and 6.13 were combined in deuterated 
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DMSO.. Five equivalents of DIPEA were added to ensure all pyridine rings were 
deprotonated and could complex with zinc. To start off, butadione was not added to the 
solution and the NMR experiment ran overnight at RT. As Figure 6.15 showed, aromatic 
peaks had a diffusion constant of approximately 2. When butadione was added, no change 
in the diffusion constant of the aromatic peak region was observed, indicating that an amine 
(not guanidine) could not promote oligomerization. 
6.3 Conclusions 
 If chemists are to reliably form building blocks for unnatural oligomers, screen 
sequences of unnatural oligomers for numerous applications, and reliably reproduce the 
properties of specific sequences, a reconceptualization of oligomer design should take 
place. We argue that if we pursue simple building block design, emphasize straightforward 
reliable linking chemistries, and backbones that are readily modified, chemists can make 
oligomers that are easier to analyze for their intended purpose. In this work, we presented 
initial studies of guanidinium-terpyridine/metal/diketone/boronic acid oligomer geared 
towards achieving modular oligomer design. Future studies will include probing the 
oligomerization and possibly polymerizing this novel compound. More importantly, these 
studies were presented to emphasize the need for new approaches for making complex 
folding that strives to emulate structures known in nature. 
6.4 Experimental 
6.4.1 General Material 
 4'-chloro-2,2':6',2''-terpyridine was purchased from Acros and from Chem-Impex 
Inc.. 1,1'-Bis(diphenylphosphino)ferrocene was purchased from Combi-Blocks.. 
Tris(dibenzylideneacetone)palladium(0) was purchased from Oakwood Chemical. Pd/C, 
TFA, thiophene-2,5-diyldiboronic acid, deuterated ammonium acetate, Zn(CN)2, and 
DIPEA were purchased from Sigma-Aldrich. Zinc triflate was purchased from Strem 
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Chemical. (2-(pyrrolidin-1-ylmethyl)phenyl)boronic acid and (2-
((methylamino)methyl)phenyl)boronic acid were provided by the Anslyn group. Solvents 
were purchased from Fisher. D2O, deuterated MeOD, and deuterated MeCN, and DMSO 
were purchased from Cambridge, Acros, and Sigma-Aldrich. 
6.4.2 General Instrumentation 
An Agilent NMR 400 was used for order of addition studies. A Varian DirectDrive 
600 was used for boron and DOSY NMR experiments. An Agilent Technologies 6530 
Accurate Mass QTofLC/MS was used for high-resolution mass spectrometry. ). An Agilent 
Technologies 6130 Single Quadrupole LC/MS with Gemini C18 3.5 micron 2.1 50 mm 
was used for online separation (0.7 mL min-1 flow rate, 5–95% MeOH +0.1% formic acid 
in water over 12 min at room temperature) and low-resolution mass spectrometry. Wilmad 
precision 300 MHZ, OD 5mm, 7” length, class A glass, with a 0.38 mm thick wall, NMR 
tubes was used for DOSY experiments. 
6.4.3 Synthesis of 1-([2,2':6',2''-terpyridin]-4'-ylmethyl)guanidine (6.1) 
 [2,2':6',2''-terpyridine]-4'-carbonitrile (6.6). 4'-chloro-2,2':6',2''-terpyridine 
(6.5) (15.1 mmole), Zn(CN)2 (9.22 mmole), Zn dust (4.14 mmole), and 
bis(diphenylphosphino)ferrocene (dppf, 1.47 mmole) were dissolved in dimethylacetamide 
under argon.  The solution was sparged with argon, followed by the introduction of 
Tris(dibenzylideneacetone)palladium(0) (4.13 mmole) (Pd2(dba)3). The reaction was 
stirred at 180 °C for 2 hrs. Solvent was removed under vacuum with mild heating. 
Compound 6.6 was purified via flash column chromatography on neutral alumina gel, 10-
15% EtOAc in hexanes. Yield: 10%. HRMS: found m/z 259.09760, calcd. 259.09780 (M 
+ H)+. 1H NMR (400 MHz, CDCl3) δ 8.65 (ddd, J = 4.8, 1.8, 0.9 Hz, 2H), 8.55 (s, 2H), 
8.47 (dt, J = 7.9, 1.1 Hz, 2H), 7.83 (td, J = 7.7, 1.8 Hz, 2H), 7.34 (ddd, J = 7.6, 4.8, 1.2 Hz, 
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2H). 13C NMR (101 MHz, CDCl3) δ 156.35, 153.88, 149.29, 137.01, 124.70, 122.18, 
122.09, 122.03, 121.08, 116.85, 77.45, 77.13, 76.81. 
 [2,2':6',2''-terpyridin]-4'-ylmethanamine (6.7). Compound 6.6 (1.47 mmole) 
was dissolved in AcOH, 10% Pd/C (0.507 mmole) was added, and the reaction mixture 
was kept under H2 balloon at RT for 12 hrs. Pd/C was then filtered off over hardened filter 
paper. Solvent was removed under vacuum with mild heating. No further purification was 
required. Yield: 90%. HRMS: found m/z 285.1110, calcd. 286.11400 (M + Na)+. 1H NMR 
(400 MHz, D2O) δ 8.56 (dt, J = 4.8, 1.3 Hz, 2H), 8.25 (dt, J = 7.9, 1.1 Hz, 2H), 8.06 (s, 
2H), 7.95 (td, J = 7.8, 1.8 Hz, 2H), 7.48 (ddd, J = 7.6, 5.0, 1.2 Hz, 2H), 4.30 (s, 2H). 
 Boc-1-([2,2':6',2''-terpyridin]-4'-ylmethyl)guanidine (6.9). Compound 6.7 (1.32 
mmole) and tert-butyl (Z)-(((tert-butoxycarbonyl)amino)(1H-imidazol-1-
yl)methylene)carbamate (1.45 mmole) (6.8) were dissolved in DCM, followed by addition 
of DIPEA (1.98 mmole). The reaction was stirred at RT for 1 hr, and then solvent was 
removed by rotary evaporation. The crude product was purified by flash column 
chromatography on neutral alumina gel, 5-20% EtOAc in hexanes. Yield: 50%. HRMS: 
found m/z 527.23820, calcd. 527.23770 (M + Na)+. 1H NMR (400 MHz, CDCl3) δ 11.57 
(s, 1H), 8.77 (t, J = 5.5 Hz, 1H), 8.68 (ddd, J = 4.8, 1.8, 0.9 Hz, 2H), 8.59 (dt, J = 8.1, 1.1 
Hz, 2H), 8.39 (s, 2H), 7.84 (td, J = 7.7, 1.8 Hz, 2H), 7.31 (ddd, J = 7.5, 4.8, 1.2 Hz, 2H), 
4.83 (d, J = 5.5 Hz, 2H), 1.47 (d, J = 7.2 Hz, 17H). 13C NMR (101 MHz, CDCl3) δ 163.56, 
156.54, 155.68, 155.61, 153.22, 148.92, 148.80, 137.25, 124.03, 121.57, 120.11, 83.43, 
79.53, 44.23, 44.19, 28.35, 28.13, 14.28. 
 1-([2,2':6',2''-terpyridin]-4'-ylmethyl)guanidine (6.1). Compound 6.9 (1.75 
mmol) was dissolved in a solution mixture of DCM and TFA (20% v/v) and stirred 
overnight at RT. Solvent was removed by rotary evaporation, and the resulting gum was 
triturated with Et2O to produce a slightly pink solid. No further purification was performed. 
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Yield: Quantitative. 1H NMR (400 MHz, D2O) δ 8.52 (ddd, J = 5.0, 1.8, 0.9 Hz, 2H), 8.09 
(dt, J = 8.0, 1.1 Hz, 2H), 7.89 (td, J = 7.8, 1.8 Hz, 2H), 7.84 (d, J = 0.9 Hz, 2H), 7.46 (ddd, 
J = 7.6, 5.0, 1.2 Hz, 2H), 4.56 – 4.51 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 154.36, 
153.94, 149.88, 148.64, 138.85, 125.13, 121.73, 120.54, 119.57, 117.63, 114.73. 
6.4.4 Order of Addition Proton NMR Studies 
 Proton NMR studies were performed using a deuterated solution with the following 
solvents and boron standards: D2O/CD3CN (3:1) (v/v) or 100mM D3CCO2ND4 with NaBF4 
(1mg/mL). 
 For each iteration involving order of addition studies, 0.009 mmol of compound 
6.1, 0.0045 mmol of zinc triflate, 0.009 mmol of compound 6.11, and 0.009-0.09 mmole 
of compound 6.2 were combined. 
6.4.5 Boron NMR Titration Studies 
 For 11B NMR titration studies, 0.2 mmol of compound 6.1, 0.1 mmol zinc triflate, 
0.2 mmol of compound 6.12, as described in section 6.4.4, were mixed in  0.67 M D7 
ammonium acetate. An NMR spectrum was taken after 1, 2, 4, 6, and 20 equivalent addition 
of compound 6.2. 
6.4.6 Proton DOSY NMR Experiments 
 For DOSY, a control study was performed on 0.015 mmol compound 6.7 dissolved 
in deuterated DMSO with 0.0075 mmol zinc triflate, and 0.0075 mmol of compound 6.13. 
The experiment ran overnight at RT using NMR tube specified in section 6.4.2, ensuring 
3.8 cm of the solution were introduced. 
 The following day 10 equivalents of butadione were added and the solution 
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Figure 6.13: HRMS for compound for 6.6. 
Target Compound Screening Report
MS Zoomed Spectrum




































Acq Method pos.m Acquired Time 12/21/2016 3:55:22 PM DA Method KS.m
Position P1-D2 Instrument Name Instrument 1 User Name
Data File MSF16-1707(119_DS_20161112)_hrESIpos1.d Sample Name 1707(119_DS_20161112) Comment 1707(119_DS_20161112)
Page 1 of 1 Printed at: 3:57 PM on:12/21/2016
 327 
 
Figure 6.14: Proton NMR for 6.7. 
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Figure 6.15: HRMS for compound for 6.7. 
Target Compound Screening Report
MS Zoomed Spectrum
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Figure 6.16: Proton (top) and carbon (bottom) for compound 6.9. 
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Figure 6.17: HRMS for compound for 6.9. 
Target Compound Screening Report
MS Zoomed Spectrum
--- End Of Report ---
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Figure 6.18: Proton (top) and carbon (bottom) for compound 6.1. 
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Figure 6.19: HRMS for compound for 6.1. 
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Figure 6.20: Proton NMR comparing compounds 6.1 (A), 6.11 (B), 6.2 (C), and Zn2+ (D). 
 
Figure 6.21: Proton NMR Comparing compounds 6.1 to B,A; C,A; D,A order of addition. 
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Figure 6.22:  Proton NMR comparing aromatic region between fully/partially bound 6.1. 
 










Figure 6.24: Proton NMR comparing compound 6.11 to a mixture of 6.11 and 6.1. 
 
Figure 6.25: Proton NMR comparing orders of addition A, D, B; B, A, D; C, A, D for 
compounds 6.1, 6.11, and Zn2+. 
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Figure 6.26: Proton NMR comparing orders of addition C, A; C, A, D for compounds 
6.1, 6.2, and Zn2+. 
 
Figure 6.27: Proton NMR comparing compound 6.11 in the presence of Ac-Arg-OH. Changes in 
chemical shifts occurred due to differences solvents. Top spectra was more aqueous 
1:1 (D2O:MeCN). Nevertheless, guanidinium did not broadened boronic aromatic 
region, suggesting interaction with terpyridine played an undetermined role 
influencing shift of boronic acid. 
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Figure 6.28: Proton NMR comparing all four orders of addition. 
 
Figure 6.29: Proton NMR comparing compound 6.11 with all four orders of addition. 
 338 
 
Figure 6.30: Proton NMR comparing compound 6.11 with all orders of addition and 




Figure 6.31: Proton NMR comparing compounds 6.9 and 6.11 individually and mixtures. 
Signal did not broadened when terpyridine or amine were present. 
 
Figure 6.32: Proton NMR comparing benzyl guanidinium and compound 6.11. Due to 
solubility complications, this study did not definitively explain broadening of 







Figure 6.33: Proton NMR study of titrating 6.2 to a solution of 6.1, 6.13, and Zn2+ for 
methylene group of 6.1. 
 




Figure 6.35: Proton NMR study of titrating 6.2 to a solution of 6.1, 6.13, and Zn2+ for 
methylene group of 6.1. 
 






Figure 6.37: Proton NMR study of titrating 6.2 to a solution of 6.1, 6.14, and Zn2+. 
 




Figure 6.39: Proton NMR study of titrating 6.2 to a solution of 6.1, 6.14, and Zn2+ (Trial 
3). 
 




Figure 6.41: Proton NMR of 6.14 post acidification with deuterated TFA (refer to Figure 
6.40). Stoichiometry of all species present previous to butadione addition 
persisted. However, it remained unclear if oligomer formed and so it DOSY 




Figure 6.42: LRMS of assembly formed between compounds 6.1, 6.2, 6.11. 
 











m/z: 520.26 (100.0%), 521.27 (31.4%), 519.27 (24.8%), 





















m/z: 881.34 (100.0%), 880.35 (49.7%), 882.35 (28.1%), 881.35 (24.7%), 882.35 (21.6%), 883.35 (8.7%), 879.35 
(6.2%), 882.35 (4.7%), 883.34 (4.5%), 882.34 (4.4%), 883.35 (3.4%), 880.35 (2.7%), 882.34 (2.2%), 881.34 (2.2%), 
884.35 (1.3%), 882.35 (1.3%), 884.34 (1.3%), 883.34 (1.2%)
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Figure 6.44: LRMS of assembly formed between compounds 6.1, 6.2, 6.14. 
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